Agilent Annual Report 2015

FY2015 Annual Report · Agilent

Loading PDF…

2015 ANNUAL REPORT

AGILENT TECHNOLOGIES, INC.
ANNUAL REPORT TO STOCKHOLDERS
ANNUAL REPORT CONSOLIDATED FINANCIAL STATEMENTS

T
R
O
P
E
R
L
A
U
N
N
A

AGILENT TECHNOLOGIES, INC.
ANNUAL REPORT TO STOCKHOLDERS
ANNUAL REPORT CONSOLIDATED FINANCIAL STATEMENTS

This page is intentionally left blank.To our Shareholders,

Fiscal 2015 was an exciting year of transformation for Agilent Technologies. Following the 2014 spin-off of
our electronic measurement business into an independent company, Agilent re-emerged as a global leader dedicated
entirely to life sciences, diagnostics and applied chemical analysis markets.

We successfully completed Agilent’s CEO transition. I was named as Agilent’s third CEO at our March 18,
2015 shareholder meeting. We offer our heartfelt appreciation for Bill Sullivan’s leadership and accomplishments as
Agilent’s CEO over the past decade. We formed a new executive leadership team that is deeply committed to
delivering results. We implemented a new company strategy, mission and vision. We restructured the company’s
operations and product portfolio, and committed to new long-term financial goals.

While building the foundation for Agilent’s future with an unprecedented amount of change, we delivered very
strong financial results, delivering increased growth and profitability. For the full fiscal year, we generated revenues
of $4.04 billion. This represents our highest annual core revenue growth rate since fiscal 2011, excluding the impact
of currency, the NMR business, and acquisitions and divestitures within the past 12 months. We increased our
fiscal 2015 operating margins, offsetting entirely the cost dis-synergies from the company split. We also returned
$400 million to our shareholders through dividends and stock repurchases.

During the year, Agilent’s leadership team focused on three areas to drive shareholder value creation:

1. Deliver above-market growth
2. Aggressively expand operating margins
3.
Increase cash return to our shareholders

Above-market growth

Our analytical lab markets, which represent 84 percent of the total company, are comprised of two externally

reported business segments: the Life Sciences and Applied Markets Group and the Agilent CrossLab Group.
Together, these businesses serve customers in pharmaceuticals and life sciences research, as well as in applied
chemical markets such as chemical and energy, food safety, environmental and forensics. We offer our customers a
strong and comprehensive portfolio of instruments, software, consumables and services.

The Life Sciences and Applied Markets Group (LSAG) brings together Agilent’s analytical laboratory
instrumentation and informatics. Throughout the year, we continued to introduce new and innovative offerings with
a significantly differentiated customer experience.

The Agilent 1290 Infinity II LC systems set new benchmarks in analytical efficiency, quality, ease of use and

integration. We further enhanced our Infinity II LC line with the 1290 Infinity II Vial-Sampler. This product
significantly lowers the entry price to the top-line product range, offering analytical laboratories a cost-effective way
to experience the advantages of ultra-high-performance liquid chromatography.

In mass spectrometry, the Agilent 6545 LC/MS Q-TOF offers higher resolving power and sensitivity for small-

molecule applications such as food screening, the environment and pharmaceuticals. The Agilent 6470 LC/MS
Triple-Quad, used in applications that range from food testing to clinical research, is engineered to be our most
robust triple-quadrupole ever.

The Agilent 5977B High-Efficiency Source GC/MSD is a tandem gas chromatograph and mass spec that
delivers lower levels of detection than any other instrument in its class, making it possible to detect pollutants and
contaminants at previously undetectable levels. And the Agilent 7800 quadrupole ICP-MS, the latest addition to our
industry-leading inductively coupled plasma mass spec portfolio, raises the standard for routine elemental and
metals analysis.

ANNUAL REPORTAnnual Report

We released a new electronic lab notebook, OpenLAB ELN 5.0, which adds several core feature enhancements

Apple

iPAD mobile client. We introduced the Agilent 4200 TapeStation system, a fully automated
that enables scientists to rapidly analyze up to 96 DNA samples at a time and sets a new sample QC
our GC QTOF

And we launched several targeted solutions, including

next-generation sequencing.

Analysis Solution and our LC QTOF Water Analysis System.

including an
instrument
standard for
Pesticide

The Agilent CrossLab Group (ACG) combines our analytical laboratory services and consumables businesses
under a new Agilent brand. The Agilent CrossLab brand is focused on delivering a new and integrated approach that
offers actionable insights to help customers achieve successful outcomes.

We introduced several new services solutions, including laboratory business intelligence reporting, RFID

(radio-frequency identification) inventory management services and laboratory asset utilization services.

The Agilent University introduced an enhanced portfolio of online training courses. This enables customers –
from lab technicians to researchers – to develop new skills and gain insights that can improve economic, operational
and scientific outcomes for their laboratories.

In consumables, we expanded the Poroshell family to include a new 4-micron particle size. We expanded our
AdvanceBio portfolio of solutions, enabling scientists to speed research and lower costs. And we introduced a new
product, the Enhanced Matrix Removal-Lipid, to help food safety labs test high-fat samples more accurately and
with reproducible results.

In addition to our continued growth through leadership in analytical laboratories, we are leveraging Agilent’s

analytical strength to further penetrate the connected clinical research and diagnostics laboratories.

The Diagnostics and Genomics Group (DGG) is a global leader in diagnostics and genomics solutions for
research and clinical laboratories. Within anatomic pathology, our Dako-branded tissue-based diagnostics are at the
forefront of workflow solutions helping pathologists to accurately diagnose cancer and determine the most effective
treatment for cancer patients.

We continued to strengthen our diagnostics and genomics portfolio throughout fiscal 2015. We entered a
strategic partnership with Cell Signaling Technology to supply antibodies for use in Dako-branded diagnostics
products. We launched updated gene expression microarray tools for researchers to better investigate expression
patterns on a highly accessible platform. And we released new target enrichment solutions for disease research that
address current limitations in exome sequencing.

In fiscal 2015, two new Agilent diagnostics products received approval from the U.S. Food and Drug

Administration. The first product was created in partnership with Merck & Co. This new companion diagnostic test
can reveal whether a patient with advanced non-small-cell lung cancer is likely to respond to Merck’s anti-PD-1
therapy KEYTRUDA.

The second product is the first complementary diagnostic developed in collaboration with Bristol-Myers Squibb.

This new test can identify PD-L1 expression levels on the surface of non-small-cell lung cancer tumor cells, and
provide information on the survival benefit with OPDIVO for patients with non-squamous, non-small-cell lung cancer.

In addition to Agilent’s internal R&D and development, we continue to make acquisitions to enhance our

comprehensive portfolio of leading technologies, products and solutions.

In fiscal 2015 we acquired Cartagenia, a leading provider of software and services for clinical genetics and molecular

pathology labs. The Cartagenia Bench platform enables technical, lab directors and clinicians to visualize, assess and
report clinical genetics data in the context of patient information. Together, Agilent and Cartagenia can help remove
bottlenecks inherent in analysis, interpretation and reporting clinical data, resulting in faster answers for patients.

In November 2015 we also acquired Seahorse Bioscience, a leader in providing instruments and assay kits for
measuring cell metabolism and bioenergetics. Seahorse’s unique technology is the perfect complement to Agilent’s
market-leading separation and mass spec solutions, in particular for metabolomics and disease research in pharma.
The combination of these two platforms gives scientists a more comprehensive and faster path to researching some
of the most challenging diseases affecting mankind.

Expanded operating margins

In fiscal 2015 we launched a multi-year “Agile Agilent” program, re-engineering the company to be more
efficient, nimble and eternally focused. As part of a company reorganization and restructuring, we established a new
sales channel and divisional structure which have been fully and successfully implemented.

We continually looked for opportunities to streamline and re-think our legacy business models. These included
closing our U.S. Government Affairs office. We also closed and sold a California chemistry manufacturing site and
consolidated production volume into an existing Agilent site.

In fiscal 2015, our actions from the “Agile Agilent” program delivered about $40 million in gross savings. In
addition, the closure of our Nuclear Magnetic Resonance business – announced at the end of fiscal 2014 – resulted
in $15 million in savings. And the Agilent Order Fulfillment organization successfully delivered $25 million in
committed savings.

The “Agile Agilent” program and order fulfillment cost savings will be key drivers behind continued non-GAAP
operating margin expansion. We increased our fiscal 2015 operating margins and are well on track to achieve a 22 percent
operating margin by fiscal 2017. At the same time, we continue to invest for long-term revenue growth. Our results in
fiscal 2015 give us confidence in our ability to deliver on this longer-term operating margin expansion commitment.

Long-term shareholder value

For the year, we returned $400 million to shareholders in the form of dividends and stock buybacks. We also
generated $491 million in operating cash flow. On May 28, 2015, the Agilent Board of Directors approved a share
repurchase program authorizing the purchase of up to $1.14 billion of the company’s common stock through and
including November 1, 2018.

Fiscal 2015 was a year of transformation for the new Agilent. The coming year will be focused on accelerating

and continuing to build our market leadership. We will leverage the power of our transformation and continue to
establish leadership in our targeted markets – the analytical laboratory and the connected clinical research and
diagnostics laboratory.

We are well positioned to help address some of the greatest global challenges currently facing our generation. These

include dealing with increasingly dangerous diseases and pathogens; improving the quality of food, air, soil, water and
living environments worldwide; and managing a fixed amount of natural resources. Our mission is to inspire discoveries
that advance the quality of life, by bring capabilities to our customers to address these major problems.

Agilent is well positioned to impact both the science and the economics of customer laboratories across our end
markets. We will impact the science by providing the most innovative offerings and leading technologies, wrapped
in complete market-focused solutions for our customers. We will impact the economics by helping our customers
manage their assets and optimize the efficiency of their laboratory operations.

Agilent’s portfolio and pipeline of leading technologies and solutions have never been stronger. We have an

energized and aligned team that is motivated to deliver on the new company’s full potential. We remain quite
confident and excited about Agilent’s long-term prospects of above-market growth, increasing profitability levels
and cash returns to our shareholders – all leading to the creation of greater shareholder value.

Mike McMullen
Agilent President and Chief Executive Officer

ANNUAL REPORTAnnual Report

t
r
o
p
e
R

l
a
u
n
n
A

Agilent at a Glance

Agilent is a global leader in life sciences, diagnostics and applied chemical markets, providing application
focused solutions that include instruments, software, services and consumables for the entire laboratory workflow.

In November 2014, we announced a change in organizational structure designed to better serve our customers.
Our life sciences business, excluding the nucleic acid solutions division, together with the chemical analysis business
combined to form a new segment called life sciences and applied markets business. Our diagnostics and genomics
businesses combined with the nucleic acid solutions division from our life sciences business and became the
diagnostics and genomics segment. Finally, the Agilent CrossLab segment was formed from the services and
consumables businesses previously part of the life sciences and chemical analysis businesses.

We sell our products primarily through direct sales, but we also utilize distributors, resellers, manufacturer's
representatives and electronic commerce. Of our total net revenue of $4.0 billion for the fiscal year ended October 31,
2015, we generated 30 percent in the U.S. and 70 percent outside the U.S. As of October 31, 2015, we employed
approximately 11,800 people worldwide. Our primary research and development and manufacturing sites are in
California, Colorado, Delaware and Texas in the U.S. and in Australia, China, Denmark, Germany, Italy, Japan,
Malaysia, Singapore and the United Kingdom.

Business Group
Life Sciences
and Applied
Markets

2015 Net Revenue
$2.0 billion

Description
Summary: Our life sciences and applied markets business provides application-
focused solutions that include instruments and software that enable customers to
identify, quantify and analyze the physical and biological properties of substances
and products, as well as enable customers in the clinical and life sciences research
areas to interrogate samples at the molecular level. We employed approximately
4,200 people as of October 31, 2015 in our life sciences and applied markets
business.
Key Markets: Our life sciences and applied markets business focuses primarily on
five markets:

Life Science Research;

• Pharmaceutical, Biotechnology, CRO & CMO;
•
• Chemical & Energy;
• Environmental & Forensic; and
• Food

Key Product Areas: Our key product and applications include the following
technologies:

Liquid Chromatography;

•
• Gas Chromatography;
• Mass Spectrometry;
Spectroscopy;
•
Software and Informatics;
•
•
Lab Automation and Robotics;
• Automated Electrophoresis and Microfluidics;
• Vacuum Technology; and
• Nuclear Magnetic Resonance

Business Group
Diagnostics and
Genomics

2015 Net Revenue
$0.7 billion

Agilent
CrossLab

$1.3 billion

Description
Summary: Our diagnostics and genomics business
the reagent
partnership, pathology, companion diagnostics, genomics and the nucleic acid
contract manufacturing businesses. We employed approximately 2,000 people as
of October 31, 2015 in our diagnostics and genomics business.

includes

Key Market: Within the diagnostics and genomics business, we focus primarily
on the Diagnostics and Clinical Market. A significant part of our clinical
diagnostic customers are in pathology labs throughout the world.
Key Product Areas:

Specific Proteins and Flow Reagents
Target Enrichment

• Pathology
•
•
• Cytogenetic Research Solutions and Microarrays
• PCR and qPCR Instrumentation and Molecular Biology Reagents; and
• Nucleic Acid Solutions

Summary: The Agilent CrossLab business spans the entire lab with its extensive
consumables and services portfolio, which is designed to improve customer
outcomes. The majority of the portfolio is vendor neutral, meaning we can serve
and supply customers regardless of their instrument purchase choices. Our Agilent
CrossLab business employed approximately 3,800 people as of October 31, 2015.
Key Markets: Our CrossLab business focuses primarily on six markets:

The Pharmaceutical, Biotechnology, CRO & CMO;
Life Science Research;

•
•
• Chemical & Energy;
• Environmental & Forensics;
• Food; and
• Diagnostics and Clinical

Key Product Areas:

• Chemistries and Supplies;
•
Services and Support; and
• Remarketed Instruments

Agilent Technologies
Research Laboratories

Global Infrastructure
Organization

Agilent Order Fulfillment
Organization

Agilent Technologies Research Laboratories is our research organization based in
Santa Clara, California, with offices in Europe and Asia. The Research Labs create
competitive advantage through high-impact technology, driving market leadership
and growth in Agilent's core businesses and expanding Agilent's footprint into
adjacent markets. At the cross-roads of the organization, the Research Labs are able
to identify and enable synergies across Agilent's businesses to create competitive
differentiation and compelling customer value.

We provide support to our businesses through our global infrastructure organization.
This support includes services in the areas of finance, legal, workplace services,
human resources and information technology. Generally these organizations are
centrally operated from Santa Clara, California, with services provided worldwide.
As of the end of October 2015, our global infrastructure organization employed
approximately 1,800 people worldwide.

Our order fulfillment and supply chain organization (“OFS”) centralizes all order
fulfillment and supply chain operations in our businesses. OFS provides resources
for manufacturing, engineering and strategic sourcing to our respective businesses.
In general, OFS employees are dedicated to specific businesses and the associated
costs are directly allocated to those businesses.

ANNUAL REPORTAnnual Report

t
r
o
p
e
R

l
a
u
n
n
A

Board
Committees

Audit & Finance
Committee
Heidi Fields,
Chairperson
Paul N. Clark
Robert J. Herbold
Daniel K. Podolsky, M.D.

Compensation Committee
Koh Boon Hwee,
Chairperson
Sue H. Rataj
George A. Scangos, Ph.D.
Tadataka Yamada, M.D.

Nominating/Corporate
Governance Committee
James G. Cullen
Chairperson
Paul N. Clark
Heidi Fields
Robert J. Herbold
Koh Boon Hwee
Daniel K. Podolsky, M.D.
Sue H. Rataj
George A. Scangos, Ph.D.
Tadataka Yamada, M.D.

Executive Committee
James G. Cullen,
Chairperson
Michael R. McMullen

Senior
Executives

Michael R. McMullen*
President and
Chief Executive Officer

Henrik Ancher-Jensen*
Senior Vice President, Agilent
President, Order Fulfillment

Richard A. Burdsall
Senior Vice President,
Chief Infrastructure Officer

Mark Doak*
Senior Vice President, Agilent
President, Agilent CrossLab Group

Rodney Gonsalves*
Vice President, Chief
Accounting Officer

Dominique Grau*
Senior Vice President,
Human Resources

Didier Hirsch*
Senior Vice President and
Chief Financial Officer

Patrick Kaltenbach*
Senior Vice President, Agilent
President, Life Sciences & Applied
Markets

Shiela B. Robertson
Senior Vice President,
Corporate Development
and Strategy

Darlene J.S. Solomon, Ph.D.
Senior Vice President,
Technology Officer and
Research

Michael Tang*
Senior Vice President,
General Counsel and
Secretary

Jacob Thaysen*
Senior Vice President, Agilent
President, Diagnostics & Genomics

Officers

Directors

Guillermo Gualino
Vice President, Treasurer

{Diana Chiu

P.
Vice President, Assistant
General Counsel and
Assistant Secretary

James G. Cullen
Chairman of the Board of
Directors of Agilent,
Retired President and
Chief Operating Officer of
Bell Atlantic Corporation
(now known as Verizon)

Paul N. Clark
Retired Chief Executive
Officer and President of
ICOS Corporation

Heidi Fields
Retired Executive Vice
President and Chief Financial
Officer of Blue Shield
of California

Robert J. Herbold
Retired Executive Vice
President of Microsoft
Corporation

Koh Boon Hwee
Managing Partner of
Credence Capital Fund II
(Cayman) Ltd.

Michael R. McMullen
President and Chief Executive
Officer, Agilent Technologies, Inc.

Daniel K. Podolsky, M.D.
President, University of Texas
Southwestern Medical Center

Sue H. Rataj
Former Chief Executive
BP plc - Petrochemicals

George A. Scangos, Ph.D.
Chief Executive Officer
Biogen Inc.

Tadataka Yamada, M.D.
Venture Partner, Life Sciences
Team and Senior Advisor,
Growth Buyout Team,
for Frazier Healthcare

* These individuals are executive officers of Agilent under Section 16 of the Securities Exchange Act of 1934.

Agilent’s annual meeting of stockholders will take place on Wednesday, March 16, 2016 at 8:00 a.m. at

Agilent’s headquarters located at 5301 Stevens Creek Boulevard, Building No. 5, Santa Clara, California.

Investor Information

Please see the full and audited financial statements and footnotes contained in this booklet. To receive paper
copies of the annual report, proxy statement, Form 10-K, earnings announcements and other financial information,
people in the United States and Canada should call our toll-free number: (877) 942-4200. In addition, you can access
this financial information at Agilent’s Investor Relations Web site. The address is http://www.investor.agilent.com.
This information is also available by writing to the address provided under the Investor Contact heading below.

Corporate Governance, Business Conduct and Ethics

Agilent’s Amended and Restated Corporate Governance Standards, the charters of our Audit and Finance
Committee, our Compensation Committee, our Executive Committee and our Nominating/Corporate Governance
Committee, as well as our Standards of Business Conduct (including code of ethics provisions that apply to our
principal executive officer, principal financial officer, principal accounting officer and senior financial officers) are
available on our website at www.investor.agilent.com under “Corporate Governance”. These items are also available
in print to any stockholder in the United States and Canada who requests them by calling (877) 942-4200. This
information is also available by writing to the company at the address provided below.

Agilent Headquarters

Agilent Technologies, Inc.
5301 Stevens Creek Boulevard
Santa Clara, CA 95051
Phone: (408) 345-8886

Transfer Agent and Registrar

Please contact our transfer agent, at the phone number or address listed below, with any questions about stock

certificates, transfer of ownership or other matters pertaining to your stock account.

Computershare Investor Services
250 Royall Street
Canton, MA 02021
United States

If calling from the United States or Canada: (877) 309-9856.

If calling from outside the United States and Canada: (312) 588-4672.

The e-mail address for general shareholder inquiries for Computershare is: www.computershare.com/contactus.

Investor Contact

Agilent Technologies, Inc.
Investor Relations Department
5301 Stevens Creek Boulevard
Santa Clara, CA 95051

You can also contact the Investor Relations Department via e-mail at the Agilent Investor Relations Web site at
http://www.investor.agilent.com. Click “Information Request” under the “Investor Information” tab to send a
message.

ANNUAL REPORTAnnual Report

Common Stock

Our common stock is listed on the New York Stock Exchange with the ticker symbol “A”. The following table
sets forth the high and low sale prices and the dividend declarations per quarter for the 2014 and 2015 fiscal years as
reported in the consolidated transaction reporting system for the New York Stock Exchange:

t
r
o
p
e
R

l
a
u
n
n
A

Fiscal 2014 (1)
First Quarter (ended January 31, 2014)
Second Quarter (ended April 30, 2014)
Third Quarter (ended July 31, 2014)
Fourth Quarter (ended October 31, 2014)

Fiscal 2015
First Quarter (ended January 31, 2015)
Second Quarter (ended April 30, 2015)
Third Quarter (ended July 31, 2015)
Fourth Quarter (ended October 31, 2015)

High

Low

$ 61.22 $ 49.84
$ 60.46 $ 51.96
$ 59.58 $ 53.66
$ 59.40 $ 49.80

High

Low

$ 42.99 $ 37.68
$ 43.59 $ 37.71
$ 42.93 $ 38.48
$ 41.35 $ 33.12

Dividends
$0.132
$0.132
$0.132
$0.132

Dividends
$0.10
$0.10
$0.10
$0.10

(1) The stock prices in the above table on or prior to November 1, 2014, the date of Keysight separation, have

not been adjusted for the distribution.

As of December 1, 2015, there were 26,412 common stockholders of record.

During fiscal 2015, we issued four quarterly dividends of $0.10 per share. All decisions regarding the declaration

and payment of dividends are at the discretion of our Board of Directors and will be evaluated regularly in light of
our financial condition, earnings, growth prospects, funding requirements, applicable law, and any other factors that
our Board deems relevant. The information required by this item with respect to equity compensation plans is
included under the caption Equity Compensation Plans in our proxy statement for the annual meeting of stockholders
to be held March 16, 2016, to be filed with the Securities and Exchange Commission pursuant to Regulation 14A,
and is incorporated herein by reference.

On November 1, 2014, we completed the distribution of the issued and outstanding common stock of Keysight to
our shareholders. Agilent shareholders of records as of the close of business on October 22, 2014, the record date for
the distribution, received one share of Keysight common stock for every two shares of Agilent common stock held as
of the record date. Agilent shareholders received cash in lieu of any fractional shares of Keysight common stock.

STOCK PRICE PERFORMANCE GRAPH

The graph below shows the cumulative total stockholder return on our common stock with the cumulative total
return of the S&P 500 Index; our Current Peer Group Index (a) and our Old Peer Group Index (b) assuming an initial
investment of $100 on October 31, 2010 and the reinvestment of all dividends. As a result of the spin-off of our
electronic measurement business (c), we reassessed our peer group. We have determined that the companies included
in the S&P 500 Information Technology Index more closely match our company characteristics than the companies
included in the S&P Materials Index, which was previously included in the Old Peer Group Index.

Agilent’s stock price performance shown in the following graph is not indicative of future stock price

performance. The data for this performance graph was compiled for us by Standard and Poor’s.

Comparison of 5 Years (10/31/2010 to 10/31/2015) Cumulative Total Return
Among Agilent Technologies, the S&P 500 Index, the New Peer Group Index and the Old Peer Group Index

$250

$200

$150

$100

$50

Agilent Technologies

S&P 500

New Peer Group

Old Peer Group

Company Name / Index
Agilent Technologies
S&P 500
New Peer Group
Old Peer Group

Base
Period
10/31/10
100
100
100
100

INDEXED RETURNS
Years Ending

10/31/11
106.52
108.09
107.74
109.05

10/31/12
104.19
124.52
127.04
125.55

10/31/13
148.49
158.36
171.16
161.97

10/31/14
163.23
185.71
207.06
200.69

10/31/15
154.90
195.37
215.35
216.93

(a) Our Current Peer Group Index includes all companies in the S&P Healthcare Sector, S&P Technology

Sector and S&P Industrial Sector.

(b) Our Old Peer Group Index included all companies in the S&P Healthcare Sector, S&P Materials Sector and

S&P Industrial Sector.

independent publicly traded company called Keysight Technologies, Inc. The cumulative returns of our
common stock have been adjusted to reflect the spin-off.

ANNUAL REPORTAnnual Report
t
r
o
p
e
R

l
a
u
n
n
A

Additional Information

This annual report, including the letter titled “To our shareholders,” contains forward-looking statements
including, without limitation, statements regarding trends, seasonality and growth in, and drivers of, the markets we
sell into, our strategic direction, our future effective tax rate and tax valuation allowance, earnings from our foreign
subsidiaries, lease and site service income from Keysight, the impact of foreign currency movements on our
performance, remediation activities, indemnification, new product and service introductions, the ability of our
products to meet market needs, adoption of our products, changes to our manufacturing processes, the use of contract
manufacturers and out sourcing, source and supply of materials used in our products, the impact of local government
regulations on our ability to pay vendors or conduct operations, our liquidity position, our ability to generate cash
from operations, growth in our businesses, our investments, the potential impact of adopting new accounting
pronouncements, our financial results, our operating margin, our sales, our purchase commitments, our capital
expenditures, our contributions to our pension plans, our strategic initiatives, our cost-control activities, timing of
completion of our restructuring programs, timing of savings and headcount reduction recognized from our
restructuring programs and other cost saving initiatives, continuation of service support to the NMR installed base,
uncertainties relating to Food and Drug Administration ("FDA") and other regulatory approvals, the integration of
our acquisitions and other transactions, impairment of goodwill and other intangible assets, remediation of our
material weakness, our stock repurchase program, our declared dividends, our transition to lower-cost regions, and
the existence of economic instability, that involve risks and uncertainties. Our actual results could differ materially
from the results contemplated by these forward-looking statements due to various factors, including those detailed in
Agilent’s filings with the Securities and Exchange Commission, including our Annual Report on Form 10-K for the
year ended October 31, 2015.

The materials contained in this annual report are as of December 18, 2015, unless otherwise noted. The content
of this annual report contains time-sensitive information that is accurate only as of this date. If any portion of this
annual report is redistributed at a later date, Agilent will not be reviewing or updating the material in this report. The
information on page 6 regarding our senior executives, officers and directors is current as of February 4, 2016.

This annual report contains Agilent’s 2015 audited financial statements and notes thereto in the following section
of this booklet with the tab “Annual Report Financials.” Within the Annual Report Financials, please refer to
“Management’s Discussion and Analysis of Financial Condition and Results of Operations” and “Risks,
Uncertainties and Other Factors That May Affect Future Results” for more complete information on each of our
businesses and Agilent as a whole.

AGILENT TECHNOLOGIES, INC.
ANNUAL REPORT TO STOCKHOLDERS
ANNUAL REPORT CONSOLIDATED FINANCIAL STATEMENTS

S
L
A
I
C
N
A
N
I
F

T
R
O
P
E
R
L
A
U
N
N
A

This page is intentionally left blank.TABLE OF CONTENTS

Selected Financial Data ...................................................................................................................................
Management’s Discussion and Analysis of Financial Condition and Results of Operations ............................
Quantitative and Qualitative Disclosures About Market Risk ..........................................................................
.............................................................................
Report of Independent Registered Public Accounting Firm
.......
Consolidated Statement of Operations for each of the three years in the period ended October 31, 2015
Consolidated Statement of Comprehensive Income for the three years in the period ended October 31, 2015
Consolidated Balance Sheet at October 31, 201 5 and 2014
..............................................................................
Consolidated Statement of Cash Flows for each of the three years in the period ended October 31, 2015
......
Consolidated Statement of Equity for each of the three years in the period ended October 31, 2015
..............
.....................................................................................................
Notes to Consolidated Financial Statements
Quarterly Summary (unaudited)
........................................................................................................................
Risks, Uncertainties and Other Factors That May Affect Future Results ........................................................
Controls and Procedures ...................................................................................................................................

.......
.......
.......
.......
.......
.......
.......
.......
.......
.......
.......
.......
.......

Page
1
2
23
24
25
26
27
28
29
30
87
88
100

s
s
l
l
a
a
i
i
c
c
n
n
a
a
n
n
i
i
F
F

t
t
r
r
o
o
p
p
e
e
R
R

l
l
a
a
u
u
n
n
n
n
A
A

This page is intentionally left blank.SELECTED FINANCIAL DATA
(Unaudited)

Years Ended October 31,

Consolidated Statement of Operations Data (3):
Net revenue
Income from continuing operations before taxes
Income from continuing operations
Income (loss) from discontinued operations, net of taxes

Net income
Net income per share — basic:
Income from continuing operations
Income (loss) from discontinued operations, net of taxes

Net income per share - basic
Net income per share — diluted:
Income from continuing operations
Income (loss) from discontinued operations, net of taxes

Net income per share - diluted
Weighted average shares used in computing basic net
income per share
Weighted average shares used in computing diluted net
income per share
Cash dividends declared per common share

Consolidated Balance Sheet Data (3):
Cash and cash equivalents and short-term investments
Working capital
Total assets
Long-term debt
Stockholders' equity

$
$
$
$
$

2015

2014 (As
Revised)

2013 (As
Revised)
(in millions, except per share data)
(1)

2012 (As
Revised)

$
$
$
$

4,038 $
480 $
438 $
(37) $

4,048 $
229 $
232 $
317 $

401 $

549 $

1.32 $
(0.12)

1.20 $

1.31 $
(0.11)

1.20 $

333

335

0.70 $
0.95

1.65 $

0.69 $
0.93

1.62 $

333

338

0.400 $

0.528

3,894 $
293 $
225 $
509 $
734 $

0.66 $
1.49
2.15 $

0.65 $
1.48
2.13 $

341

345
0.460 $

3,543 $
237 $
353 $
775 $

1,128 $

1.01 $
2.23

3.24 $

1.00 $
2.20

3.20 $

348

353

0.300 $

October 31,

2011 (As
Revised)

3,299
232
252
776

1,028

0.73
2.24

2.97

0.71
2.19

2.90

347

355

—

2015

2014 (As
Revised)

(2)

2,003 $
2,710 $
7,479 $
1,655 $
4,167 $

2,218 $
3,817 $
10,815 $
1,663 $
5,301 $

2013 (As
Revised)
(in millions)
(2)
2,675 $
3,392 $
10,608 $
2,699 $
5,297 $

2012 (As
Revised)

2011 (As
Revised)

(1)(2)

2,351 $
2,775 $
10,439 $
2,112 $
5,183 $

(2)
3,527
3,732
9,049
1,932
4,346

(1) Consolidated financial data includes Dako, acquired on June 21, 2012 and a non-recurring tax benefit relating to the
reversal of U.S. valuation allowance of $280 million.

(2) The above consolidated balance sheet includes Keysight which is presented as a discontinued operation until October
31, 2014. See Note 4, "Discontinued Operations" for additional information.
(3) We made adjustments to correct immaterial misstatements within this selected financial data. For a detailed explanation
of these adjustments, please refer to Note 2, "Revision of Prior Period Financial Statements". These adjustments also
affected years 2012 and 2011. There was a $17 million decrease of income from continuing operations and $8 million
decrease of income from discontinued operations, net of taxes in 2012. In addition, there was a $20 million increase of
income from continuing operations and $4 million decrease of income from discontinued operations, net of taxes in 2011.
Working Capital increased $11 million, $39 million and zero as of October 31, 2013, 2012 and 2011, respectively with total
assets decreasing $78 million, $97 million and $8 million as of October 31, 2013, 2012 and 2011, respectively.
Stockholders’ Equity increased $38 million as of October 31, 2011.

s
l
a
i
c
n
a
n
i
F

t
r
o
p
e
R

l
a
u
n
n
A

MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION
AND RESULTS OF OPERATIONS

The following discussion should be read in conjunction with the consolidated financial statements and notes
thereto included elsewhere in this annual report. This report contains forward-looking statements including, without
limitation, statements regarding trends, seasonality and growth in, and drivers of, the markets we sell into, our
strategic direction, our future effective tax rate and tax valuation allowance, earnings from our foreign subsidiaries,
lease and site service income from Keysight, the impact of foreign currency movements on our performance,
remediation activities, indemnification, new product and service introductions, the ability of our products to meet
market needs, adoption of our products, changes to our manufacturing processes, the use of contract manufacturers
and out sourcing, source and supply of materials used in our products, the impact of local government regulations on
our ability to pay vendors or conduct operations, our liquidity position, our ability to generate cash from operations,
growth in our businesses, our investments, the potential impact of adopting new accounting pronouncements, our
financial results, our operating margin, our sales, our purchase commitments, our capital expenditures, our
contributions to our pension plans, our strategic initiatives, our cost-control activities, timing of completion of our
restructuring programs, timing of savings and headcount reduction recognized from our restructuring programs and
other cost saving initiatives, continuation of service support to the NMR installed base, uncertainties relating to Food
and Drug Administration ("FDA") and other regulatory approvals, the integration of our acquisitions and other
transactions, impairment of goodwill and other intangible assets, remediation of our material weakness, our stock
repurchase program, our declared dividends, our transition to lower-cost regions, and the existence of economic
instability, that involve risks and uncertainties. Our actual results could differ materially from the results
contemplated by these forward-looking statements due to various factors, including those discussed in this annual
report.

Overview and Executive Summary

Agilent Technologies Inc. ("we", "Agilent" or the "company"), incorporated in Delaware in May 1999, is a
global leader in life sciences, diagnostics and applied chemical markets, providing application focused solutions that
includes instruments, software, services and consumables for the entire laboratory workflow.

On November 1, 2014, we completed the distribution of 100% of the outstanding common shares of Keysight
Technologies, Inc. ("Keysight") to Agilent stockholders who received one share of Keysight common stock for every
two shares of Agilent held as of the close of business on the record date, October 22, 2014. The historical results of
operations and the financial position of Keysight are included in the consolidated financial statements of Agilent and
are reported as discontinued operations within this annual report. For additional information see Note 4,
"Discontinued Operations".

The results from operations presented within management's discussion and analysis of financial condition and
results of operations are reported for the continuing operations of Agilent. Income taxes are presented on a revised
basis for prior periods see Note 2, " Revision of Prior Period Financial Statements".

On April 30, 2015 we announced that we have completed an agreement with Rigaku, a privately held scientific
instrumentation company headquartered in Tokyo, to acquire Agilent's X-ray diffraction (XRD) business, a key
manufacturer of single-crystal X-ray instruments for the global chemical crystallography market. The transaction did
not have a material impact to our results of operations, statement of financial position or statement of cash flows in
the current or prior fiscal periods.

On May 19, 2015 we announced that we have completed the acquisition of 100% of the shares of Cartagenia, a
leading provider of software and services for clinical genetics and molecular pathology laboratories for €60 million.
Cartagenia, provides software solutions for variant assessment and reporting of clinical genomics data from next-
generation sequencing and microarrays. The Cartagenia Bench platform enables technicians, laboratory directors and
clinicians to visualize, assess and report clinical genetics data in the context of patient information.

On November 2, 2015 we announced that we have completed the acquisition of Seahorse Bioscience
("Seahorse"), a leader in providing instruments and assay kits for measuring cell metabolism and bioengergetics for
$242 million in cash. Seahorse's technology enables researchers to better understand cell health, function and
signaling, and how the cell may be impacted by the introduction of a specific drug, by providing real-time kinetics to
unlock essential cellular bioenergetics data. The financial results of Seahorse will be included within Agilent's from
the beginning of the first quarter of 2016.

Agilent's net revenue of $4,038 million in 2015 was flat when compared to 2014. Foreign currency movements
for 2015 had an unfavorable impact of approximately 6 percentage points compared to 2014. Agilent's net revenue of
$4,048 million increased 4 percent in 2014 when compared to 2013.

The life sciences and applied markets business brings together Agilent's analytical laboratory instrumentation
and informatics. Revenue decreased 2 percent in 2015 when compared to 2014. Foreign currency movements had an
unfavorable impact of approximately 5 percentage points in 2015 when compared to 2014. In addition, an
unfavorable impact on revenue of approximately 2 percentage point in 2015 was largely due to the NMR business
which we are exiting. For the year ended October 31, 2015 and excluding the impact of currency movements and the
NMR business, our performance within the life sciences business showed consistent revenue growth from sales to the
pharmaceutical and biotechnology market partially offset by a decrease in the revenue generated from sales to the life
sciences research market. Within applied markets and excluding the impact of currency movements and the NMR
business, there was weakness in the chemical and energy markets in the year ended October 31, 2015 when compared
to the prior year. Revenue from sales to the life sciences and applied markets business increased 2 percent in 2014
when compared to 2013. For the year ended October 31, 2014 our performance within the life sciences business
improved with sales to the pharmaceutical and biotechnology market partially offset by a decrease in the revenue
generated from the life sciences research market when compared to the prior year. Within applied markets there was
revenue growth from sales to all markets in the year ended October 31, 2014 when compared to the prior year.

The diagnostics and genomics business is comprised of three areas of activity. First, we are focused on
pathology, companion diagnostics and reagent partnerships. Second, the genomics business includes our arrays, NGS
target enrichment and our other genomics solutions. Third, the nucleic acid solutions business manufactures synthetic
RNA to be potentially used as active pharmaceutical ingredients. Revenue was flat in 2015 when compared to 2014.
Foreign currency movements had an unfavorable impact of approximately 8 percentage points in 2015 when
compared to 2014. Excluding the impact of foreign currency movements, growth in revenue from sales to the
diagnostics and clinical research market was strong in the year ended October 31, 2015 when compared to the prior
year. Revenue increased 5 percent in 2014 when compared to 2013. For the year ended October 31, 2014 our
performance within the diagnostics and genomics business improved from sales to the diagnostics and clinical
markets when compared to the prior year.

The Agilent CrossLab business combines our analytical laboratory services and consumables business. Revenue
increased 2 percent in 2015 when compared to 2014. Foreign currency movements had an unfavorable impact of
approximately 7 percentage points in 2015 when compared to 2014. Excluding the impact of foreign currency
movements there was growth in sales to all key end markets, in particular, the pharmaceutical and biotechnology
market in the year ended October 31, 2015 when compared to last year. Within the applied markets revenue in
chemical and energy end markets were slower but still reported growth when adjusted for currency movements.
Revenue increased 7 percent in 2014 when compared to 2013. Revenue growth from sales to all markets was similar
to that of our life sciences and applied markets business in the year ended October 31, 2014 when compared to last
year.

Net income from continuing operations was $438 million in 2015 compared to net income from continuing
operations of $232 million and $225 million in 2014 and 2013, respectively. As of October 31, 2015 and 2014 we
had cash and cash equivalents balances of $2,003 million and $2,218 million, respectively.

s
l
a
i
c
n
a
n
i
F

t
r
o
p
e
R

l
a
u
n
n
A

million diluted shares. For the years ended October 31, 2015, 2014 and 2013 we repurchased 6 million shares for
$267 million, 4 million shares for $200 million and 20 million shares for $900 million, respectively. All such shares
and related costs are held as treasury stock and accounted for using the cost method. On May 28, 2015 we announced
that our board of directors had approved a new share repurchase program (the "2015 repurchase program"). The 2015
share repurchase program authorizes the purchase of up to $1.14 billion of our common stock through and including
November 1, 2018. The 2015 share repurchase program will commence, at the option of the company, on either
November 1, 2015, or the date on which we complete the purchase of the remaining $98 million for a total of $365
million of common stock in fiscal 2015 under the existing stock repurchase program. Upon commencement, the 2015
share repurchase program replaces our existing stock repurchase program, which authorized the repurchase of shares
to reduce or eliminate share dilution from equity programs. The 2015 repurchase program does not require the
company to acquire a specific number of shares and may be suspended or discontinued at any time.

For the years ended October 31, 2015, 2014 and 2013 cash dividends of $133 million, $176 million and $156
million were paid on the company's outstanding common stock, respectively. On November 19, 2015, we declared a
quarterly dividend of $0.115 per share of common stock, or approximately $38 million which will be paid on January
27, 2016 to shareholders of record as of the close of business on January 5, 2016. The timing and amounts of any
future dividends are subject to determination and approval by our board of directors.

In 2015 we introduced an improvement initiative to transform a number of the company's operations. These

actions produced savings of approximately $40 million in total in 2015.

Looking forward, we expect to focus on organic growth and expand the operating margin of our businesses. In
addition, we anticipate returning a significant proportion of our cash flow to shareholders through our dividend and
share repurchase programs. The unfavorable effects of changes in foreign currency exchange rates has decreased
revenue by approximately 6 percentage points for the year ended October 31, 2015. Costs and expenses, incurred in
local currency, were subject to the favorable effects due to changes in foreign currency exchange rates reducing our
overall net exposure. The impact of foreign currency exchange rates movements can be positive or negative in any
period and is calculated by applying the prior period foreign currency exchange rates to the current year period. We
anticipate that changes in foreign currency exchange rates will continue to have an unfavorable impact on our
performance for the near future.

Critical Accounting Policies and Estimates

The preparation of financial statements in accordance with accounting principles generally accepted in the U.S.
requires management to make estimates and assumptions that affect the amounts reported in our consolidated
financial statements and accompanying notes. Management bases its estimates on historical experience and various
other assumptions believed to be reasonable. Although these estimates are based on management's best knowledge of
current events and actions that may impact the company in the future, actual results may be different from the
estimates. An accounting policy is deemed to be critical if it requires an accounting estimate to be made based on
assumptions about matters that are highly uncertain at the time the estimate is made, and if different estimates that
reasonably could have been used or changes in the accounting estimate that are reasonably likely to occur could
materially change the financial statements. Our critical accounting policies are those that affect our financial
statements materially and involve difficult, subjective or complex judgments by management. Those policies are
inventory valuation, share-based compensation, retirement and post-retirement plan
revenue recognition,
assumptions, valuation of goodwill and purchased intangible assets, restructuring and accounting for income taxes.

Revenue recognition. We enter into agreements to sell products (hardware or software), services, and other
arrangements (multiple element arrangements) that include combinations of products and services. Revenue from
product sales, net of trade discounts and allowances, is recognized provided that persuasive evidence of an
arrangement exists, delivery has occurred, the price is fixed or determinable, and collectability is reasonably assured.
Delivery is considered to have occurred when title and risk of loss have transferred to the customer. Revenue is
reduced for estimated product returns, when appropriate. For sales that include customer-specified acceptance
criteria, revenue is recognized after the acceptance criteria have been met. For products that include installation, if the
installation meets the criteria to be considered a separate element, product revenue is recognized upon delivery, and
recognition of installation revenue occurs when the installation is complete. Otherwise, neither the product nor the
installation revenue is recognized until the installation is complete. Revenue from services is deferred and recognized
over the contractual period or as services are rendered and accepted by the customer. We allocate revenue to each
element in our multiple-element arrangements based upon their relative selling prices. We determine the selling price
for each deliverable based on a selling price hierarchy. The selling price for a deliverable is based on our vendor
specific objective evidence (VSOE) if available, third-party evidence (TPE) if VSOE is not available, or estimated

selling price (ESP) if neither VSOE nor TPE is available. Revenue from the sale of software products that are not
required to deliver the tangible product's essential functionality are accounted for under software revenue recognition
rules. Revenue allocated to each element is then recognized when the basic revenue recognition criteria for that
element have been met. The amount of product revenue recognized is affected by our judgments as to whether an
arrangement includes multiple elements.

We use VSOE of selling price in the selling price allocation in all instances where it exists. VSOE of selling
price for products and services is determined when a substantial majority of the selling prices fall within a reasonable
range when sold separately. TPE of selling price can be established by evaluating largely interchangeable competitor
products or services in standalone sales to similarly situated customers. As our products contain a significant element
of proprietary technology and the solution offered differs substantially from that of competitors, it is difficult to
obtain the reliable standalone competitive pricing necessary to establish TPE. ESP represents the best estimate of the
price at which we would transact a sale if the product or service were sold on a standalone basis. We determine ESP
for a product or service by using historical selling prices which reflect multiple factors including, but not limited to
customer type, geography, market conditions, competitive landscape, gross margin objectives and pricing practices.
The determination of ESP is made through consultation with and approval by management. We may modify or
develop new pricing practices and strategies in the future. As these pricing strategies evolve changes may occur in
ESP. The aforementioned factors may result in a different allocation of revenue to the deliverables in multiple
element arrangements, which may change the pattern and timing of revenue recognition for these elements but will
not change the total revenue recognized for the arrangement.

Inventory valuation. We assess the valuation of our inventory on a periodic basis and make adjustments to the
value for estimated excess and obsolete inventory based upon estimates about future demand and actual usage. Such
estimates are difficult to make under most economic conditions. The excess balance determined by this analysis
becomes the basis for our excess inventory charge. Our excess inventory review process includes analysis of sales
forecasts, managing product rollovers and working with manufacturing to maximize recovery of excess inventory. If
actual market conditions are less favorable than those projected by management, additional write-downs may be
required. If actual market conditions are more favorable than anticipated, inventory previously written down may be
sold to customers, resulting in lower cost of sales and higher income from operations than expected in that period. In
the fourth quarter of 2014, Agilent announced it is exiting the NMR business, and as a result, recorded an excess
inventory charge of $30 million. For the year ended October 31, 2015 additional excess inventory charges were
recorded in respect of the exiting of the NMR business of $4 million.

Share-based compensation. We account for share-based awards in accordance with the authoritative guidance.
Under the authoritative guidance, share-based compensation expense is primarily based on estimated grant date fair
value and is recognized on a straight line basis. The fair value of share-based awards for employee stock option
awards was estimated using the Black-Scholes option pricing model. Shares granted under the Long-Term
Performance Program ("LTPP") were valued using the Monte Carlo simulation model. The estimated fair value of
restricted stock unit awards is determined based on the market price of Agilent's common stock on the date of grant
adjusted for expected dividend yield. The Employee Stock Purchase Plan ("ESPP") allows eligible employees to
purchase shares of our common stock at 85 percent of the fair market value at the purchase date.

Both the Black-Scholes and Monte Carlo simulation fair value models require the use of highly subjective and
complex assumptions, including the option's expected life and the price volatility of the underlying stock. Due to the
separation of Keysight on November 1, 2014, expected volatility for grants of options in 2015 was based on a 5.5
year average historical stock price volatility of a group of our peer companies. We believe our historical volatility
prior to the separation of Keysight is no longer relevant. For the grants of options prior to November 1, 2014, the
expected stock price volatility assumption was determined using the historical volatility of Agilent’s stock options
over the most recent historical period equivalent to the expected life of 5.8 years. A 10 percent increase in our
historical estimated volatility from 28 percent to 38 percent for our most recent employee stock option grant would
generally increase the value of an award and the associated compensation cost by approximately 31 percent if no
other factors were changed.

For the grants awarded under the 2009 stock plan after November 1, 2010, we increased the period available to
retirement eligible employees to exercise their options from three years at retirement date to the full contractual term
of ten years. In developing our estimated life of our employee stock options of 5.8 years for 2013 to 2014, we
considered the historical option exercise behavior of our executive employees who were granted the majority of the
options in the annual grants, which we believe is representative of future behavior. See Note 5, "Share-based
Compensation," to the consolidated financial statements for more information.

s
l
a
i
c
n
a
n
i
F

t
r
o
p
e
R

l
a
u
n
n
A

The assumptions used in calculating the fair value of share-based awards represent our best estimates, but these
estimates involve inherent uncertainties and the application of management judgment. Although we believe the
assumptions and estimates we have made are reasonable and appropriate, changes in assumptions could materially
impact our reported financial results.

Retirement and post-retirement benefit plan assumptions. Retirement and post-retirement benefit plan costs are
a significant cost of doing business. They represent obligations that will ultimately be settled sometime in the future
and therefore are subject to estimation. Pension accounting is intended to reflect the recognition of future benefit
costs over the employees' average expected future service to Agilent based on the terms of the plans and investment
and funding decisions. To estimate the impact of these future payments and our decisions concerning funding of these
obligations, we are required to make assumptions using actuarial concepts within the framework of accounting
principles generally accepted in the U.S. Two critical assumptions are the discount rate and the expected long-term
return on plan assets. Other important assumptions include, expected future salary increases, expected future
increases to benefit payments, expected retirement dates, employee turnover, retiree mortality rates, and portfolio
composition. We evaluate these assumptions at least annually.

The discount rate is used to determine the present value of future benefit payments at the measurement date -
October 31 for both U.S. and non-U.S. plans. For 2014 and 2015, the U.S. discount rates were based on the results of
matching expected plan benefit payments with cash flows from a hypothetically constructed bond portfolio. In 2015,
discount rates for the U.S. Plans remained relatively flat from the previous year. For 2015 and 2014, the discount rate
for non-U.S. plans was generally based on published rates for high quality corporate bonds and in 2015, remained the
same or decreased from the previous year. If we changed our discount rate by 1 percent, the impact would be $5
million on U.S. pension expense and $12 million on non-U.S. pension expense. Lower discount rates increase present
values and subsequent year pension expense; higher discount rates decrease present values and subsequent year
pension expense.

The company uses alternate methods of amortization as allowed by the authoritative guidance which amortizes
the actuarial gains and losses on a consistent basis for the years presented. For U.S. Plans, gains and losses are
amortized over the average future working lifetime. For most Non-U.S. Plans and U.S. Post-Retirement Benefit
Plans, gains and losses are amortized using a separate layer for each year's gains and losses. The expected long-term
return on plan assets is estimated using current and expected asset allocations as well as historical and expected
returns. Plan assets are valued at fair value. If we changed our estimated return on assets by 1 percent, the impact
would be $3 million on U.S. pension expense and $8 million on non-U.S. pension expense. For 2015, actual return on
assets was below expectations which, along with contributions during the year, increased next year’s pension cost as
well as resulting in a degradation of the funded status at year end. The net periodic pension and post-retirement
benefit costs recorded in continuing operations were $26 million in 2015, $15 million in 2014, and $36 million in
2013.

Goodwill and Purchased Intangible Assets. Under the authoritative guidance we have the option to perform a
qualitative assessment to determine whether further impairment testing is necessary. The accounting standard gives
an entity the option to first assess qualitative factors to determine whether performing the two-step test is necessary.
If an entity believes, as a result of its qualitative assessment, that it is more-likely-than-not (i.e. greater than 50%
chance) that the fair value of a reporting unit is less than its carrying amount, the quantitative impairment test will be
required. Otherwise, no further testing will be required.

The guidance includes examples of events and circumstances that might indicate that a reporting unit's fair value
is less than its carrying amount. These include macro-economic conditions such as deterioration in the entity's
operating environment or industry or market considerations; entity-specific events such as increasing costs, declining
financial performance, or loss of key personnel; or other events such as an expectation that a reporting unit will be
sold or a sustained decrease in the stock price on either an absolute basis or relative to peers.

If it is determined, as a result of the qualitative assessment, that it is more-likely-than-not that the fair value of a
reporting unit is less than its carrying amount, the provisions of authoritative guidance require that we perform a two-
step impairment test on goodwill. In the first step, we compare the fair value of each reporting unit to its carrying
value. The second step (if necessary) measures the amount of impairment by applying fair-value-based tests to the
individual assets and liabilities within each reporting unit. As defined in the authoritative guidance, a reporting unit is
an operating segment, or one level below an operating segment. We aggregate components of an operating segment
that have similar economic characteristics into our reporting units.

In fiscal year 2015, we assessed goodwill impairment for our three reporting units which consisted of three
segments: life sciences and applied markets, diagnostics and genomics and Agilent CrossLab. Due to the new
segment structure in November 2014 we performed a quantitative test for goodwill impairment of the three reporting
units, as of September 30, 2015. Based on the results of our testing, the fair value of these reporting units are greater
than their respective carrying values. Each quarter we review the events and circumstances to determine if goodwill
impairment is indicated. There was no impairment of goodwill during the years ended October 31, 2015, 2014 and
2013.

Purchased intangible assets consist primarily of acquired developed technologies, proprietary know-how,
trademarks, and customer relationships and are amortized using the best estimate of the asset's useful life that reflect
the pattern in which the economic benefits are consumed or used up or a straight-line method ranging from 6 months
to 15 years. In-process research and development ("IPR&D") is initially capitalized at fair value as an intangible asset
with an indefinite life and assessed for impairment thereafter. When the IPR&D project is complete, it is reclassified
as an amortizable purchased intangible asset and is amortized over its estimated useful life. If an IPR&D project is
abandoned, Agilent will record a charge for the value of the related intangible asset to Agilent's condensed
consolidated statement of operations in the period it is abandoned.

Agilent's indefinite-lived intangible assets are IPR&D intangible assets. The accounting guidance allows a
qualitative approach for testing indefinite-lived intangible assets for impairment, similar to the issued impairment
testing guidance for goodwill and allows the option to first assess qualitative factors (events and circumstances) that
could have affected the significant inputs used in determining the fair value of the indefinite-lived intangible asset to
determine whether it is more-likely-than-not (i.e. greater than 50% chance) that the indefinite-lived intangible asset is
impaired. An organization may choose to bypass the qualitative assessment for any indefinite-lived intangible asset
in any period and proceed directly to calculating its fair value. We performed a qualitative test for impairment of
indefinite-lived intangible assets as of September 30, 2015. Based on the results of our qualitative testing, we believe
that it is more-likely-than-not that the fair value of these indefinite-lived intangible assets is greater than their
respective carrying values. Each quarter we review the events and circumstances to determine if impairment of
indefinite-lived intangible asset is indicated. In the years ended October 31, 2015, 2014 and 2013, we recorded an
impairment of $3 million, $4 million and zero, respectively due to the cancellation of certain IPR&D projects. In
addition, in the year ended October 31, 2014, we also recorded $12 million of impairment of other intangibles due to
the exit of our NMR business.

Restructuring and exit of NMR business. During the fourth quarter of fiscal year 2014, we made the decision to
cease the manufacture and sale of our nuclear magnetic resonance (“NMR”) product line within our life sciences and
applied markets segment.

The main components of expenses are related to workforce reductions, assets impairments and write-downs and
special charges to inventory, which mainly relates to exiting of one of our businesses. Workforce reduction charges
are accrued when payment of benefits that the employees are entitled to becomes probable and the amounts can be
estimated. We have also assessed the recoverability of our long-lived assets, by determining whether the carrying
value of such assets will be recovered through undiscounted future cash flows. Asset impairments primarily consist
of property, plant and equipment and are based on an estimate of the amounts and timing of future cash flows related
to the expected future remaining use and ultimate sale or disposal of buildings and equipment net of costs to sell. The
charges related to inventory include estimated future inventory disposal payments that we are contractually obliged to
make to our suppliers and inventory written-down to net realizable value. If the amounts and timing of cash flows
from restructuring activities are significantly different from what we have estimated, the actual amount of
restructuring and asset impairment charges could be materially different, either higher or lower, than those we have
recorded.

Accounting for income taxes. We must make certain estimates and judgments in determining income tax
expense for financial statement purposes. These estimates and judgments occur in the calculation of tax credits,
benefits and deductions, and in the calculation of certain tax assets and liabilities which arise from differences in the
timing of recognition of revenue and expense for tax and financial statement purposes, as well as interest and
penalties related to uncertain tax positions. Significant changes to these estimates may result in an increase or
decrease to our tax provision in a subsequent period.

s
l
a
i
c
n
a
n
i
F

t
r
o
p
e
R

l
a
u
n
n
A

Significant management judgment is also required in determining whether deferred tax assets will be realized in
full or in part. When it is more-likely-than-not that all or some portion of specific deferred tax assets such as net
operating losses or foreign tax credit carryforwards will not be realized, a valuation allowance must be established for
the amount of the deferred tax assets that cannot be realized. We consider all available positive and negative evidence
on a jurisdiction-by-jurisdiction basis when assessing whether it is more likely than not that deferred tax assets are
recoverable. We consider evidence such as our past operating results, the existence of losses in recent years and our
forecast of future taxable income. In the fourth quarter of fiscal 2012 we released the valuation allowance for the
majority of our U.S. deferred tax assets. At October 31, 2015, we continue to recognize a valuation allowance for
certain U.S. state and foreign deferred tax assets. We intend to maintain a valuation allowance in these jurisdictions
until sufficient positive evidence exists to support its reversal.

We have not provided for all U.S. federal income and foreign withholding taxes on the undistributed earnings of
some of our foreign subsidiaries because we intend to reinvest such earnings indefinitely. Should we decide to remit
this income to the U.S. in a future period, our provision for income taxes will increase materially in that period.

The calculation of our tax liabilities involves dealing with uncertainties in the application of complex tax law and
regulations in a multitude of jurisdictions. Although the guidance on the accounting for uncertainty in income taxes
prescribes the use of a recognition and measurement model, the determination of whether an uncertain tax position
has met those thresholds will continue to require significant judgment by management. In accordance with the
guidance on the accounting for uncertainty in income taxes, for all U.S. and other tax jurisdictions, we recognize
potential liabilities for anticipated tax audit issues based on our estimate of whether, and the extent to which,
additional taxes and interest will be due. The ultimate resolution of tax uncertainties may differ from what is
currently estimated, which could result in a material impact on income tax expense. If our estimate of income tax
liabilities proves to be less than the ultimate assessment, a further charge to expense would be required. If events
occur and the payment of these amounts ultimately proves to be unnecessary, the reversal of the liabilities would
result in tax benefits being recognized in the period when we determine the liabilities are no longer necessary. We
include interest and penalties related to unrecognized tax benefits within the provision for income taxes on the
consolidated statements of operations.

As a part of our accounting for business combinations, intangible assets are recognized at fair values and
goodwill is measured as the excess of consideration transferred over the net estimated fair values of assets acquired.
Impairment charges associated with goodwill are generally not tax deductible and will result in an increased effective
income tax rate in the period that any impairment is recorded. Amortization expenses associated with acquired
intangible assets are generally not tax deductible and therefore deferred tax liabilities have been recorded for non-
deductible amortization expenses as a part of the accounting for business combinations.

Adoption of New Pronouncements

See Note 3, "New Accounting Pronouncements," to the consolidated financial statements for a description of

new accounting pronouncements.

Exit of NMR Business

During the fourth quarter of fiscal year 2014, we made the decision to cease the manufacture and sale of our
nuclear magnetic resonance (“NMR”) product line within our life sciences and applied markets segment. The exit of
the NMR business was primarily due to the lack of growth and profitability of the product line. These actions
involved severance and other personnel costs related to the workforce reduction of approximately 300 employees
primarily located in the United Kingdom and California and non-cash charges related to intangible asset impairments
and other asset write-downs including inventory. After including employee reductions due to attrition and the
application to open positions and acceptance of employment within the company of some employees previously
affected, we have approximately 30 employees that are pending termination under the above actions as of October 31,
2015. We expect to complete these restructuring activities by early fiscal 2016. For the year ended October 31,
2015, the exit of the NMR business has positively impacted our operating profit by $15 million. As of October 31,
2015, approximately $15 million was paid to date under these restructuring activities. We will continue to provide
service support to the NMR installed base.

Foreign Currency

Our revenues, costs and expenses, and monetary assets and liabilities are exposed to changes in foreign currency
exchange rates as a result of our global operating and financing activities. The unfavorable effects of changes in
foreign currency exchange rates has decreased revenue by approximately 6 percentage points for the year ended
October 31, 2015. Costs and expenses, incurred in local currency, were subject to the favorable effects due to
changes in foreign currency exchange rates for the year ended October 31, 2015, reducing our overall net exposure.
The impact of foreign currency exchange rates movements can be positive or negative in any period and is calculated
by applying the prior period foreign currency exchange rates to the current year period. We hedge revenues, expenses
and balance sheet exposures that are not denominated in the functional currencies of our subsidiaries on a short term
and anticipated basis. We do experience some fluctuations within individual lines of the condensed consolidated
statement of operations and balance sheet because our hedging program is not designed to offset the currency
movements in each category of revenues, expenses, monetary assets and liabilities. Our hedging program is designed
to hedge currency movements on a relatively short-term basis (up to a rolling twelve month period). Therefore, we
are exposed to currency fluctuations over the longer term. To the extent that we are required to pay for all, or
portions, of an acquisition price in foreign currencies, Agilent may enter into foreign exchange contracts to reduce the
risk that currency movements will impact the U.S. dollar cost of the transaction.

Results from Operations

Net Revenue

Net revenue:
Products
Services and other

Total net revenue

% of total net revenue:

Products
Services and other
Total

Years Ended October 31,

2015

2014

(in millions)

2013

2015 over 2014
% Change

2014 over 2013
% Change

$
$
$

3,146
892
4,038

$
$
$

3,185 $
863 $
4,048 $

3,083
811

3,894

(1)%
4%
—

3%
6%
4%

Years Ended October 31,

2015

2014

2013

2015 over 2014
Ppts Change

2014 over 2013
Ppts Change

78 %
22 %
100 %

79 %
21 %
100 %

(1) ppt
1 ppt

—
—

s
l
a
i
c
n
a
n
i
F

t
r
o
p
e
R

l
a
u
n
n
A

Services and other revenue includes revenue generated from servicing our installed base of products, warranty
extensions and consulting including companion diagnostics. Services and other revenue increased 4 percent in 2015
as compared to 2014. The service and other revenue growth is impacted by a portion of the revenue being driven by
the current and previously installed product base. Service and other revenue increased due to increased service
contract renewals, laboratory productivity services and strong companion diagnostics revenue. Services and other
revenue increased 6 percent in 2014 as compared to 2013.

Costs and Expenses

Gross margin on products
Gross margin on services and other
Total gross margin
Operating margin

(in millions)

Years Ended October 31,

2015

2014

2013

2015 over 2014
Change

2014 over 2013
Change

52.5%
43.8%
50.5%
12.9%

50.8%
41.6%
48.8%
10.4%

50.6%
43.0%
49.0%
9.9%

2 ppts
2 ppts
2 ppts
3 ppts

—
(1) ppt
—
1 ppt

6%
1%

Research and development
Selling, general and administrative

$
$

330 $
1,189 $

358 $
1,199 $

337
1,184

(8)%
(1)%

Total gross margins for the year ended October 31, 2015 increased 2 percentage points when compared to last
year. Increases in total gross margins for the year ended October 31, 2015 were the result of lower intangible asset
amortization, favorable product mix and improved manufacturing efficiencies partially offset by the impact of
unfavorable currency movements and wage increases. Total gross margins for the year ended October 31, 2014 were
flat when compared to prior year. Total gross margins for the year ended October 31, 2014 were impacted by
favorable product mix offset by higher regulatory costs to address an FDA warning letter, which is now lifted and
wage increases.

Total operating margins increased 3 percentage points for the year ended October 31, 2015, when compared to
last year. Operating margins improved due to increased gross margins and reduced expenses on lower revenue
compared to last year. Total operating margins increased 1 percentage point for the year ended October 31, 2014,
when compared to last year. In 2014 there were higher costs as a result of the exit from the NMR business together
with some pre separation expenses associated with the separation of Keysight.

Gross inventory charges, included in continuing operations, were $30 million in 2015, $46 million in 2014 and
$27 million in 2013. Sales of previously written down inventory, included in continuing operations, were $13 million
in 2015, $8 million in 2014 and $6 million in 2013.

Our research and development efforts focus on potential new products and product improvements covering a
wide variety of technologies, none of which is individually significant to our operations. We conduct three types of
research and development: basic research, foundation technologies and life sciences. Our research seeks to improve
on various technical competencies in software, systems and solutions, life sciences and diagnostics. In each of these
research fields, we conduct research that is focused on specific product development for release in the short-term as
well as other research that is intended to be the foundation for future products over a longer time-horizon. Some of
our product development research is designed to improve products already in production, focus on major new product
releases, and develop new product segments for the future. Due to the breadth of research and development projects
across all of our businesses, there are a number of drivers of this expense. We remain committed to invest
significantly in research and development and have focused our development efforts on key strategic opportunities to
align our business with available markets and position ourselves to capture market share.

Research and development expenses decreased 8 percent for the year ended October 31, 2015 when compared
with last year. R&D expenditure decreased due to the impact of foreign currency movements, savings from the exit
from the NMR business and transformation initiatives, offset by wage increases. Research and development expenses
increased 6 percent for the year ended October 31, 2014 when compared with last year. R&D expenditure increased
due to continued investment in next generation products and expanding our product portfolios.

Selling, general and administrative expenses decreased 1 percent in 2015 compared to 2014. There were
increases in expenditure mostly due to the impact of wage increases, higher commissions and costs associated with
business improvement and transformation initiatives more than offset by favorable foreign currency movements and
the decline in NMR expenses due to the exiting of that business together with a decrease in pre separation expenses
related to the separation of Keysight. Selling, general and administrative expenses increased 1 percent in 2014
compared to 2013. Selling, general and administrative expenditure increased mostly due to the impact of wage
increases and higher commissions.

Interest expense for the years ended October 31, 2015, 2014 and 2013 was $66 million, $110 million and $107
million, respectively, and relates to the interest charged on our senior notes offset by the amortization of deferred
gains recorded upon termination of interest rate swap contracts. The decrease in interest expense in 2015 compared
with 2014 and 2013 is due to debt redemptions as part of the debt repositioning as a result of the separation of the
Keysight business.

At October 31, 2015, our headcount was approximately 11,800 compared to 11,900 in 2014.

Other income (expense), net

For the year ended October 31, 2015 other income (expense), net includes $25 million of income in respect of
the provision of certain IT and site service costs to, and lease income from, Keysight. The costs associated with these
services are reported within income from operations. Agilent expects to receive lease income and site service income
from Keysight over the next 4-5 years of approximately $13 million per year. For the year ended October 31, 2014
other income (expense) net, included a net loss on the early redemption of senior notes of $89 million.

Income Taxes

Years Ended October 31,

2015

2014

2013

(in millions)

Provision (benefit) for income taxes

42 $

(3) $

For 2015, the company’s effective tax rate from continuing operations was 8.7 percent. The income tax expense
from continuing operations was $42 million. The income tax provision from continuing operations for the year ended
October 31, 2015 included net discrete tax benefits of $55 million. The net discrete tax benefit for the year ended
October 31, 2015 included $32 million of net tax benefit primarily due to the settlement of an Internal Revenue
Service (“IRS) audit in the U.S. and the recognition of tax expense related to the repatriation of dividends to the U.S.
The remaining $23 million net tax benefit for the year ended October 31, 2015 included $16 million of tax benefit
related to the de-registration of certain foreign branches and statutue of limitations lapses, $6 million of tax benefit
for the extension of the U.S. research and development tax credit attributable to the company's prior fiscal year and
$1 million of other discrete benefits.

s
l
a
i
c
n
a
n
i
F

t
r
o
p
e
R

l
a
u
n
n
A

For 2014, the company's effective tax rate from continuing operations was (1.3) percent. The income tax benefit
from continuing operations was $3 million. The income tax benefit for the year ended October 31, 2014 included a
net discrete benefit of $33 million primarily due to the settlement of an Internal Revenue Service ("IRS") audit in the
U.S. and the recognition of tax expense related to the repatriation of dividends.

For 2013, the effective tax rate from continuing operations was 23.4 percent. The 23.4 percent effective tax rate
is lower than the U.S. statutory rate primarily due to the mix of earnings in non-U.S. jurisdictions taxed at lower
statutory rates; in particular Singapore where we enjoy tax holidays.

Agilent enjoys tax holidays in several different jurisdictions, most significantly in Singapore. The tax holidays
provide lower rates of taxation on certain classes of income and require various thresholds of investments and
employment or specific types of income in those jurisdictions. The tax holidays are due for renewal between 2016
and 2023. As a result of the incentives, the impact of the tax holidays decreased income taxes by $65 million, $27
million, and $44 million in 2015, 2014, and 2013, respectively. The benefit of the tax holidays on net income per
share (diluted) was approximately $0.19, $0.08, and $0.13 in 2015, 2014 and 2013, respectively.

In accordance with the guidance on the accounting for uncertainty in income taxes, for all U.S. and other tax
jurisdictions, we recognize potential liabilities for anticipated tax audit issues based on our estimate of whether, and
the extent to which, additional taxes and interest will be due. If our estimate of income tax liabilities proves to be less
than the ultimate assessment, a further charge to expense would be required. If events occur and the payment of these
amounts ultimately proves to be unnecessary, the reversal of the liabilities would result in tax benefits being
recognized in the period when we determine the liabilities are no longer necessary. We include interest and penalties
related to unrecognized tax benefits within the provision for income taxes on the consolidated statements of
operations.

On November 1, 2014, Agilent transferred deferred tax assets of $237 million, deferred tax liabilities of $37
million, current income tax payable of $40 million, and other long-term liabilities related to uncertain tax positions
totaling $8 million to Keysight as part of its separation from Agilent. A current prepaid income tax asset of $19
million and long-term prepaid income tax asset of $3 million related to sales of intercompany assets was also
transferred to Keysight upon separation from Agilent. In addition, for the year ended October 31, 2015, a $6 million
return to provision adjustment for Keysight associated with bonus depreciation was recognized through retained
earnings.

In the U.S., tax years remain open back to the year 2012 for federal income tax purposes and the year 2000 for
significant states. On September 22, 2015, we reached an agreement with the IRS for the tax years 2008 through
2011. We expect to make a payment of approximately $9 million as part of closing the exam. As a result, in 2015
we reclassified a portion of other long-term liabilities to other accrued liabilities related to uncertain tax positions of
continuing operations that we expect to pay within the next twelve months. This amount is partially offset by a
prepaid tax account of approximately $3 million that the IRS is allowing as an offset to the $12 million in incremental
taxes. The settlement resulted in the recognition, within the continuing operations, of previously unrecognized tax
benefits of $119 million, offset by a tax liability on foreign distributions of approximately $99 million principally
related to the repatriation of foreign earnings.

On January 29, 2014, we reached an agreement with the IRS for the tax years 2006 through 2007. The settlement
resulted in the recognition, within the continuing operations, of previously unrecognized tax benefits of $111 million,
offset by a tax liability on foreign distributions of approximately $75 million principally related to the repatriation of
foreign earnings.

In other major jurisdictions where the company conducts business, the tax years generally remain open back to
the year 2003. With these jurisdictions and the U.S., it is reasonably possible that there could be significant changes
to our unrecognized tax benefits in the next twelve months due to either the expiration of a statute of limitation or a
tax audit settlement which will be partially offset by an anticipated tax liability related to unremitted foreign earnings,
where applicable. Given the number of years and numerous matters that remain subject to examination in various tax
jurisdictions, management is unable to estimate the range of possible changes to the balance of our unrecognized tax
benefits.

On July 27, 2015, the U.S. Tax Court issued an opinion in Altera Corp. v. Commissioner related to the treatment
of stock-based compensation expense in an intercompany cost-sharing arrangement. A final decision was entered by
the U.S. Tax Court on December 1, 2015. At this time, the U.S. Department of the Treasury has not withdrawn the
requirement from its regulations to include stock-based compensation. The I.R.S. has the right to appeal the U.S. Tax
Court decision. We concluded that no adjustment to our consolidated financial statements is appropriate at this time
due to the uncertainties with respect to the ultimate resolution of this case.

Segment Overview

Life Sciences and Applied Markets

Our life sciences and applied markets business provides application-focused solutions that include instruments
and software that enable customers to identify, quantify and analyze the physical and biological properties of
substances and products, as well as enable customers in the clinical and life sciences research areas to interrogate
samples at the molecular level. Key product categories include: liquid chromatography ("LC") systems and
components; liquid chromatography mass spectrometry ("LCMS") systems; gas chromatography ("GC") systems and
components; gas chromatography mass spectrometry ("GCMS") systems; inductively coupled plasma mass
spectrometry ("ICP-MS") instruments; atomic absorption ("AA") instruments; microwave plasma-atomic emission
spectrometry (“MP-AES”) instruments; inductively coupled plasma optical emission spectrometry ("ICP-OES")
instruments; laboratory software and informatics systems; laboratory automation and robotic systems; dissolution
testing; vacuum pumps and measurement technologies.

Net Revenue

Years Ended October 31,

2015

2014

2013

2015 over 2014
Change

2014 over 2013
Change

(in millions)

Net revenue

2,046 $

2,078 $

2,035

(2)%

Life science and applied markets business revenue in 2015 decreased 2 percent compared to 2014. Foreign
currency movements for 2015 had an unfavorable impact of 5 percentage points on revenue growth when compared
to the same period last year. Geographically, revenue grew 4 percent in the Americas with a 3 percentage point
unfavorable currency impact, grew 2 percent in Asia Pacific excluding Japan with a 1 percentage point unfavorable
currency impact, declined 8 percent in Europe with a 10 percentage point unfavorable currency impact and declined
20 percent in Japan with a 13 percentage point unfavorable currency impact. Double digit revenue growth in the
pharmaceutical market helped drive the revenue growth in the Americas, but was partially offset by declines in the
life science and research market due to reductions in academia and government spending. In Europe, our
pharmaceutical market revenue growth was not enough to offset declines in revenue from our life science and
research market and softness in applied markets. Product revenue results were led by solid demand across the entire
product folio, offset by decline in NMR revenue reducing overall growth by 2 percentage points. Life science and
applied markets business revenue in 2014 increased 2 percent compared to 2013. Product revenue results in 2014
were led by growth in GCMS and spectroscopy, and partially offset by declines in LCMS and NMR.

End market performance reflected mixed growth across markets in 2015. Our pharmaceutical and biotechnology
market revenue growth was strong, and driven by technology refreshes. Larger pharmaceutical companies, continue
to upgrade to the latest technologies and help drive revenue growth in this market. In life science research, reduced
budgets and delayed spending on capital equipment from government entities, led to a decline in revenue in this
market segment. Applied market revenue growth was weaker primarily due to the revenue from the chemical and
energy market where lower oil prices have reduced capital spending. Excluding currency movements and the NMR
business, environmental decreased when compared to last year as weakness in the US oil and gas markets is now

s
l
a
i
c
n
a
n
i
F

t
r
o
p
e
R

l
a
u
n
n
A

spreading to related environmental testing markets. Sales to the food market were down slightly when compared to
last year excluding currency movements and the NMR business. Revenue growth in 2014 was led by strong
pharmaceutical sales and moderate revenue growth in applied markets, partially offset by a reduction in revenue from
the life science and research markets compared to the prior year.

Looking forward we are optimistic about continued growth from pharmaceutical sales and the technology
replacement business from our strong portfolio offering. While low spending levels in life science research and
reduced chemical and energy spending continue to be a concern, we continue to see opportunities for customers
buying replacement instruments and we will keep strengthening our product and technology portfolio accordingly.

Gross Margin and Operating Margin

The following table shows the life sciences and applied markets business' margins, expenses and income from

operations for 2015 versus 2014, and 2014 versus 2013.

Total gross margin
Operating margin

(in millions)

Years Ended October 31,

2015

2014

2013

2015 over 2014
Change

2014 over 2013
Change

56.2%
18.6%

55.8%
17.7%

53.9%
16.6%

—
1 ppt

2 ppts
1 ppt

Research and development
Selling, general and administrative
Income from operations

$
$
$

192 $
576 $
380 $

215 $
576 $
369 $

207
551
338

(10)%
—
3%

4%
4%
9%

Gross margins were flat in 2015 compared to 2014. The effects of product mix in 2015 had a negligible affect on
gross margins relative to 2014. Increases for wages and materials were largely offset by improvement in operational
efficiencies. Gross margins in 2014 increased by 2 percentage points compared to 2013. Improvement in all major
product groups contributed to the year on year gain due partly to increased sales volume and improved operational
efficiency. Product mix also had a favorable impact on gross margins.

Research and development expenses decreased 10 percent in 2015 when compared to 2014. Excluding NMR,
research and development expenses were down 4 percent from the prior year impacted by our transformation
initiatives. Research and development expenses increased 4 percent in 2014 compared to 2013. Investments in
software and higher infrastructure costs contributed to the increase.

Selling, general and administrative expenses were flat in 2015 compared to 2014. Excluding NMR, selling,
general and administrative expenses grew 3 percent primarily due to dis-synergies in infrastructure costs from the
separation of Keysight. Selling, general and administrative expenses increased 4 percent in 2014 compared to 2013.
The 2014 increase was primarily related to increased commissions and infrastructure costs.

Operating margins increased by 1 percentage point in 2015 compared to 2014. Expenses declined more than
revenue to help with the improvement. Our NMR business, which we made a decision to exit at the end of 2014, had
an unfavorable impact on operating margin for fiscal year 2015 as we continued to ship off backlog in winding down
the operation. Operating margins increased by 1 percentage point in 2014 compared to 2013, due to slightly higher
revenue and improved gross margins.

Income from Operations

Income from operations in 2015 increased by $11 million or 3 percent compared to 2014 on a revenue decrease
of $32 million. Income from operations in 2014 increased by $31 million or 9 percent compared to 2013 on a revenue
increase of $43 million, a 72 percent year-over-year operating margin incremental. Operating margin incremental is
measured by the increase in income from operations compared to the prior period divided by the increase in revenue
compared to the prior period.

Diagnostics and Genomics

Our diagnostics and genomics business includes the reagent partnership, pathology, companion diagnostics,

genomics and the nucleic acid solutions businesses.

Our diagnostics and genomics business is comprised of three areas of activity providing solutions that include
reagents, instruments, software and consumables, which enable customers in the clinical and life sciences research
areas to interrogate samples at the cellular and molecular level. First, our pathology solutions business is focused on
product offerings to cancer diagnostics and anatomic pathology workflows. The broad portfolio of offerings includes
immunohistochemistry (“IHC”), In Situ Hybridization (“ISH”), Hematoxylin and Eosin (“H&E”) staining and special
staining. We also collaborate with a number of major pharmaceutical companies to develop new potential
pharmacodiagnostics, also known as companion diagnostics, which may be used to identify patients most likely to
benefit from a specific targeted therapy. Second, our genomics business includes arrays for DNA mutation detection,
genotyping, gene copy number determination, identification of gene rearrangements, DNA methylation profiling,
gene expression profiling, as well as Next Generation Sequencing ("NGS") target enrichment. Finally, our nucleic
acid solutions business provides equipment and expertise focused on production of synthesized oligonucleotides
under pharmaceutical Good Manufacturing Practices ("GMP") conditions for use as Active Pharmaceutical
Ingredients ("API") in an emerging class of drugs that utilize nucleic acid molecules for disease therapy.

Net Revenue

Years Ended October 31,

2015

2014

2013

2015 over 2014
Change

2014 over 2013
Change

(in millions)

Net revenue

662 $

663 $

635

—

Diagnostics and genomics business revenue in 2015 was flat compared to 2014, significantly impacted by
currency. Foreign currency movements for 2015 had an unfavorable currency impact of 8 percentage points on
revenue growth when compared to the same period last year. Geographically, revenue grew 4 percent in the Americas
with a 1 percentage point unfavorable currency impact, grew 1 percent in Europe with a 13 percentage point
unfavorable currency impact, but declined 25 percent in Japan with a 12 percentage point unfavorable currency
impact and declined 2 percent in Asia Pacific excluding Japan with a 6 percentage point unfavorable currency impact.

The positive local currency revenue growth was driven by continued market demand in the nucleic acid solutions
business related to therapeutic oligo programs, good revenue performance in pathology and companion diagnostics
businesses as well as continued growth momentum of the NGS solution offering within the genomics business. The
end markets in diagnostics and clinical research continue to be strong and growing driven by aging population and
life style. We saw a revenue growth trend in 2015 in our pathology business as we regained customer confidence
once the FDA warning letter was lifted earlier in the year. The growth was driven by Omnis instruments placements
throughout the year with record shipments and installations in the last quarter. We also continued to see strong
performance from our companion diagnostics business driven by our new and existing pharmaceutical partners. Our
genomics business continued to see strong demand for our target enrichment portfolio due to the increasing adoption
of next-generation sequencing at a rapid pace by delivering products that suit the changing market in this research
and clinical research space.

Looking forward, we are optimistic about our growth opportunities in the diagnostics markets and continue to
invest in expanding and improving our applications and solutions portfolio. We remain positive about our revenue
growth in our markets, as adoption of our Omnis products, SureSelect and HaloPlex sequencing target enrichment
solutions continue. We will continue to invest in research and development, and seek to expand our position in
developing countries and emerging markets.

Gross Margin and Operating Margin

The following table shows the diagnostics and genomics business's margins, expenses and income from

operations for 2015 versus 2014, and 2014 versus 2013.

s
l
a
i
c
n
a
n
i
F

t
r
o
p
e
R

l
a
u
n
n
A

Years Ended October 31,

2015

2014

2013

2015 over 2014
Change

2014 over 2013
Change

54.4%
13.3%

56.4%
14.0%

60.1%
15.0%

(2) ppts
(1) ppt

(4) ppts
(1) ppt

Total gross margin
Operating margin

(in millions)

Research and development
Selling, general and administrative
Income from operations

$
$
$

78 $
195 $
88 $

86 $
195 $
93 $

83
202
95

(10)%
—
(5)%

3%
(4)%
(3)%

Gross margins decreased by 2 percentage points in 2015 compared to 2014. Gross margins reflected unfavorable
currency movement impact, change in business mix, higher inventory charges, and wage increases. Gross margins in
2014 decreased by 4 percentage points compared to 2013. Gross margins reflected higher costs to address the now
lifted FDA warning letter and higher infrastructure expenses and wage increases.

Research and development expenses decreased 10 percent in 2015 when compared to 2014; however remained
flat as a percentage of revenue. The decline was mainly due to favorable currency movements and business
improvement intiatives partially offset by wage increases. Research and development expenses increased 3 percent in
2014 compared to 2013. The increase was due to higher wages, higher cost to address the now lifted FDA warning
letter partially offset by lower infrastructure costs.

Selling, general and administrative expenses were flat in 2015 compared to 2014, favorable currency
movements, and business improvement initiatives and were offset by higher allocated infrastructure expenses
following the Keysight separation and wage increases. Selling, general and administrative expenses decreased 4
percent in 2014 compared to 2013. The reduction was due to lower program spending and efficiency gains in sales
channels partially offset by wage increases.

Operating margins decreased by 1 percentage point in 2015 compared to 2014. The reduction was due to lower
gross margins due to higher inventory charges and wage increases. Operating margins decreased by 1 percentage
point in 2014 compared to 2013 due to higher costs to address the now lifted FDA warning letter, higher
infrastructure expenses and wage increases.

Income from Operations

Income from operations in 2015 decreased by $5 million or 5 percent compared to 2014 on a revenue decrease of
$1 million. The reduction was due to lower gross margins. Income from operations in 2014 decreased by $2 million
or 3 percent compared to 2013 on a revenue increase of $28 million mainly due to higher costs to address the now
lifted FDA warning letter.

Agilent CrossLab

The Agilent CrossLab business spans the entire lab with its extensive consumables and services portfolio, which
is designed to improve customer outcomes. The majority of the portfolio is vendor neutral, meaning Agilent can
serve and supply customers regardless of their instrument purchase choices. Solutions range from chemistries and
supplies to services and software helping to connect the entire lab. Key product categories in consumables include
GC and LC columns, sample preparation products, custom chemistries, and a large selection of laboratory instrument
supplies. Services include startup, operational, training and compliance support, as well as asset management and
consultative services that help increase customer productivity. Custom service and consumable bundles are tailored
to meet the specific application needs of various industries and to keep instruments fully operational and compliant
with the respective industry requirements.

Net Revenue

Years Ended October 31,

2015

2014

2013

2015 over 2014
Change

2014 over 2013
Change

(in millions)

Total net revenue

1,330 $

1,307 $

1,224

Agilent CrossLab business revenue in 2015 increased 2 percent compared to 2014. Foreign currency movements
for 2015 had an unfavorable impact of 7 percentage points compared to 2014. Revenue growth in 2015 was led by
strength in the overall aftermarket service agreement business, the remarketed instrument business, and our
chemistries portfolio of LC columns and sample preparation products. Revenue grew 6 percent over 2014 in the
Americas with a 3 percentage point unfavorable currency impact. Revenue declined 5 percent below 2014 in Europe
with a 13 percentage point unfavorable currency impact. Revenue declined 13 percent below 2014 in Japan with a 14
percentage point unfavorable currency impact. Revenue grew 10 percent over 2014 in Asia Pacific excluding Japan
with a 4 percentage point unfavorable currency impact. Agilent CrossLab business revenue in 2014 increased
7 percent compared to 2013. Revenue growth in 2014 was led by strength in the overall service agreement business,
the remarketed instrument business, and our portfolio of LC columns and generic supply products.

Agilent CrossLab business saw positive revenue growth in all the key end markets after accounting for the
unfavorable currency impact in 2015. Growth was led by the pharmaceutical and biotechnology markets. Revenue
in chemical and energy end markets were slower but still reported growth, adjusted for currency movements.

Looking forward, we expect strength in the pharmaceutical and biotechnology markets will continue to offset
weakness in the chemical and energy markets in the near term. The drivers of organic revenue growth in the short-
term will be our commitment to bringing innovative solutions to market and our focus on expanding the partnerships
we have with our customers. Our launch of the Agilent CrossLab brand promise is beginning to help us
communicate the value we bring to our customers, and we are optimistic that this will translate into continued long-
term growth. We will also remain committed to fiscal discipline by optimizing gross margins across all our product
lines.

Gross Margin and Operating Margin

The following table shows the Agilent CrossLab business's margins, expenses and income from operations for

2015 versus 2014 and 2014 versus 2013.

Total gross margin
Operating margin

(in millions)

Years Ended October 31,

2015

2014

2013

2015 over 2014
Change

2014 over 2013
Change

49.6%
22.5%

48.5%
23.0%

48.7%
24.4%

1 ppt
(1) ppt

—
(1) ppt

Research and development
Selling, general and administrative
Income from operations

$
$
$

46 $
315 $
299 $

45 $
287 $
301 $

31
266
299

3%
10%
(1)%

45%
8%
1%

Gross margins increased by 1 percentage point in 2015 compared to 2014, primarily due to the favorable
currency hedging gains recognized in 2015, which were partially offset by higher logistical costs. Gross margins
remained flat in 2014 compared to 2013.

Research and development expenses increased 3 percent in 2015 when compared to 2014, due to higher project
expenses and wage increases. Research and development expenses increased 45 percent in 2014 compared to 2013,
due to increased investment into expanding our biocolumn and LC column product portfolio.

s
l
a
i
c
n
a
n
i
F

t
r
o
p
e
R

l
a
u
n
n
A

Selling, general and administrative expenses increased 10 percent in 2015 compared to 2014, due to the increase
in allocated infrastructure costs following our separation of Keysight and wage increases. Selling, general and
administrative expenses increased 8 percent in 2014 compared to 2013, due to higher field selling costs and higher
infrastructure expenses.

Operating margins declined 1 percentage point in 2015 compared to 2014, due to the increase in allocated
infrastructure costs following our separation of Keysight, which were partially offset by the favorable currency
hedging gains recognized in 2015. Operating margins decreased 1 percentage point in 2014 compared to 2013, due
to the higher infrastructure expenses.

Income from Operations

Income from operations in 2015 decreased by $2 million or 1 percent compared to 2014 on a revenue increase of
$23 million. Income from operations in 2014 increased by $2 million or 1 percent compared to 2013 on a revenue
increase of $83 million, a 3 percent year-over-year operating margin incremental.

Financial Condition

Liquidity and Capital Resources

Our financial position as of October 31, 2015 consisted of cash and cash equivalents of $2,003 million as
compared to $2,218 million as of October 31, 2014, which excludes $810 million of cash and cash equivalents held
by Keysight.

On November 1, 2014, we completed the distribution of 100% of the outstanding common shares of Keysight to
Agilent stockholders who received one share of Keysight common stock for every two shares of Agilent held as of
the close of business on the record date, October 22, 2014. The separation agreement provided that prior to the
distribution, Keysight make a cash distribution to Agilent in an amount equal to $900 million. The distribution of
such cash to Agilent was intended to be a return of capital to Agilent that ensures that Keysight had approximately
$700 million of total cash immediately following distribution. For the year ended October 31 2015, we transferred a
net amount of $734 million to Keysight.

As of October 31, 2015, approximately $1,780 million of our cash and cash equivalents is held outside of the
U.S. in our foreign subsidiaries. Most of the amounts held outside of the U.S. could be repatriated to the U.S. but,
under current law, would be subject to U.S. federal and state income taxes, less applicable foreign tax credits. Agilent
has accrued for U.S. federal and state tax liabilities on the earnings of its foreign subsidiaries except when the
earnings are considered indefinitely reinvested outside of the U.S. Repatriation could result in additional material
U.S. federal and state income tax payments in future years. We utilize a variety of funding strategies in an effort to
ensure that our worldwide cash is available in the locations in which it is needed.

We believe our cash and cash equivalents, cash generated from operations, and ability to access capital markets
and credit lines will satisfy, for at least the next twelve months, our liquidity requirements, both globally and
domestically, including the following: working capital needs, capital expenditures, business acquisitions, stock
repurchases, cash dividends, contractual obligations, commitments, principal and interest payments on debt, and other
liquidity requirements associated with our operations.

Net Cash Provided by Operating Activities

Net cash provided by operating activities was $491 million in 2015 as compared to $711 million provided in
2014 and $1,152 million provided in 2013. For the years ended 2014 and 2013, net cash provided by operating
activities included the cash provided by Keysight operating activities. We paid approximately $129 million of net
taxes in 2015, as compared to net $131 million in taxes in 2014 and net $110 million in 2013. Income taxes,
including those paid for the Keysight business, were paid by Agilent for the years ended October 31, 2014 and 2013.
The increase in cash paid for income taxes for the year ended October 31, 2015 was due to tax payments related to
the separation. Operating cash flows in 2014 were impacted by pre-separation costs and separation related taxes, the
redemption of senior notes including payments related to accrued interest and the timing of the purchase of shares
under the employee stock purchase plan. For the years ended October 31, 2015, 2014 and 2013 other assets and
liabilities used cash of $262 million, $45 million and provided cash of $8 million, respectively. The increase in the
usage of cash for the year ended October 31, 2015 in other assets and liabilities was largely the result of

contributions to defined benefit plans, changes in interest and restructuring accruals, income tax liabilities and
transaction tax assets and liabilities.

In 2015, the change in accounts receivable used cash of $24 million, $119 million in 2014 and provided cash of
$14 million in 2013. For the years ended October 31, 2014 and 2013 the change in accounts receivable included $25
million of cash used and $44 million of cash provided by Keysight, respectively. Days' sales outstanding were
53 days in 2015, 49 days in 2014 and 47 days in 2013. The change in accounts payable used cash of $26 million in
2015, provided cash of $50 million in 2014 and used cash of $27 million in 2013. For the years ended October 31,
2014 and 2013 the change in accounts payable included $32 million of cash provided and $24 million of cash used by
Keysight, respectively. Cash used in inventory was $24 million in 2015, $99 million in 2014 and $100 million in
2013. For the years ended October 31, 2014 and 2013 the change in inventory included $31 million and $53 million
of cash used by Keysight, respectively. Inventory days on-hand decreased to 97 days in 2015 compared to 106 days
in 2014 and 118 days in 2013.

We contributed $15 million, $30 million and $30 million to our U.S. defined benefit plans in 2015, 2014 and
2013, respectively. For the years ended October 31, 2014 and 2013 we contributed $15 million and $15 million,
respectively, to our U.S. defined benefit plans on behalf of Keysight. We contributed $25 million, $72 million and
$89 million to our non-U.S. defined benefit plans in 2015, 2014 and 2013, respectively. For the years ended October
31, 2014 and 2013 we contributed $41 million and $45 million, respectively, to our non-U.S. defined benefit plans on
behalf of Keysight. We contributed less than $1 million to our U.S. post-retirement benefit plans in 2015 and $1
million in both 2014 and 2013. Our non-U.S. defined benefit plans are generally funded ratably throughout the year.
Total contributions in 2015 were $40 million or 61 percent less than 2014. Total contributions in 2014 were $103
million or 14 percent more than 2013. Our annual contributions are highly dependent on the relative performance of
our assets versus our projected liabilities, among other factors. We expect to contribute approximately $25 million to
our U.S. and non-U.S. defined benefit plans and $1 million to our U.S. post-retirement benefit plans during 2016.

Net Cash Used in Investing Activities

Net cash used in investing activities in 2015 was $400 million and in 2014 was $230 million as compared to net
cash used of $248 million in 2013. For the years ended October 31, 2014 and 2013 cash used in investing activities
included $82 million and $85 million of cash used by Keysight, respectively.

Investments in property, plant and equipment were $98 million in 2015, $205 million in 2014 and $195 million
in 2013. For the years ended October 31, 2014 and 2013 investments in plant and equipment included $70 million
and $69 million, respectively, related to Keysight. Proceeds from sale of property, plant and equipment were $12
million in 2015, $14 million in 2014 and $2 million in 2013. In 2015 we invested $74 million in acquisitions of
businesses and intangible assets, net of cash acquired compared to $13 million in 2014 and $21 million in 2013. In
2015 we increased our investment in our equity method investment by $1 million. In 2014, there were $25 million of
purchases of equity method investments including a $3.5 million loan converted to equity compared with $46 million
of purchases of investments including $21 million for equity method investments in 2013. Proceeds from a
divestiture was $3 million in 2015 compared to $2 million in 2014. Proceeds from the sale of investment securities in
2015 were zero, $1 million in 2014 and $12 million in 2013. We made a payment of $2 million in exchange for
convertible note in 2015. Change in restricted cash and cash equivalents was $240 million in 2015 related to our
Seahorse Biosciences acquisition and $4 million and zero in 2014 and 2013 respectively.

Net Cash Used in Financing Activities

Net cash used in financing activities in 2015 was $1,068 million compared to $97 million in 2014 and
$554 million in 2013, respectively. The increase in cash used in 2015 when compared to 2014 was largely due to the
net cash transferred to Keysight.

s
l
a
i
c
n
a
n
i
F

t
r
o
p
e
R

l
a
u
n
n
A

Treasury stock repurchases

On November 22, 2013 we announced that our board of directors had authorized a share repurchase program.
The existing program is designed to reduce or eliminate dilution resulting from issuance of stock under the company's
employee equity incentive programs to target maintaining a weighted average share count of approximately 335
million diluted shares. For the years ended October 31, 2015, 2014 and 2013 we repurchased 6 million shares for
$267 million, 4 million shares for $200 million and 20 million shares for $900 million, respectively. All such shares
and related costs are held as treasury stock and accounted for using the cost method.

On May 28, 2015 we announced that our board of directors had approved a new share repurchase program (the
"2015 repurchase program"). The 2015 share repurchase program authorizes the purchase of up to $1.14 billion of
our common stock through and including November 1, 2018. The 2015 share repurchase program will commence,
at the option of the company, on either November 1, 2015, or the date on which we complete the purchase of the
remaining $98 million for a total of $365 million of common stock in fiscal 2015 under the existing stock repurchase
program. Upon commencement, the 2015 share repurchase program replaces our existing stock repurchase program,
which authorized the repurchase of shares to reduce or eliminate share dilution from equity programs. The 2015
repurchase program does not require the company to acquire a specific number of shares and may be suspended or
discontinued at any time.

Dividends

Credit Facility

On September 15, 2014, Agilent entered into a credit agreement with a financial institution which provides for a
$400 million five-year unsecured credit facility that will expire on September 15, 2019. On June 9, 2015, the
commitments under the existing credit facility were increased by $300 million so that the aggregate commitments
under the facility now total $700 million. As of October 31, 2015, the company had no borrowings outstanding under
the facility. We were in compliance with the covenants for the credit facility during the years ended October 31, 2015
and 2014.

Long-term debt

In October 2007, the company issued an aggregate principal amount of $600 million in senior notes ("2017
senior notes"). The 2017 senior notes were issued at 99.60% of their principal amount. The notes will mature on
November 1, 2017, and bear interest at a fixed rate of 6.50% per annum. The interest is payable semi-annually on
May 1st and November 1st of each year and payments commenced on May 1, 2008.

On November 25, 2008, we terminated two interest rate swap contracts associated with our 2017 senior notes
that represented the notional amount of $400 million. The asset value, including interest receivable, upon termination
was approximately $43 million and the amount to be amortized at October 31, 2015 was $2 million. The gain is being
deferred and amortized to interest expense over the remaining life of the 2017 senior notes. On October 20, 2014, we
settled the redemption of $500 million of the $600 million outstanding aggregate principal amount of our 2017 senior
notes due November 1, 2017 that had been called for redemption on September 19, 2014.

In July 2010, the company issued an aggregate principal amount of $500 million in senior notes ("2020 senior
notes"). The 2020 senior notes were issued at 99.54% of their principal amount. The notes will mature on July 15,
2020, and bear interest at a fixed rate of 5.00% per annum. The interest is payable semi-annually on January 15th and
July 15th of each year, payments commenced on January 15, 2011.

On August 9, 2011, we terminated our interest rate swap contracts related to our 2020 senior notes that
represented the notional amount of $500 million. The asset value, including interest receivable, upon termination for
these contracts was approximately $34 million and the amount to be amortized at October 31, 2015 was $19 million.
The gain is being deferred and amortized to interest expense over the remaining life of the 2020 senior notes.

In September 2012, the company issued an aggregate principal amount of $400 million in senior notes ("2022
senior notes"). The senior notes were issued at 99.80% of their principal amount. The notes will mature on October 1,
2022, and bear interest at a fixed rate of 3.20% per annum. The interest is payable semi-annually on April 1st and
October 1st of each year, payments commenced on April 1, 2013.

In June 2013, the company issued aggregate principal amount of $600 million in senior notes ("2023 senior
notes"). The 2023 senior notes were issued at 99.544% of their principal amount. The notes will mature on July 15,
2023 and bear interest at a fixed rate of 3.875% per annum. Interest is payable semi-annually on January 15th and
July 15th of each year and payments commenced January 15, 2014.

As of October 31, 2015, we have mortgage debts, secured on buildings in Denmark, in Danish Krone equivalent
of $38 million aggregate principal outstanding with a Danish financial institution. The loans have a variable interest
rate based on 3 months Copenhagen Interbank Rate ("Cibor") and will mature on September 30, 2027. Interest
payments are made in March, June, September and December of each year.

Off Balance Sheet Arrangements and Other

We have contractual commitments for non-cancelable operating leases. See Note 18, "Commitments and
Contingencies", to our consolidated financial statements for further information on our non-cancelable operating
leases.

Our liquidity is affected by many factors, some of which are based on normal ongoing operations of our business
and some of which arise from fluctuations related to global economics and markets. Our cash balances are generated
and held in many locations throughout the world. Local government regulations may restrict our ability to move cash
balances to meet cash needs under certain circumstances. We do not currently expect such regulations and restrictions
to impact our ability to pay vendors and conduct operations throughout our global organization.

Contractual Commitments

Our cash flows from operations are dependent on a number of factors, including fluctuations in our operating
results, accounts receivable collections, inventory management, and the timing of tax and other payments. As a result,
the impact of contractual obligations on our liquidity and capital resources in future periods should be analyzed in
conjunction with such factors.

The following table summarizes our total contractual obligations at October 31, 2015 for Agilent operations and

excludes amounts recorded in our consolidated balance sheet (in millions):

Less than one
year

One to three
years

Three to five
years

More than five
years

Operating leases

Commitments to contract manufacturers and
suppliers
Other purchase commitments

Retirement plans

Total

35 $

581

695 $

—
—
—
54

26 $

—
—
—
26 $

—
—
—
34

Operating leases. Commitments under operating leases relate primarily to leasehold property, see Note 18,

"Commitments and Contingencies".

s
l
a
i
c
n
a
n
i
F

t
r
o
p
e
R

l
a
u
n
n
A

Commitments to contract manufacturers and suppliers. We purchase components from a variety of suppliers
and use several contract manufacturers to provide manufacturing services for our products. During the normal course
of business, we issue purchase orders with estimates of our requirements several months ahead of the delivery dates.
However, our agreements with these suppliers usually provide us the option to cancel, reschedule, and adjust our
requirements based on our business needs prior to firm orders being placed. Typically purchase orders outstanding
with delivery dates within 30 days are non-cancelable. Therefore, only approximately 38 percent of our reported
purchase commitments arising from these agreements are firm, non-cancelable, and unconditional commitments. We
expect to fulfill most of our purchase commitments for inventory within one year.

In addition to the above mentioned commitments to contract manufacturers and suppliers, we record a liability
for firm, non-cancelable and unconditional purchase commitments for quantities in excess of our future demand
forecasts consistent with our policy relating to excess inventory. As of October 31, 2015, the liability for our firm,
non-cancelable and unconditional purchase commitments was $5 million compared to $10 million, as of October 31,
2014 and less than $1 million as of October 31, 2013. These amounts are included in other accrued liabilities in our
consolidated balance sheet.

Other purchase commitments. We have categorized "other purchase commitments" related to contracts with
professional services suppliers. Typically we can cancel contracts without penalties. For those contracts that are not
cancelable without penalties, we are disclosing the termination fees and costs or commitments for continued spending
that we are obligated to pay to a supplier under each contact's termination period before such contract can be
cancelled. Our contractual obligations with these suppliers under "other purchase commitments" were approximately
$53 million within the next year.

Retirement Plans. Commitments under the retirement plans relate to expected contributions to be made to
our U.S. and non-U.S. defined benefit plans and to our post-retirement medical plans for the next year only.
Contributions after next year are impractical to estimate.

We had no material off-balance sheet arrangements as of October 31, 2015 or October 31, 2014.

On Balance Sheet Arrangements

The following table summarizes our total contractual obligations at October 31, 2015 related to our long-term

debt and interest expense (in millions):

Senior notes
Other debt
Interest expense
Total

Less than one
year

One to three years
100
—
132
232

— $
—
68
68

Three to five years
500
—
123
623

More than five years
1,000
38
96
1,134

Other long-term liabilities include $227 million and $286 million of liabilities for uncertain tax positions as of
October 31, 2015 and October 31, 2014, respectively. We are unable to accurately predict when these amounts will
be realized or released. However, it is reasonably possible that there could be significant changes to our unrecognized
tax benefits in the next twelve months due to either the expiration of a statute of limitations or a tax audit settlement.

QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK

We are exposed to foreign currency exchange rate risks inherent in our sales commitments, anticipated sales, and
assets and liabilities denominated in currencies other than the functional currency of our subsidiaries. We hedge
future cash flows denominated in currencies other than the functional currency using sales forecasts up to twelve
months in advance. Our exposure to exchange rate risks is managed on an enterprise-wide basis. This strategy utilizes
derivative financial instruments, including option and forward contracts, to hedge certain foreign currency exposures
with the intent of offsetting gains and losses that occur on the underlying exposures with gains and losses on the
derivative contracts hedging them. We do not currently and do not intend to utilize derivative financial instruments
for speculative trading purposes.

Our operations generate non-functional currency cash flows such as revenues, third party vendor payments and
inter-company payments. In anticipation of these foreign currency cash flows and in view of volatility of the currency
market, we enter into such foreign exchange contracts as are described above to manage our currency risk.
Approximately 57 percent of our revenue in 2015, 61 percent of our revenues in 2014 and 63 percent of our revenues
in 2013 were generated in U.S. dollars.

We performed a sensitivity analysis assuming a hypothetical 10 percent adverse movement in foreign exchange
rates to the hedging contracts and the underlying exposures described above. As of October 31, 2015 and 2014, the
analysis indicated that these hypothetical market movements would not have a material effect on our consolidated
financial position, results of operations, statement of comprehensive income or cash flows.

We are also exposed to interest rate risk due to the mismatch between the interest expense we pay on our loans at
fixed rates and the variable rates of interest we receive from cash, cash equivalents and other short-term investments.
We have issued long-term debt in U.S. dollars or foreign currencies at fixed interest rates based on the market
conditions at the time of financing. We believe that the fair value of our fixed rate debt changes when the underlying
market rates of interest change, and we may use interest rate swaps to modify such market risk.

We performed a sensitivity analysis assuming a hypothetical 10 percent adverse movement in interest rates
relating to the underlying fair value of our fixed rate debt. As of October 31, 2015 and 2014, the sensitivity analyses
indicated that a hypothetical 10 percent adverse movement in interest rates would result in an immaterial impact to
the fair value of our fixed interest rate debt.

s
l
a
i
c
n
a
n
i
F

t
r
o
p
e
R

l
a
u
n
n
A

Report of Independent Registered Public Accounting Firm

To the Stockholders and Board of Directors of Agilent Technologies, Inc.

Internal Control - Integrated Framework (2013)

In our opinion, the accompanying consolidated balance sheets and the related consolidated statements of operations,
comprehensive income, cash flows, and equity present fairly, in all material respects, the financial position of
Agilent Technologies, Inc. and its subsidiaries at October 31, 2015 and October 31, 2014, and the results of their
operations and their cash flows for each of the three years in the period ended October 31, 2015 in conformity with
accounting principles generally accepted in the United States of America. Also in our opinion, the Company did not
maintain, in all material respects, effective internal control over financial reporting as of October 31, 2015, based on
criteria established in
issued by the Committee of Sponsoring
Organizations of the Treadway Commission (COSO) because a material weakness in internal control over financial
reporting related to the completeness and accuracy of the accounting for income taxes existed as of that date. A
material weakness is a deficiency, or a combination of deficiencies, in internal control over financial reporting, such
that there is a reasonable possibility that a material misstatement of the annual or interim financial statements will not
be prevented or detected on a timely basis. The material weakness referred to above is described in Management's
Report on Internal Control over Financial Reporting. We considered this material weakness in determining the
nature, timing, and extent of audit tests applied in our audit of the October 31, 2015 consolidated financial statements,
and our opinion regarding the effectiveness of the Company’s internal control over financial reporting does not affect
our opinion on those consolidated financial statements. The Company's management is responsible for these
financial statements, for maintaining effective internal control over financial reporting and for its assessment of the
effectiveness of internal control over financial reporting included in management's report referred to above. Our
responsibility is to express opinions on these financial statements and on the Company's internal control over
financial reporting based on our integrated audits. We conducted our audits in accordance with the standards of the
Public Company Accounting Oversight Board (United States). Those standards require that we plan and perform the
audits to obtain reasonable assurance about whether the financial statements are free of material misstatement and
whether effective internal control over financial reporting was maintained in all material respects. Our audits of the
financial statements included examining, on a test basis, evidence supporting the amounts and disclosures in the
financial statements, assessing the accounting principles used and significant estimates made by management, and
evaluating the overall financial statement presentation. Our audit of internal control over financial reporting included
obtaining an understanding of internal control over financial reporting, assessing the risk that a material weakness
exists, and testing and evaluating the design and operating effectiveness of internal control based on the assessed risk.
Our audits also included performing such other procedures as we considered necessary in the circumstances. We
believe that our audits provide a reasonable basis for our opinions.

A company’s internal control over financial reporting is a process designed to provide reasonable assurance regarding
the reliability of financial reporting and the preparation of financial statements for external purposes in accordance
with generally accepted accounting principles. A company’s internal control over financial reporting includes those
policies and procedures that (i) pertain to the maintenance of records that, in reasonable detail, accurately and fairly
reflect the transactions and dispositions of the assets of the company; (ii) provide reasonable assurance that
transactions are recorded as necessary to permit preparation of financial statements in accordance with generally
accepted accounting principles, and that receipts and expenditures of the company are being made only in accordance
with authorizations of management and directors of the company; and (iii) provide reasonable assurance regarding
prevention or timely detection of unauthorized acquisition, use, or disposition of the company’s assets that could have
a material effect on the financial statements.

Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements.
Also, projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become
inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may
deteriorate.

/s/ PRICEWATERHOUSECOOPERS LLP

San Jose, California
December 18, 2015

AGILENT TECHNOLOGIES, INC.
CONSOLIDATED STATEMENT OF OPERATIONS

2015

Years Ended October 31,

2014 (As
Revised)
(in millions, except per
share data)

2013 (As
Revised)

Net revenue:
Products
Services and other

Total net revenue
Costs and expenses:
Cost of products
Cost of services and other

Total costs
Research and development
Selling, general and administrative

Total costs and expenses

Income from operations
Interest income
Interest expense
Other income (expense), net

Income from continuing operations before taxes
Provision (benefit) for income taxes

Income from continuing operations
Income (loss) from discontinued operations, net of tax expense
(benefit) of $(2), $100 and $57
Net income

Net income per share - basic:

Income from continuing operations
Income (loss) from discontinued operations

Net income per share - basic

Net income per share - diluted:

Income from continuing operations
Income (loss) from discontinued operations

Net income per share - diluted

Weighted average shares used in computing net income per share:

Basic
Diluted

3,146 $
892

4,038

3,185 $
863
4,048

1,496
501

1,997
330
1,189

3,516
522
7
(66)
17

480
42

438

(37) $

401 $

1.32 $
(0.12)

1.20 $

1.31 $
(0.11)

1.20 $

333
335

1,568
504
2,072
358
1,199
3,629
419
9
(110)
(89)
229
(3)
232

317
$
549 $

0.70 $
0.95
1.65 $

0.69 $
0.93
1.62 $

333
338

3,083
811

3,894

1,525
462

1,987
337
1,184

3,508
386
7
(107)
7

293
68

225

509

734

0.66
1.49

2.15

0.65
1.48

2.13

341
345

Cash dividends declared per common share

0.400 $

0.528 $

0.460

The accompanying notes are an integral part of these consolidated financial statements.

s
l
a
i
c
n
a
n
i
F

t
r
o
p
e
R

l
a
u
n
n
A

AGILENT TECHNOLOGIES, INC.
CONSOLIDATED STATEMENT OF COMPREHENSIVE INCOME
(in millions)

Net income

Other comprehensive income (loss):

Years Ended October 31,

2015

2014 (As
Revised)

2013 (As
Revised)

401 $

549 $

734

Unrealized gain on investments, net of tax (expense) benefit of $0, $(1) and $(2)

Amounts reclassified into earnings related to investments, net of tax of $0, $0 and $0

Gain on derivative instruments, net of tax (expense) of $(3), $(5) and $(2)

Amounts reclassified into earnings related to derivative instruments, net of tax benefit
of $6, $0 and $3

—
—
8

(12)

11
(1)
8

Foreign currency translation, net of tax benefit of $24, $8 and $8

(336)

(269)

Net defined benefit pension cost and post retirement plan costs:

Change in actuarial net loss, net of tax (expense) benefit of $17, $65, and $(114)

Change in net prior service benefit, net of tax benefit of $6, $16, and $16

Other comprehensive income (loss)

Total comprehensive income

(38)

(11)

(143)

(32)

(389)
12 $

(425)
124 $

—

(10)

228

(32)

202

936

The accompanying notes are an integral part of these condensed consolidated financial statements.

AGILENT TECHNOLOGIES, INC.
CONSOLIDATED BALANCE SHEET

ASSETS

Current assets:

Cash and cash equivalents
Short-term restricted cash and cash equivalents
Accounts receivable, net
Inventory
Other current assets
Current assets of discontinued operations

Total current assets
Property, plant and equipment, net
Goodwill
Other intangible assets, net
Long-term investments
Other assets
Non-current assets of discontinued operations

Total assets

Current liabilities:

LIABILITIES AND EQUITY

Accounts payable
Employee compensation and benefits
Deferred revenue
Other accrued liabilities
Current liabilities of discontinued operations

Total current liabilities

Long-term debt
Retirement and post-retirement benefits
Other long-term liabilities
Long-term liabilities of discontinued operations

Total liabilities

Commitments and contingencies (Note 18)
Total equity:

Stockholders' equity:

Preferred stock; $0.01 par value; 125 million shares authorized; none issued and outstanding
Common stock; $0.01 par value; 2 billion shares authorized; 611 million shares at October 31,
2015 and 608 million shares at October 31, 2014 issued
Treasury stock at cost; 279 million shares at October 31, 2015 and 273 million shares at
October 31, 2014
Additional paid-in-capital
Retained earnings
Accumulated other comprehensive loss

Total stockholders' equity
Non-controlling interest

Total equity
Total liabilities and equity

October 31,

2015

2014 (As
Revised)

(in millions, except
par value and
share data)

2,003 $
242
606
541
294
—
3,686
604
2,366
445
86
292
—
7,479 $

279 $
221
258
218
—
976
1,655
264
414
—
3,309

—

(10,074)
9,045
5,581
(391)
4,167
3
4,170
7,479 $

2,218
—
626
574
263
1,828

5,509
631
2,507
649
96
268
1,155

10,815

302
228
260
279
623

1,692
1,663
209
513
1,434

5,511

—

(9,807)

8,967
6,469
(334)
5,301
3

5,304
10,815

s
l
a
i
c
n
a
n
i
F

t
r
o
p
e
R

l
a
u
n
n
A

The accompanying notes are an integral part of these consolidated financial statements.

AGILENT TECHNOLOGIES, INC.
CONSOLIDATED STATEMENT OF CASH FLOWS

Years Ended October 31,

2015

2014 (As
Revised)
(in millions)

2013 (As
Revised)

401 $

549

Cash flows from operating activities:

Net income

Adjustments to reconcile net income to net cash provided by operating activities:

Depreciation and amortization
Accelerated amortization of interest rate swap gain (due to early redemption of debt)
Share-based compensation
Excess tax benefit from share-based plans
Deferred taxes
Excess and obsolete inventory and inventory related charges
Non-cash restructuring and asset impairment charges
Net gain on sale of investments
Net (gain) loss on sale of assets and divestitures
Other
Changes in assets and liabilities:
Accounts receivable, net
Inventory
Accounts payable
Employee compensation and benefits
Other assets and liabilities

Net cash provided by operating activities

Cash flows from investing activities:

Investments in property, plant and equipment
Proceeds from the sale of property, plant and equipment
Proceeds from the sale of investment securities
Proceeds from divestitures
Payment to acquire equity method investment
Payment in exchange for convertible note
Purchase of other investments
Change in restricted cash, cash equivalents and investments, net
Acquisitions of businesses and intangible assets, net of cash acquired

Net cash used in investing activities

Cash flows from financing activities:

Issuance of common stock under employee stock plans
Treasury stock repurchases
Payment of dividends
Issuance of senior notes
Debt issuance costs
Repayment of senior notes
Purchase of non-controlling interest
Proceeds from debts and credit facility
Net transfer of cash and cash equivalents to Keysight
Repayment of debts and credit facility
Excess tax benefit from share-based plans
Net cash used in financing activities

Effect of exchange rate movements

Net increase (decrease) in cash and cash equivalents

253
—
54
(8)
70
30
3
—
3
13

(24)
(24)
(26)
8
(262)
491

(98)
12
—
3
(1)
(2)
—
(240)
(74)
(400)

384
(22)
96
(1)
(192)
79
23
(1)
(10)
10

(119)
(99)
50
9
(45)
711

(205)
14
1
2
(25)
—
—
(4)
(13)
(230)

58
(267)
(133)
—
—
—
—
—
(734)
—
8
(1,068)
(48)
(1,025)
810
2,218
2,003 $

188
(200)
(176)
1,099
(9)
(1,000)
—
87
—
(87)
1
(97)
(31)
353
—
2,675
3,028

734

372
—
85
(2)
(4)
48
3
(1)
3
3

14
(100)
(27)
16
8
1,152

(195)
2
12
—
(21)
—
(25)
—
(21)
(248)

161
(900)
(156)
597
(5)
(250)
(3)
—
—
—
2
(554)
(26)
324
—
2,351
2,675

Change in cash and cash equivalents within current assets of discontinued operations
Cash and cash equivalents at beginning of year
Cash and cash equivalents at end of year

The accompanying notes are an integral part of these consolidated financial statements.

-
n
o
N

l
a
t
o
T

d
e
t
a
l
u
m
u
c
c
A

r
e
h
t
O

l
a
t
o
T

y
t
i
u
q
E

s
t
s
e
r
e
t
n
I

y
t
i
u
q
E

g
n
i
l
l
o
r
t
n
o
C

'
s
r
e
d
l
o
h
k
c
o
t
S

e
v
i
s
n
e
h
e
r
p
m
o
C

)
s
s
o
L

(
/
e
m
o
c
n
I

d
e
n
i
a
t
e
R

s
g
n
i
n
r
a
E

k
c
o
t
S
y
r
u
s
a
e
r
T

k
c
o
t
S
n
o
m
m
o
C

y
r
u
s
a
e
r
T

t
a
k
c
o
t
S

t
s
o
C

r
e
b
m
u
N

l
a
n
o
i
t
i
d
d
A

f
o

s
e
r
a
h
S

n
i
-
d
i
a
P

l
a
t
i
p
a
C

r
a
P

e
u
l
a
V

r
e
b
m
u
N

f
o

s
e
r
a
h
S

)
s
d
n
a
s
u
o
h
t
n
i

s
e
r
a
h
s

f
o
r
e
b
m
u
n
t
p
e
c
x
e

,
s
n
o
i
l
l
i

m
n
i
(

C
N
I

S
E
I
G
O
L
O
N
H
C
E
T
T
N
E
L
I
G
A

Y
T
I
U
Q
E
F
O
T
N
E
M
E
T
A
T
S
D
E
T
A
D
I
L
O
S
N
O
C

5
8
1
,
5

2
8
1
,
5

)
1
1
1
(

5
0
5
,
5

)
7
0
7
,
8
(

)
6
8
7
,
8
4
2
(

9
8
4
,
8

9
5
2
,
5
9
5

2
1
0
2
,
1
3
r
e
b
o
t
c
O

f
o

s
a

e
c
n
a
l
a
B

—

3
1

—

)
2
1
(

—

6
8
1
,
5

3
8
1
,
5

)
1
1
1
(

8
1
5
,
5

)
7
0
7
,
8
(

)
6
8
7
,
8
4
2
(

7
7
4
,
8

9
5
2
,
5
9
5

4
3
7

2
0
2

6
3
9

)
6
5
1
(

7
4
1

)
0
0
9
(

5
8

—

4
3
7

2
0
2

6
3
9

)
6
5
1
(

7
4
1

)
0
0
9
(

5
8

0
0
3
,
5

7
9
2
,
5

9
4
5

)
5
2
4
(

4
2
1

)
6
7
1
(

—

0
7
1

)
1
1
(

6
9

)
0
0
2
(

—

9
4
5

)
5
2
4
(

4
2
1

)
6
7
1
(

—

0
7
1

)
1
1
(

6
9

)
0
0
2
(

—

2
0
2

—

1
9

—

)
5
2
4
(

—

4
3
7

)
6
5
1
(

—

)
0
0
9
(

)
4
4
5
,
0
2
(

—

7
4
1

—

5
8

—

0
7
3
,
6

6
9
0
,
6

)
7
0
6
,
9
(

)
0
3
3
,
9
6
2
(

1
1
7
,
8

9
2
6
,
1
0
6

—

9
4
5

)
6
7
1
(

—

)
0
0
2
(

—

)
4
9
5
,
3
(

—

0
7
1

)
1
1
(

—

6
9

—

1
6
2
,
6

—

4
0
3
,
5

1
0
3
,
5

)
4
3
3
(

9
6
4
,
6

)
7
0
8
,
9
(

)
4
2
9
,
2
7
2
(

7
6
9
,
8

0
9
8
,
7
0
6

1
0
4

)
9
8
3
(

2
1

)
3
3
1
(

)
2
5
8
(

4
4

4
5

)
7
6
2
(

—

1
0
4

)
9
8
3
(

2
1

)
3
3
1
(

)
2
5
8
(

4
4

4
5

)
7
6
2
(

—

)
9
8
3
(

—

2
3
3

—

1
0
4

)
3
3
1
(

)
6
5
1
,
1
(

—

)
7
6
2
(

—

)
1
7
4
,
6
(

—

)
8
2
(

4
4

—

4
5

—

4
6
9
,
2

0
7
1
,
4

7
6
1
,
4

)
1
9
3
(

1
8
5
,
5

)
4
7
0
,
0
1
(

)
5
9
3
,
9
7
2
(

5
4
0
,
9

4
5
8
,
0
1
6

d
o
i
r
e
P
r
o
i
r
P
f
o

n
o
i
s
i
v
e
R
"

e
t
o
N
e
e
s

,
n
o
i
s
i
v
e
r

f
o

t
c
a
p
m

e
v
i
t
a
l
u
m
u
C

"
s
t
n
e
m
e
t
a
t
S
l
a
i
c
n
a
n
i
F

:
x
a
t

f
o
t
e
n

,
e
m
o
c
n
i

e
v
i
s
n
e
h
e
r
p
m
o
c

f
o

s
t
n
e
n
o
p
m
o
C

2
1
0
2
,
1
3
r
e
b
o
t
c
O

f
o

s
a

e
c
n
a
l
a
B
d
e
s
i
v
e
R

)
e
r
a
h
s
n
o
m
m
o
c

r
e
p

6
4
.
0
$
(
d
e
r
a
l
c
e
d

s
d
n
e
d
i
v
i
d

h
s
a
C

k
c
o
t
s

n
o
m
m
o
c

f
o
e
s
a
h
c
r
u
p
e
R

d
e
u
s
s
i

s
d
r
a
w
a
d
e
s
a
b
-
e
r
a
h
S

:
x
a
t

f
o
t
e
n

,
e
m
o
c
n
i

e
v
i
s
n
e
h
e
r
p
m
o
c

f
o

s
t
n
e
n
o
p
m
o
C

d
e
u
s
s
i

s
d
r
a
w
a
d
e
s
a
b
-
e
r
a
h
s
m
o
r
f

s
t
i
f
e
n
e
b

x
a
T

3
1
0
2
,
1
3
r
e
b
o
t
c
O

f
o
s
a

e
c
n
a
l
a
B

n
o
i
t
a
s
n
e
p
m
o
c
d
e
s
a
b
-
e
r
a
h
S

e
m
o
c
n
i

e
v
i
s
n
e
h
e
r
p
m
o
c

r
e
h
t
O

e
m
o
c
n
i

e
v
i
s
n
e
h
e
r
p
m
o
c

l
a
t
o
T

e
m
o
c
n
i

t
e
N

s
s
o
l

e
v
i
s
n
e
h
e
r
p
m
o
c

r
e
h
t
O

e
m
o
c
n
i

e
v
i
s
n
e
h
e
r
p
m
o
c

l
a
t
o
T

e
m
o
c
n
i

t
e
N

d
e
s
a
b
e
r
a
h
s
m
o
r
f
d
e
z
i
l
a
e
r

s
t
i
f
e
n
e
b

x
a
t

s
s
e
c
x
e

e
v
i
t
a
l
u
m
u
c
o
t

t
n
e
m
t
s
u
j
d
A

"
n
o
i
t
a
s
n
e
p
m
o
C
d
e
s
a
b
-
e
r
a
h
S
"

,
5
e
t
o
N
e
e
s

,
d
e
u
s
s
i

s
d
r
a
w
a

d
e
u
s
s
i

s
d
r
a
w
a
d
e
s
a
b
-
e
r
a
h
s
m
o
r
f

s
t
i
f
e
n
e
b

x
a
T

)
e
r
a
h
s
n
o
m
m
o
c

r
e
p

8
2
5
.
0
$
(
d
e
r
a
l
c
e
d

s
d
n
e
d
i
v
i
d

h
s
a
C

t
s
e
r
e
t
n
i
g
n
i
l
l
o
r
t
n
o
c
-
n
o
n
n
i

e
g
n
a
h
C

d
e
u
s
s
i

s
d
r
a
w
a
d
e
s
a
b
-
e
r
a
h
S

:
x
a
t

f
o

t
e
n

,
e
m
o
c
n
i

e
v
i
s
n
e
h
e
r
p
m
o
c

f
o

s
t
n
e
n
o
p
m
o
C

k
c
o
t
s

n
o
m
m
o
c

f
o
e
s
a
h
c
r
u
p
e
R

n
o
i
t
a
s
n
e
p
m
o
c
d
e
s
a
b
-
e
r
a
h
S

4
1
0
2
,
1
3
r
e
b
o
t
c
O

f
o

s
a

e
c
n
a
l
a
B

e
m
o
c
n
i

e
v
i
s
n
e
h
e
r
p
m
o
c

l
a
t
o
T

s
s
o
l

e
v
i
s
n
e
h
e
r
p
m
o
c

r
e
h
t
O

e
m
o
c
n
i

t
e
N

)
e
r
a
h
s

n
o
m
m
o
c

r
e
p

0
4
.
0
$
(
d
e
r
a
l
c
e
d

s
d
n
e
d
i
v
i
d

h
s
a
C

d
e
u
s
s
i

s
d
r
a
w
a

d
e
s
a
b

e
r
a
h
s
m
o
r
f

t
i
f
e
n
e
b

x
a
T

d
e
u
s
s
i

s
d
r
a
w
a
d
e
s
a
b
-
e
r
a
h
S

t
h
g
i
s
y
e
K

f
o

n
o
i
t
u
b
i
r
t
s
i
D

k
c
o
t
s

n
o
m
m
o
c

f
o
e
s
a
h
c
r
u
p
e
R

n
o
i
t
a
s
n
e
p
m
o
c
d
e
s
a
b
-
e
r
a
h
S

5
1
0
2
,
1
3
r
e
b
o
t
c
O

f
o

s
a

e
c
n
a
l
a
B

s
l
a
i
c
n
a
n
i
F

t
r
o
p
e
R

l
a
u
n
n
A

The accompanying notes are an integral part of these consolidated financial statements.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

1. OVERVIEW AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

Overview. Agilent Technologies Inc. ("we", "Agilent" or the "company"), incorporated in Delaware in
May 1999, is a global leader in life sciences, diagnostics and applied chemical markets, providing application
focused solutions that includes instruments, software, services and consumables for the entire laboratory
workflow.

Keysight Separation. On November 1, 2014, we completed the distribution of 100% of the outstanding
common shares of Keysight Technologies, Inc. ("Keysight") to Agilent stockholders who received one share of
Keysight common stock for every two shares of Agilent held as of the close of business on the record date,
October 22, 2014. The historical results of operations and the financial position of Keysight are included in the
consolidated financial statements of Agilent and are reported as discontinued operations within this annual
report.

Exit of Nuclear Magnetic Resonance Business. During the fourth quarter of fiscal year 2014, we made the
decision to cease the manufacture and sale of our nuclear magnetic resonance (“NMR”) product line within our
life sciences and applied markets segment. In connection with the exit from this business, we recorded
approximately $6 million and $68 million in restructuring and other related costs in 2015 and 2014, respectively.
For additional details related to the exit of the NMR business see Note 15, "Exit of NMR Business". We will
continue to provide service support to the NMR installed base.

New Segment Structure. In November 2014, we announced a change in organizational structure designed to
better serve our customers. Our life sciences business, excluding the nucleic acid solutions division, together
with the chemical analysis business combined to form a new segment called life sciences and applied markets
business. Our diagnostics and genomics businesses combined with the nucleic acid solutions division from our
life sciences business and became the diagnostics and genomics segment. Finally, the Agilent CrossLab segment
was formed from the services and consumables businesses previously part of the life sciences and chemicals
analysis businesses. Financial reporting under this new structure is included within this annual report and
historical financial segment information has been recast to conform to this new presentation within our financial
statements.

Basis of presentation. The accompanying financial data has been prepared by us pursuant to the rules and
regulations of the U.S. Securities and Exchange Commission ("SEC") and is in conformity with U.S. generally
accepted accounting principles ("GAAP"). Our fiscal year end is October 31. Unless otherwise stated, all years
and dates refer to our fiscal year.

Principles of consolidation. The consolidated financial statements include the accounts of the company
and our wholly- and majority-owned subsidiaries. All significant intercompany accounts and transactions have
been eliminated.

Revision of Services and other and Product Net Revenues and related Cost of Sales. In 2015 we revised
amounts shown in our consolidated statement of operations to more accurately reflect the character of items
delivered to customers. Our diagnostic and genomics segment identified a stream of service revenues that had
been presented as product revenue in previous years. We have now revised those years’ presentation to show the
revenue within services and other. The cost of sales associated with these newly identified service revenues has
also been revised to align with the new presentation. For the year ended October 31, 2014 service and other
revenue increased $21 million and service and other cost of sales increased $19 million with corresponding
reductions in product revenue and cost of sales. For the year ended October 31, 2013 service and other revenue
increased $17 million and service and other cost of sales increased$12 million with corresponding reductions in
product revenue and cost of sales. These corrections to the classifications are not considered to be material to
current or prior periods and had no impact to our consolidated statement of operations.

Use of estimates. The preparation of financial statements in accordance with U.S. GAAP requires
management to make estimates and assumptions that affect the amounts reported in our consolidated financial

statements and accompanying notes. Management bases its estimates on historical experience and various other
assumptions believed to be reasonable. Although these estimates are based on management's best knowledge of
current events and actions that may impact the company in the future, actual results may be different from the
estimates. Our critical accounting policies are those that affect our financial statements materially and involve
difficult, subjective or complex judgments by management. Those policies are revenue recognition, valuation of
goodwill and purchased intangible assets, inventory valuation, share-based compensation, retirement and post-
retirement plan assumptions, restructuring and accounting for income taxes.

Revenue recognition. We enter into agreements to sell products (hardware and/or software), services and

other arrangements (multiple element arrangements) that include combinations of products and services.

We recognize revenue, net of trade discounts and allowances, provided that (1) persuasive evidence of an
arrangement exists, (2) delivery has occurred, (3) the price is fixed or determinable and (4) collectability is
reasonably assured. Delivery is considered to have occurred when title and risk of loss have transferred to the
customer for products, or when the service has been provided. We consider the price to be fixed or determinable
when the price is not subject to refund or adjustments. We consider arrangements with extended payment terms
not to be fixed or determinable, and accordingly we defer revenue for these sales arrangements for which the
payment is not yet due. At the time of the transaction, we evaluate the creditworthiness of our customers to
determine the appropriate timing of revenue recognition.

Product revenue. Our product revenue is generated predominantly from the sales of various types of
analytical instrumentation. Product revenue, including sales to resellers and distributors, is reduced for estimated
returns when appropriate. For sales or arrangements that include customer-specified acceptance criteria,
including those where acceptance is required upon achievement of performance milestones, revenue is
recognized after the acceptance criteria have been met. For products that include installation, if the installation
meets the criteria to be considered a separate element, product revenue is recognized upon delivery, and
recognition of installation revenue is delayed until the installation is complete. Otherwise, neither the product nor
the installation revenue is recognized until the installation is complete.

Where software is licensed separately, revenue is recognized when the software is delivered and has been
transferred to the customer or, in the case of electronic delivery of software, when the customer is given access to
the licensed software programs.

We also evaluate whether collection of the receivable is probable, the fee is fixed or determinable and
whether any other undelivered elements of the arrangement exist on which a portion of the total fee would be
allocated based on vendor-specific objective evidence.

Service revenue. Revenue from services includes extended warranty, customer and software support,
consulting including companion diagnostics and training and education. Service revenue is deferred and
recognized over the contractual period or as services are rendered and accepted by the customer. For example,
customer support contracts are recognized ratably over the contractual period, while training revenue is
recognized as the training is provided to the customer. In addition the four revenue recognition criteria described
above must be met before service revenue is recognized.

Revenue Recognition for Arrangements with Multiple Deliverables. Our multiple-element arrangements
are generally comprised of a combination of measurement instruments, installation or other start-up services,
and/or software and/or support or services. Hardware and software elements are typically delivered at the same
time and revenue is recognized upon delivery once title and risk of loss pass to the customer. Delivery of
installation, start-up services and other services varies based on the complexity of the equipment, staffing levels
in a geographic location and customer preferences, and can range from a few days to a few months. Service
revenue is deferred and recognized over the contractual period or as services are rendered and accepted by the
customer. Revenue from the sale of software products that are not required to deliver the tangible product's
essential functionality are accounted for under software revenue recognition rules which require vendor specific
objective evidence (VSOE) of fair value to allocate revenue in a multiple element arrangement. Our
arrangements generally do not include any provisions for cancellation, termination, or refunds that would
significantly impact recognized revenue.

s
l
a
i
c
n
a
n
i
F

t
r
o
p
e
R

l
a
u
n
n
A

We have evaluated the deliverables in our multiple-element arrangements and concluded that they are
separate units of accounting if the delivered item or items have value to the customer on a standalone basis and
for an arrangement that includes a general right of return relative to the delivered item(s), delivery or
performance of the undelivered item(s) is considered probable and substantially in our control. We allocate
revenue to each element in our multiple-element arrangements based upon their relative selling prices. We
determine the selling price for each deliverable based on a selling price hierarchy. The selling price for a
deliverable is based on VSOE if available, third-party evidence (TPE) if VSOE is not available, or estimated
selling price (ESP) if neither VSOE nor TPE is available. Revenue allocated to each element is then recognized
when the basic revenue recognition criteria for that element have been met.

We use VSOE of selling price in the selling price allocation in all instances where it exists. VSOE of selling
price for products and services is determined when a substantial majority of the selling prices fall within a
reasonable range when sold separately. TPE of selling price can be established by evaluating largely
interchangeable competitor products or services in standalone sales to similarly situated customers. As our
products contain a significant element of proprietary technology and the solution offered differs substantially
from that of competitors, it is difficult to obtain the reliable standalone competitive pricing necessary to establish
TPE. ESP represents the best estimate of the price at which we would transact a sale if the product or service
were sold on a standalone basis. We determine ESP for a product or service by using historical selling prices
which reflect multiple factors including, but not limited to customer type, geography, market conditions,
competitive landscape, gross margin objectives and pricing practices. The determination of ESP is made through
consultation with and approval by management. We may modify or develop new pricing practices and strategies
in the future. As these pricing strategies evolve changes may occur in ESP. The aforementioned factors may
result in a different allocation of revenue to the deliverables in multiple element arrangements, which may
change the pattern and timing of revenue recognition for these elements but will not change the total revenue
recognized for the arrangement.

Deferred revenue. Deferred revenue represents the amount that is allocated to undelivered elements in
multiple element arrangements. We limit the revenue recognized to the amount that is not contingent on the
future delivery of products or services or meeting other specified performance conditions.

Accounts receivable, net. Trade accounts receivable are recorded at the invoiced amount and do not bear
interest. Such accounts receivable has been reduced by an allowance for doubtful accounts, which is our best
estimate of the amount of probable credit losses in our existing accounts receivable. We determine the allowance
based on customer specific experience and the aging of such receivables, among other factors. The allowance for
doubtful accounts as of October 31, 2015 and 2014 was not material. We do not have any off-balance-sheet
credit exposure related to our customers. Accounts receivable are also recorded net of product returns.

Shipping and handling costs. Our shipping and handling costs charged to customers are included in net

revenue, and the associated expense is recorded in cost of products for all periods presented.

Inventory. Inventory is valued at standard cost, which approximates actual cost computed on a first-in,
first-out basis, not in excess of market value. We assess the valuation of our inventory on a periodic basis and
make adjustments to the value for estimated excess and obsolete inventory based on estimates about future
demand. The excess balance determined by this analysis becomes the basis for our excess inventory charge. Our
excess inventory review process includes analysis of sales forecasts, managing product rollovers and working
with manufacturing to maximize recovery of excess inventory.

Goodwill and Purchased Intangible Assets. Under the authoritative guidance we have the option to perform
a qualitative assessment to determine whether further impairment testing is necessary. The accounting standard
gives an entity the option to first assess qualitative factors to determine whether performing the two-step test is
necessary. If an entity believes, as a result of its qualitative assessment, that it is more-likely-than-not (i.e. greater
than 50% chance) that the fair value of a reporting unit is less than its carrying amount, the quantitative
impairment test will be required. Otherwise, no further testing will be required.

entity's operating environment or industry or market considerations; entity-specific events such as increasing
costs, declining financial performance, or loss of key personnel; or other events such as an expectation that a
reporting unit will be sold or a sustained decrease in the stock price on either an absolute basis or relative to
peers.

If it is determined, as a result of the qualitative assessment, that it is more-likely-than-not that the fair value
of a reporting unit is less than its carrying amount, the provisions of authoritative guidance require that we
perform a two-step impairment test on goodwill. In the first step, we compare the fair value of each reporting
unit to its carrying value. The second step (if necessary) measures the amount of impairment by applying fair-
value-based tests to the individual assets and liabilities within each reporting unit. As defined in the authoritative
guidance, a reporting unit is an operating segment, or one level below an operating segment. We aggregate
components of an operating segment that have similar economic characteristics into our reporting units.

In fiscal year 2015, we assessed goodwill impairment for our three reporting units which consisted of three
segments: life sciences and applied markets, diagnostics and genomics and Agilent CrossLab. Due to the new
segment structure in November 2014 we performed a quantitative test for goodwill impairment of the three
reporting units, as of September 30, 2015. Based on the results of our testing, the fair value of these reporting
units are greater than their respective carrying values. Each quarter we review the events and circumstances to
determine if goodwill impairment is indicated. There was no impairment of goodwill during the years ended
October 31, 2015, 2014 and 2013.

Purchased intangible assets consist primarily of acquired developed technologies, proprietary know-how,
trademarks, and customer relationships and are amortized using the best estimate of the asset's useful life that
reflect the pattern in which the economic benefits are consumed or used up or a straight-line method ranging
from 6 months to 15 years. In-process research and development ("IPR&D") is initially capitalized at fair value
as an intangible asset with an indefinite life and assessed for impairment thereafter. When the IPR&D project is
complete, it is reclassified as an amortizable purchased intangible asset and is amortized over its estimated useful
life. If an IPR&D project is abandoned, Agilent will record a charge for the value of the related intangible asset
to Agilent's condensed consolidated statement of operations in the period it is abandoned.

Agilent's indefinite-lived intangible assets are IPR&D intangible assets. The accounting guidance allows a
qualitative approach for testing indefinite-lived intangible assets for impairment, similar to the issued impairment
testing guidance for goodwill and allows the option to first assess qualitative factors (events and circumstances)
that could have affected the significant inputs used in determining the fair value of the indefinite-lived intangible
asset to determine whether it is more-likely-than-not (i.e. greater than 50% chance) that the indefinite-lived
intangible asset is impaired. An organization may choose to bypass the qualitative assessment for any indefinite-
lived intangible asset in any period and proceed directly to calculating its fair value. We performed a qualitative
test for impairment of indefinite-lived intangible assets as of September 30, 2015. Based on the results of our
qualitative testing, we believe that it is more-likely-than-not that the fair value of these indefinite-lived intangible
assets is greater than their respective carrying values. Each quarter we review the events and circumstances to
determine if impairment of indefinite-lived intangible asset is indicated. In the years ended October 31, 2015,
2014 and 2013, we recorded an impairment of $3 million, $4 million and zero, respectively due to the
cancellation of certain IPR&D projects. In addition, in the year ended October 31, 2014, we also recorded $12
million of impairment of other intangibles due to the exit of our NMR business.

Share-based compensation. For the years ended 2015, 2014 and 2013, we accounted for share-based
awards made to our employees and directors including employee stock option awards, restricted stock units,
employee stock purchases made under our Employee Stock Purchase Plan ("ESPP") and performance share
awards under Agilent Technologies, Inc. Long-Term Performance Program ("LTPP") using the estimated grant
date fair value method of accounting. Under the fair value method, we recorded compensation expense, in
continuing operations, for all share-based awards of $55 million in 2015, $59 million in 2014 and $51 million in
2013. For the stock option and long term performance plan grants in 2015 we are now using a volatility measure
derived from a selection of our peer companies. In prior periods, we used Agilent stock historical volatility. We
currently consider this method to not be reflective of our future volatility due to the separation of Keysight. See
Note 5, "Share-based compensation" for additional information.

s
l
a
i
c
n
a
n
i
F

t
r
o
p
e
R

l
a
u
n
n
A

Retirement and post-retirement plans. Substantially all of our employees are covered under various defined
benefit and/or defined contribution retirement plans. Additionally we sponsor post-retirement health care
benefits for our eligible U.S. employees. Assumptions used to determine the benefit obligations and the expense
for these plans are derived annually. See Note 16, “Retirement plans and post-retirement pension plans” for
additional information.

Restructuring and exit of NMR business. The main components of expenses are related to workforce
reductions, assets impairments and write-downs and special charges to inventory, which mainly relates to exiting
of one of our businesses. Workforce reduction charges are accrued when payment of benefits that the employees
are entitled to becomes probable and the amounts can be estimated. We have also assessed the recoverability of
our long-lived assets, by determining whether the carrying value of such assets will be recovered through
undiscounted future cash flows. Asset impairments primarily consist of property, plant and equipment and are
based on an estimate of the amounts and timing of future cash flows related to the expected future remaining use
and ultimate sale or disposal of buildings and equipment net of costs to sell. The charges related to inventory
include estimated future inventory disposal payments that we are contractually obliged to make to our suppliers
and inventory written-down to net realizable value. If the amounts and timing of cash flows from restructuring
activities are significantly different from what we have estimated, the actual amount of restructuring and asset
impairment charges could be materially different, either higher or lower, than those we have recorded.

Taxes on income. Income tax expense or benefit is based on income or loss before taxes. Deferred tax
assets and liabilities are recognized principally for the expected tax consequences of temporary differences
between the tax bases of assets and liabilities and their reported amounts. See Note 6, "Income Taxes" for more
information.

Warranty. Our standard warranty terms typically extend for one year from the date of delivery. We accrue
for standard warranty costs based on historical trends in warranty charges as a percentage of net product revenue.
The accrual is reviewed regularly and periodically adjusted to reflect changes in warranty cost estimates.
Estimated warranty charges are recorded within cost of products at the time products are sold. See Note 17,
"Guarantees".

Advertising. Advertising costs are generally expensed as incurred and amounted to $25 million in 2015,

$31 million in 2014 and $28 million in 2013.

Research and development. Costs related to research, design and development of our products are charged

to research and development expense as they are incurred.

Sales Taxes. Sales taxes collected from customers and remitted to governmental authorities are not

included in our revenue.

Net income per share. Basic net income per share is computed by dividing net income - the numerator - by
the weighted average number of common shares outstanding - the denominator - during the period excluding the
dilutive effect of stock options and other employee stock plans. Diluted net income per share gives effect to all
potential common shares outstanding during the period unless the effect is anti-dilutive. The dilutive effect of
share-based awards is reflected in diluted net income per share by application of the treasury stock method,
which includes consideration of unamortized share-based compensation expense, the tax benefits and shortfalls
charged to additional paid-in capital and the dilutive effect of in-the-money options and non-vested restricted
stock units. Under the treasury stock method, the amount the employee must pay for exercising stock options,
unamortized share-based compensation expense and tax benefits or shortfalls are assumed proceeds to be used to
repurchase hypothetical shares. See Note 7, "Net Income Per Share".

Cash, cash equivalents and short term investments. We classify investments as cash equivalents if their
original or remaining maturity is three months or less at the date of purchase. Cash equivalents are stated at cost,
which approximates fair value.

As of October 31, 2015, approximately $1,780 million of our cash and cash equivalents is held outside of the
U.S. in our foreign subsidiaries. Under current tax laws, the cash could be repatriated to the U.S. but most of it
would be subject to U.S. federal and state income taxes, less applicable foreign tax credits. Our cash and cash
equivalents mainly consist of short term deposits held at major global financial institutions, institutional money
market funds, and similar short duration instruments with original maturities of 90 days or less. We continuously
monitor the creditworthiness of the financial institutions and institutional money market funds in which we
invest our funds.

We classify investments as short-term investments if their original maturities are greater than three months

and their remaining maturities are one year or less. Currently, we have no short-term investments.

Fair Value of Financial Instruments. The carrying values of certain of our financial instruments including
cash and cash equivalents, accounts receivable, accounts payable, accrued compensation and other accrued
liabilities approximate fair value because of their short maturities. The fair value of long-term equity investments
is determined using quoted market prices for those securities when available. For those long-term equity
investments accounted for under the cost or equity method, their carrying value approximates their estimated fair
value. Equity method investments are reported at the amount of the company’s initial investment and adjusted
each period for the company’s share of the investee’s income or loss and dividend paid. The fair value of our
long-term debt, calculated from quoted prices which are primarily Level 1 inputs under the accounting guidance
fair value hierarchy, exceeds the carrying value by approximately $30 million and $53 million as of October 31,
2015 and 2014, respectively. The fair value of foreign currency contracts used for hedging purposes is estimated
internally by using inputs tied to active markets. These inputs, for example, interest rate yield curves, foreign
exchange rates, and forward and spot prices for currencies are observable in the market or can be corroborated by
observable market data for substantially the full term of the assets or liabilities. See also Note 13, "Fair Value
Measurements" for additional information on the fair value of financial instruments.

Concentration of credit risk. Financial instruments that potentially subject Agilent to significant
concentration of credit risk include money market fund investments, time deposits and demand deposit balances.
These investments are categorized as cash and cash equivalents. In addition, Agilent has credit risk from
derivative financial instruments used in hedging activities and accounts receivable. We invest in a variety of
financial instruments and limit the amount of credit exposure with any one financial institution. We have a
comprehensive credit policy in place and credit exposure is monitored on an ongoing basis.

Credit risk with respect to our accounts receivable is diversified due to the large number of entities
comprising our customer base and their dispersion across many different industries and geographies. Credit
evaluations are performed on customers requiring credit over a certain amount and we sell the majority of our
products through our direct sales force. Credit risk is mitigated through collateral such as letter of credit, bank
guarantees or payment terms like cash in advance. No single customer accounted for more than 10 percent of
combined accounts receivable as of October 31, 2015, or 2014.

Derivative instruments. Agilent is exposed to global foreign currency exchange rate and interest rate risks
in the normal course of business. We enter into foreign exchange hedging contracts, primarily forward contracts
and purchased options and, in the past, interest rate swaps to manage financial exposures resulting from changes
in foreign currency exchange rates and interest rates. In the vast majority of cases, these contracts are designated
at inception as hedges of the related foreign currency or interest exposures. Foreign currency exposures include
committed and anticipated revenue and expense transactions and assets and liabilities that are denominated in
currencies other than the functional currency of the subsidiary. Interest rate exposures are associated with the
company's fixed-rate debt. For option contracts, we exclude time value from the measurement of effectiveness.
To qualify for hedge accounting, contracts must reduce the foreign currency exchange rate and interest rate risk
otherwise inherent in the amount and duration of the hedged exposures and comply with established risk
management policies; foreign exchange hedging contracts generally mature within twelve months and interest
rate swaps, if any, mature at the same time as the maturity of the debt. In order to manage foreign currency
exposures in a few limited jurisdictions we may enter into foreign exchange contracts that do not qualify for
hedge accounting. In such circumstances, the local foreign currency exposure is offset by contracts owned by the
parent company. We do not use derivative financial instruments for speculative trading purposes.

s
l
a
i
c
n
a
n
i
F

t
r
o
p
e
R

l
a
u
n
n
A

All derivatives are recognized on the balance sheet at their fair values. For derivative instruments that are
designated and qualify as a fair value hedge, changes in value of the derivative are recognized in the consolidated
statement of operations in the current period, along with the offsetting gain or loss on the hedged item
attributable to the hedged risk. For derivative instruments that are designated and qualify as a cash flow hedges,
changes in the value of the effective portion of the derivative instrument is recognized in comprehensive income
(loss), a component of stockholders' equity. Amounts associated with cash flow hedges are reclassified and
recognized in income when either the forecasted transaction occurs or it becomes probable the forecasted
transaction will not occur. Derivatives not designated as hedging instruments are recorded on the balance sheet at
their fair value and changes in the fair values are recorded in the income statement in the current period.
Derivative instruments are subject to master netting arrangements and are disclosed gross in the balance sheet.
Changes in the fair value of the ineffective portion of derivative instruments are recognized in earnings in the
current period. Ineffectiveness in 2015, 2014 and 2013 was not material. Cash flows from derivative instruments
are classified in the statement of cash flows in the same category as the cash flows from the hedged or
economically hedged item, primarily in operating activities.

Property, plant and equipment. Property, plant and equipment are stated at cost less accumulated
depreciation. Additions, improvements and major renewals are capitalized; maintenance, repairs and minor
renewals are expensed as incurred. When assets are retired or disposed of, the assets and related accumulated
depreciation and amortization are removed from our general ledger, and the resulting gain or loss is reflected in
the consolidated statement of operations. Buildings and improvements are depreciated over the lesser of their
useful lives or the remaining term of the lease and machinery and equipment over three to ten years. We use the
straight-line method to depreciate assets.

Leases. We lease buildings, machinery and equipment under operating leases for original terms ranging
generally from one year to twenty years. Certain leases contain renewal options for periods up to six years. In
addition, we lease equipment to customers in connection with our diagnostics business using both capital and
operating leases. As of October 31, 2015 and 2014 our diagnostics and genomics segment has approximately $11
million and $8 million, respectively, of lease receivables related to capital leases and approximately $31 million
and $33 million, respectively, of net assets for operating leases. We depreciate the assets related to the operating
leases over their estimated useful lives.

Capitalized software. We capitalize certain internal and external costs incurred to acquire or create internal
use software. Capitalized software is included in property, plant and equipment and is depreciated over three to
five years once development is complete.

Impairment of long-lived assets. We continually monitor events and changes in circumstances that could
indicate carrying amounts of long-lived assets, including intangible assets, may not be recoverable. When such
events or changes in circumstances occur, we assess the recoverability of long-lived assets by determining
whether the carrying value of such assets will be recovered through undiscounted expected future cash flows. If
the total of the undiscounted future cash flows is less than the carrying amount of those assets, we recognize an
impairment loss based on the excess of the carrying amount over the fair value of the assets.

Employee compensation and benefits. Amounts owed to employees, such as accrued salary, bonuses and
vacation benefits are accounted for within employee compensation and benefits. The total amount of accrued
vacation benefit was $86 million and $100 million as of October 31, 2015, and 2014, respectively.

Foreign currency translation. We translate and remeasure balance sheet and income statement items into
U.S. dollars. For those subsidiaries that operate in a local currency functional environment, all assets and
liabilities are translated into U.S. dollars using current exchange rates at the balance sheet date; revenue and
expenses are translated using monthly exchange rates which approximate to average exchange rates in effect
during each period. Resulting translation adjustments are reported as a separate component of accumulated other
comprehensive income (loss) in stockholders' equity.

For those subsidiaries that operate in a U.S. dollar functional environment, foreign currency assets and
liabilities are remeasured into U.S. dollars at current exchange rates except for non-monetary assets and capital
accounts which are remeasured at historical exchange rates. Revenue and expenses are generally remeasured at

monthly exchange rates which approximate average exchange rates in effect during each period. Gains or losses
from foreign currency remeasurement are included in consolidated net income. Net gains or losses resulting from
foreign currency transactions, including hedging gains and losses, are reported in other income (expense), net
and was $9 million loss for fiscal year 2015, $4 million loss for 2014 and $2 million loss for 2013, respectively.

2. REVISION OF PRIOR PERIOD FINANCIAL STATEMENTS

During the year ended October 31, 2014 the company identified and recorded various out of period income
tax adjustments. Specifically, $13 million tax expense for corrections to U.S. deferred taxes, $12 million tax
expense for the correction of transfer pricing for prior years, $9 million tax benefit related to the correction of the
tax basis of land in the U.K. and $3 million of tax expense to correct tax related balance sheet accounts. During
the year ended October 31, 2015 the company identified additional income tax out of period adjustments.
Specifically, $13 million of tax benefit from the reduction in deferred tax liabilities due to tax rate changes in
Denmark occurring in the prior year, $10 million of tax benefit to correct the overstatement of U.S. income taxes
payable, $7 million of tax benefit to correct the understatement of international prepaid income taxes, $17
million of tax expense to correct deferred tax liabilities associated with unremitted foreign earnings, $4 million
of tax expense attributable to an error discovered on a prior year U.S. tax return, $4 million tax expense related to
foreign deferred tax assets, and a $2 million net tax benefit associated with errors in prior year international
income tax provisions. The aggregated impact of the out of period income tax adjustments identified, including
the reversing effect of prior year errors, resulted in the provision for income taxes in 2014 and 2013 to be
overstated by $45 million and $10 million, respectively.

We evaluated the aggregate effects of the errors to our previously issued financial statements in accordance
with SEC Staff Accounting Bulletins No. 99 and No. 108 and, based upon quantitative and qualitative factors,
determined that the errors were not material to the previously issued financial statements and disclosures
included in our Annual Report on Form 10-K for the year ended October 31, 2014 or for any quarterly periods
included therein or through our most recent Quarterly Report on Form 10-Q. As part of this evaluation, we
considered a number of qualitative factors, including, among others, that the errors did not change a net loss into
net income or vice versa, did not have an impact on our long-term debt covenant compliance, and did not mask a
change in earnings or other trends when considering the overall competitive and economic environment within
the industry during the periods. However, as a result of the Company presenting continuing operations and
discontinued operations for the first time in our Annual Report on Form 10-K, we determined the effect of the
errors is significant to our financial results for the year ending October 31, 2014 and 2013. Accordingly, we are
revising our historical financial statements.

Due to the immaterial nature of the misstatement corrections, the cumulative adjustments required to correct
the misstatements in the financial statements prior to the fiscal year ended October 31, 2013 are reflected in the
revised stockholders’ equity as of October 31, 2012. The cumulative effect of those adjustments increased
previously reported retained earnings by $13 million and reduced additional paid in capital by $12 million. The
cumulative effect to retained earnings includes the $65 million related to adjusting the cumulative effect of a
change in accounting principle to reduce our long-term tax liabilities that was previously recorded in 2014.

s
l
a
i
c
n
a
n
i
F

t
r
o
p
e
R

l
a
u
n
n
A

These adjustments also cumulatively impacted the following balance sheet line items as of October 31,

2014:

Other current assets
Current assets of discontinued operations

Total current assets

Other assets
Non-current assets of discontinued operations

Total assets

Other accrued liabilities

Total current liabilities
Other long-term liabilities
Total liabilities

Retained earnings

Total stockholders equity

As
Reported

October 31, 2014

Adjustments

(in millions)

As
Revised

$
$
$

$
$
$
$

261 $

1,821
5,500

283
1,165
10,831 $

289 $
1,702 $
522 $
5,530 $

6,466 $

5,298 $

2 $
7 $
9 $
(15 ) $
(10 ) $
(16) $

(10) $
(10) $
(9) $
(19) $

3 $
3 $

263
1,828
5,509

268
1,155
10,815

279
1,692
513
5,511

6,469

5,301

The errors discussed above resulted in an understatement of net income of $45 million and $10 million

relating to the provision for income taxes for the years ended October 31, 2014 and 2013, respectively.

$
$

Income before taxes
Provision (benefit) for income taxes
Income from continuing operations before taxes
Provision for income taxes on continuing operations
Income from continuing operations
Income from discontinued operations, net of tax expense of
$100

Net income

Net income per share:

Basic
Diluted

Net income per share - basic

Income from continuing operations
Income from discontinued operations
Net income per share - basic

Net income per share - diluted

Income from continuing operations
Income from discontinued operations
Net income per share - diluted

Year Ended October 31, 2014

As Reported

Adjustments

Revised

Reclassified
for
Discontinued
Operations

(in millions, except per share data)
646
97

(45)

646
142

229
(3)
232

317

549

0.70
0.95
1.65

0.69
0.93
1.62

504 $

45 $

549 $

1.51 $
1.49 $

0.14 $
0.13 $

1.65
1.62

$
$
$

Total comprehensive income

79 $

45 $

124

s
l
a
i
c
n
a
n
i
F

t
r
o
p
e
R

l
a
u
n
n
A

Year Ended October 31, 2013

As Reported

Adjustments

Revised

Reclassified
for
Discontinued
Operations

$
$

Net income

Net income per share:

Basic
Diluted

Net income per share - basic

Income from continuing operations
Income form discontinued operations
Net income per share - basic

Net income per share - diluted

Income from continuing operations
Income form discontinued operations
Net income per share - diluted

(in millions, except per share data)
859
125

(10)

859
135

293
68
225

509

734

0.66
1.49
2.15

0.65
1.48
2.13

724 $

10 $

734 $

2.12 $
2.10 $

0.03 $
0.03 $

2.15
2.13

$
$
$

Total comprehensive income

926 $

10 $

936

The adjustments resulted in the following revisions to our consolidated cash flow statements.

Net income
Deferred taxes
Changes in assets and liabilities:
Other assets and liabilities

Year Ended October 31, 2014

As
Reported

Adjustments

(in millions)

As
Revised

504 $
(132) $

45 $
(60) $

549
(192)

(60) $

15 $

(45)

Year Ended October 31, 2013

As
Reported

Adjustments

(in millions)

As
Revised

724 $
31

(17)

10 $
(35) $

25 $

734
(4)

$
$

All financial information presented in the accompanying notes to these consolidated financial statements

was revised to reflect the correction of these errors.

3. NEW ACCOUNTING PRONOUNCEMENTS

In April 2014, Financial Accounting Standards Board ("FASB") issued amendments to the guidance on
discontinued operations. The guidance changes the criteria for reporting discontinued operations while enhancing
disclosures in this area. Under the new guidance, only disposals representing a strategic shift in operations should
be presented as discontinued operations. Those strategic shifts should have a major effect on the organization’s
operations and financial results. Examples include a disposal of a major geographic area, a major line of
business, or a major equity method investment. Additionally, the new guidance requires expanded disclosures
about discontinued operations that will provide financial statement users with more information about the assets,
liabilities, income, expenses of discontinued operations and of the pre-tax income attributable to a disposal of a
significant part of an organization that does not qualify for discontinued operations reporting. The new guidance
is effective for Agilent prospectively for all disposals (or classifications as held for sale) of components of an
entity that occur after November 1, 2016.

The disposal of Keysight meets the definition of a discontinued operation under both the existing and
amended accounting guidance. The historical results of operations and the financial position of Keysight are
included in the consolidated financial statements of Agilent and are reported as discontinued operations within
this annual report.

In May 2014, the FASB issued an amendment to the accounting guidance related to revenue recognition.
The amendment was the result of a joint project between the FASB and the International Accounting Standards
Board ("IASB") to clarify the principles for recognizing revenue and to develop common revenue standards for
U.S. GAAP and International Financial Reporting Standards ("IFRS"). To meet those objectives, the FASB is
amending the FASB Accounting Standards Codification and creating a new Topic 606, Revenue from Contracts
with Customers, and the IASB is issuing IFRS 15, Revenue from Contracts with Customers. We are evaluating
the impact of adopting this guidance to our consolidated financial statements.

In January 2015, FASB issued guidance on simplifying income statement presentation by eliminating the
concept of extraordinary items from U.S. GAAP. The amendments in this update are effective for us from
November 1, 2016, and in interim periods during that year. A reporting entity may apply the amendments
prospectively and retrospectively to all periods presented in the financial statements. Early adoption is permitted
provided that the guidance is applied from the beginning of the fiscal year of adoption. We have evaluated the
accounting guidance and determined that there is no impact of this update to our consolidated financial
statements.

In February 2015, FASB issued an amendment to the analysis that a reporting entity must perform to
determine whether it should consolidate certain types of legal entities. All legal entities are subject to
reevaluation under the revised consolidation model. The amendments in this update are effective for us from
November 1, 2016, and for interim periods within that year. We do not expect that adopting this guidance will
have an impact to our consolidated financial statements.

In April 2015, FASB issued an amendment to simplify the presentation of debt issuance costs. The
amendments in this update require that debt issuance costs related to a recognized debt liability be presented in
the balance sheet as a direct deduction from the carrying amount of that debt liability, consistent with debt
discounts. The recognition and measurement guidance for debt issuance costs remain unchanged. The
amendments in this update are effective for us from November 1, 2016, and for interim periods within that year.
Earlier adoption is permitted and we are currently evaluating when we will implement the guidance. We do not
expect the impact of adopting this guidance to be material to our consolidated financial statements.

In July 2015, FASB issued guidance to simplify the accounting for inventory and to more closely align their
guidance with international accounting standards. The amendments in this update apply to companies which use
inventory valuation methods other than last in, first-out and the retail inventory method to change the way that
they subsequently measure the value of inventory on their balance sheet. Under the new guidance, inventory
should be valued at the lower of cost and net realizable value rather than the lower of cost and market. The
amendments in this update are effective for us from November 1, 2017, and for interim periods in the following

s
l
a
i
c
n
a
n
i
F

t
r
o
p
e
R

l
a
u
n
n
A

year. We do not expect this amended guidance to have an impact to our consolidated financial statements, as the
new guidance aligns with our current practice of using net realizable value as our estimate of market value.

In July 2015, FASB announced that the implementation date of Topic 606, Revenue from Contracts with
Customers, would be delayed by one year. It will now be effective for us in fiscal 2019, with early adoption
permitted for us from November 1, 2017. We are evaluating the timing of our adoption and the impact of this
guidance to our consolidated financial statements.

In September 2015, FASB issued guidance intended to simplify accounting for adjustments to provisional
amounts recorded in connection with business combinations. Beginning in November 1, 2017 and in the interim
periods from November 1, 2018, adjustments will be recorded in the period that they are determined rather than
applied retrospectively via revision to the period of acquisition and each period thereafter. Early adoption is
permitted. We do not expect this guidance to have a material impact to our consolidated financial statements,
but we are currently evaluating the timing of our adoption.

In November 2015, FASB issued guidance intended to simplify accounting for deferred taxes. Beginning
on November 1, 2017 including the interim periods following that date we will present all deferred tax balances
as non-current. Existing GAAP guidance requires us to record deferred tax balances as either current or non-
current in accordance with the classification of the underlying attributes. Early adoption is permitted. We are
still evaluating when we will adopt this guidance as we expect adoption will cause significant balance sheet
reclassifications. See Note 6, “Income Taxes” for details of the current and non-current deferred tax liability
balances.

Other amendments to GAAP in the U.S. that have been issued by the FASB or other standards-setting bodies
that do not require adoption until a future date are not expected to have a material impact on our consolidated
financial statements upon adoption.

4. DISCONTINUED OPERATIONS

On September 19, 2013, Agilent announced its intention to separate its electronic measurement business,
Keysight, which was previously a separate reportable segment, into a stand-alone publicly traded company.
Keysight was incorporated in Delaware as a wholly-owned subsidiary of Agilent on December 6, 2013. On
November 1, 2014, we completed the distribution of 100% of the outstanding common stock of Keysight to
Agilent stockholders, who received one share of Keysight common stock for every two shares of Agilent
common stock held as of the close of business on the record date, October 22, 2014. The separation agreement
ensured that Keysight had approximately $700 million of total cash and cash equivalents immediately following
distribution. For the year ended October 31, 2015, we transferred a total amount of cash and cash equivalents of
$734 million to Keysight.

The historical results of operations and statement of financial position of Keysight have been presented as
discontinued operations in the consolidated financial statements and prior periods have been restated.
Discontinued operations include results of Keysight's business except for certain allocated corporate overhead
costs and certain costs associated with transition services provided by Agilent to Keysight. Discontinued
operations also includes other costs incurred by Agilent to separate Keysight. These costs include transaction
charges, advisory and consulting fees and information system expenses.

The following table summarizes results from discontinued operations of Keysight included in the

consolidated statement of operations:

Years Ended October 31,

2015

2014

2013

(in millions)

Net revenue
Costs and expenses

Operating income (loss)
Other income (expense), net

Income (loss) from discontinued operations before tax

Provision (benefit) for income taxes

Net income (loss) from discontinued operations

(39)
—

— $ 2,933 $ 2,888
2,521
2,323
39
412
5
417
100
317 $

565
1

(37) $

(39)

(2)

566

509

Net income (loss) from discontinued operations includes transaction, information systems and other costs to
effect the separation of $39 million and $178 million for the years ended October 31, 2015 and 2014,
respectively. In the year ended October 31, 2015 only those costs incurred to effect the separation have been
included. No income or expense has been recorded for the Keysight business after separation from Agilent on
November 1, 2014.

s
l
a
i
c
n
a
n
i
F

t
r
o
p
e
R

l
a
u
n
n
A

The following table presents Agilent's electronic measurement business assets and liabilities removed from
the consolidated balance sheet as of November 1, 2014 and presented as discontinued operations as of October
31, 2014:

October 31, 2014

(in millions)

Assets:
Cash and cash equivalents
Accounts receivable, net
Inventory
Other current assets

Current assets of discontinued operations
Property, plant and equipment, net
Goodwill
Other intangible assets, net
Long-term investments
Other assets

Non-current assets of discontinued operations
Total assets of discontinued operations

Liabilities:
Accounts payable
Employee compensation and benefits
Deferred revenue
Other accrued liabilities

Current liabilities of discontinued operations
Long-term debt
Retirement and post-retirement benefits
Other long-term liabilities

Long-term liabilities of discontinued operations
Total liabilities of discontinued operations

810
357
498
163

1,828
470
392
18
63
212

1,155
2,983

173
167
175
108

623
1,099
213
122

1,434
2,057

In addition, $332 million of accumulated other comprehensive loss, net of income taxes, primarily related to
pension and other post-retirement benefits plans and currency translation was also transferred to Keysight
together with $28 million of additional paid in capital related to share based compensation windfall tax benefits.
The removal of Keysight net assets and equity related adjustments is presented as a reduction in Agilent's
retained earnings and represents a non cash financing activity excluding cash transferred. See Note 6 “Income
Taxes” for tax implications and adjustments due to the distribution and Note 5 “Share Based Compensation” for
changes to share based compensation awards as a result of the distribution of Keysight.

In order to effect the separation and govern our relationship with Keysight after the separation, we entered
into a Separation and Distribution Agreement and other agreements including a Tax Matters Agreement, an
Employee Matters Agreement and a Transition Services Agreement. The Separation and Distribution Agreement
governs the separation of the electronic measurement business, the transfer of assets and other matters related to
our relationship with Keysight. Any costs incurred by Agilent in respect of these agreements after separation are
recorded in the continuing operations of Agilent.

The Tax Matters Agreement governs the respective rights, responsibilities and obligations of Keysight and

Agilent with respect to taxes, tax attributes, tax returns, tax proceedings and certain other tax matters.

The Employee Matters Agreement governs the compensation and employee benefit obligations with respect
to the current and former employees and non-employee directors of Keysight and Agilent, and generally
allocates liabilities and responsibilities relating to employee compensation, benefit plans and programs. The
Employee Matters Agreement provides that employees of Keysight will no longer participate in benefit plans
sponsored or maintained by Agilent. In addition, the Employee Matters Agreement provides that each of the
parties will be responsible for their respective former and current employees and compensation plans for such
current employees.

Under the terms of the Transition Services Agreement, we agreed to provide administrative, site services,
information technology systems and various other corporate and support services to Keysight over the period of
12-18 months after the separation on a cost or cost-plus basis. The most significant component of the service
income is the provision of IT services that was completed by the end of the second quarter of 2015. In total we
have recorded income for all services provided to Keysight of approximately $12 million. In addition, Agilent
expects to receive lease income together with site service income from Keysight over the next 4-5 years of
approximately $13 million per year. In the year ended October 31, 2015 other income (expense), net includes
$25 million of income in respect of the provision of services to, and lease income from Keysight.

5. SHARE-BASED COMPENSATION

Agilent accounts for share-based awards in accordance with the provisions of the accounting guidance
which requires the measurement and recognition of compensation expense for all share-based payment awards
made to our employees and directors including employee stock option awards, restricted stock units, employee
stock purchases made under our ESPP and performance share awards granted to selected members of our senior
management under the LTPP based on estimated fair values.

Description of Share-Based Plans

Employee stock purchase plan. Effective November 1, 2000, we adopted the ESPP. The ESPP allows
eligible employees to contribute up to ten percent of their base compensation to purchase shares of our common
stock at 85 percent of the closing market price at purchase date. Shares authorized for issuance in connection
with the ESPP are subject to an automatic annual increase of the lesser of one percent of the outstanding shares
of common stock of Agilent on November 1, or an amount determined by the Compensation Committee of our
Board of Directors. Under the terms of the ESPP, in no event shall the number of shares issued under the ESPP
exceed 75 million shares.

Under our ESPP, employees purchased 346,472 shares for $12 million in 2015, 1,604,406 shares for $73
million in 2014 and 1,454,724 shares for $48 million in 2013. As of October 31, 2015, the number of shares of
common stock authorized and available for issuance under our ESPP was 42,605,407.

Incentive compensation plans. On November 19, 2008 and March 11, 2009, the Compensation Committee
of Board of Directors and the stockholders, respectively, approved the Agilent Technologies, Inc. 2009 Stock
Plan (the "2009 Stock Plan") to replace the Company's 1999 Stock Plan and 1999 Stock Non-Employee Director
Stock Plan and subsequently reserved 25 million shares of Company common stock that may be issued under the
2009 Plan, plus any shares forfeited or cancelled under the 1999 Stock Plan. The 2009 Stock Plan provides for
the grant of awards in the form of stock options, stock appreciation rights ("SARs"), restricted stock, restricted
stock units ("RSUs"), performance shares and performance units with performance-based conditions on vesting
or exercisability, and cash awards. The 2009 Plan has a term of ten years. As of October 31, 2015, 13,524,407
shares were available for future awards under the 2009 Stock Plan.

Stock options granted under the 2009 Stock Plans may be either "incentive stock options", as defined in
Section 422 of the Internal Revenue Code, or non-statutory. Options generally vest at a rate of 25 percent per
year over a period of four years from the date of grant and generally have a maximum contractual term of ten

s
l
a
i
c
n
a
n
i
F

t
r
o
p
e
R

l
a
u
n
n
A

years. The exercise price for stock options is generally not less than 100 percent of the fair market value of our
common stock on the date the stock award is granted.

Effective November 1, 2003, the Compensation Committee of the Board of Directors approved the LTPP,
which is a performance stock award program administered under the 2009 Stock Plan, for the company's
executive officers and other key employees. Participants in this program are entitled to receive unrestricted
shares of the company's stock after the end of a three-year period, if specified performance targets are met. LTPP
awards are generally designed to meet the criteria of a performance award with the performance metrics and peer
group comparison set at the beginning of the performance period. Based on the performance metrics the final
award may vary from zero to 200 percent of the target award. The maximum contractual term for awards under
the LTPP program is three years. We consider the dilutive impact of this program in our diluted net income per
share calculation only to the extent that the performance conditions are met.

In March 2007, we began to issue restricted stock units under our share-based plans. The estimated fair
value of the restricted stock unit awards granted under the Stock Plans is determined based on the market price of
Agilent's common stock on the date of grant adjusted for expected dividend yield. Restricted stock units
generally vest, with some exceptions, at a rate of 25 percent per year over a period of four years from the date of
grant.

In connection with the separation of Keysight Technologies on November 1, 2014 and in accordance with
the Employee Matters Agreement we made certain adjustments to the exercise price and number of our share-
based compensation awards with the intention of preserving the intrinsic value of the awards prior to the
separation. Exercisable and non-exercisable stock options converted to those of the entity where the employee is
working post-separation. Restricted stock units awards and long-term performance plan grants were adjusted to
provide holders restricted stock units and long-term performance plan grants in the company that employs such
employee following the separation. These adjustments to our stock-based compensation awards did not have a
material impact on compensation expense.

Impact of Share-based Compensation Awards

We have recognized compensation expense based on the estimated grant date fair value method under the
authoritative guidance. For all share-based awards we have recognized compensation expense using a straight-
line amortization method. As the guidance requires that share-based compensation expense be based on awards
that are ultimately expected to vest, estimated share-based compensation has been reduced for estimated
forfeitures.

The impact on our results for share-based compensation was as follows:

Cost of products and services
Research and development
Selling, general and administrative

Share-based compensation expense in continuing operations

Share-based compensation expense in discontinued operations

Total share-based compensation expense

Years Ended October 31,

2015

2014

2013

(in millions)

11 $
5
39

—
55 $

13 $
7
39
59

39
98 $

12
5
34

37
88

At October 31, 2015 and 2014 there was no share-based compensation capitalized within inventory. The
windfall income tax benefit realized from the exercised stock options and similar awards recognized was $8
million in 2015, $1 million in 2014 and $2 million in 2013, respectively. Approximately $11 million of
previously recognized windfall tax benefits was reversed due to the favorable settlement of a tax authority
examination in first quarter of 2014. The weighted average grant date fair value of options, granted in 2015, 2014
and 2013 was $10.58, $18.73 and $12.18 per share, respectively.

Included in the 2015, 2014 and 2013 expense is incremental expense for acceleration of share-based
compensation related to the announced workforce reduction plan of $2 million, $1 million and $2 million,
respectively. Upon termination of the employees impacted by workforce reduction, the non-vested Agilent
awards held by these employees immediately vests. Employees have a period of up to three months in which to
exercise the Agilent options before such options are cancelled.

Valuation Assumptions

For all periods presented, the fair value of share based awards for employee stock option awards was
estimated using the Black-Scholes option pricing model. For all periods presented, shares granted under the
LTPP were valued using a Monte Carlo simulation. The estimated fair value of restricted stock unit awards was
determined based on the market price of Agilent's common stock on the date of grant adjusted for expected
dividend yield. The ESPP allows eligible employees to purchase shares of our common stock at 85 percent of the
fair market value at the purchase date.

The following assumptions were used to estimate the fair value of employee stock options and LTPP grants.

Stock Option Plans:

Weighted average risk-free interest rate

Dividend yield
Weighted average volatility
Expected life

LTPP:

Volatility of Agilent shares

Years Ended October 31,

2015

2014

2013

1.75%

1%
28%
5.5 years

1.69%

1%
39%
5.8 years

0.86%

1%
39%
5.8 years

25%

36%

37%

Volatility of selected peer-company shares

12%-57%

13%-57%

6%-64%

Price-wise correlation with selected peers

37%

47%

49%

Both the Black-Scholes and Monte Carlo simulation fair value models require the use of highly subjective
and complex assumptions, including the option’s expected life and the price volatility of the underlying stock.
Due to the separation of Keysight on November 1, 2014, expected volatility for grants of options in fiscal 2015
was based on a 5.5 year average historical stock price volatility of a group of our peer companies. For the
volatility of our 2015 LTPP grants, we used the 3 year average historical stock price volatility of a group of our
peer companies. We believe our historical volatility prior to the separation of Keysight is no longer relevant to
use. For the grants of options and LTPP prior to November 1, 2014, the expected stock price volatility
assumption was determined using the historical volatility of Agilent’s stock over the most recent historical period
equivalent to the expected life of the stock options and LTPP.

In developing our estimated life of our employees' stock options of 5.5 years, we considered the separation
of Keysight and the historical option exercise behavior for our executive employees who were granted the
majority of the options in the annual grants made which we believe is representative of future behavior. In
developing our estimated life of our employee stock options of 5.8 years for 2013 to 2014, we considered the
historical option exercise behavior of our executive employees who were granted the majority of the options in
the annual grants made which we believe is representative of future behavior.

s
l
a
i
c
n
a
n
i
F

t
r
o
p
e
R

l
a
u
n
n
A

Share-based Payment Award Activity

Employee Stock Options

The following table summarizes employee stock option award activity made to our employees and directors
for 2015. The amount of options outstanding and the weighted average exercise price at October 31, 2014, have
been revised to reflect the impact of the Keysight separation.

Outstanding at October 31, 2014
Granted
Exercised
Cancelled/Forfeited/Expired

Outstanding at October 31, 2015

Options
Outstanding

(in thousands)

Weighted
Average
Exercise Price

6,584 $
1,347 $
(1,925) $
(294) $

5,712

27
41
24
35

Forfeited and expired options from total cancellations in 2015 were as follows:

Forfeited
Expired

Total Options Cancelled during 2015

Options
Cancelled

(in thousands)

Weighted
Average
Exercise Price

277 $
17 $
294 $

36
20

The options outstanding and exercisable for equity share-based payment awards at October 31, 2015 were as

follows:

Options Outstanding

Options Exercisable

Range of
Exercise Prices

Number
Outstanding

$0 - 25

$25.01 - 30

$30.01 - 40

$40.01 - over

(in thousands)
1,120
2,425
921
1,246
5,712

Weighted
Average
Remaining
Contractual
Life

(in years)

1.9 $

6.1 $

8.1 $

9.1 $

6.2 $

Weighted
Average
Exercise
Price

Aggregate
Intrinsic
Value

Number
Exercisable

(in thousands)
18,873

(in thousands)
1,120

21 $

27,504

—

31 $

46,377

1,539

224

2,896

Weighted
Average
Remaining
Contractual
Life

(in years)

Weighted
Average
Exercise
Price

Aggregate
Intrinsic
Value

1.9 $
5.7 $
8.1 $
8.6 $
4.4 $

(in thousands)
18,873

21 $

17,545

—

25 $

36,418

The aggregate intrinsic value in the table above represents the total pre-tax intrinsic value, based on the
company's closing stock price of $37.76 at October 31, 2015, which would have been received by award holders
had all award holders exercised their awards that were in-the-money as of that date. The total number of in-the-
money awards exercisable at October 31, 2015 was approximately 2.7 million.

The following table summarizes the aggregate intrinsic value of options exercised and the fair value of

options granted in 2015, 2014 and 2013:

Options exercised in fiscal 2013
Black-Scholes per share value of options granted during fiscal 2013
Options exercised in fiscal 2014
Black-Scholes per share value of options granted during fiscal 2014
Options exercised in fiscal 2015
Black-Scholes per share value of options granted during fiscal 2015

Aggregate
Intrinsic Value

(in thousands)

71,499 $

98,075 $

33,258 $

Weighted
Average
Exercise
Price

Per Share Value
Using
Black-Scholes
Model

As of October 31, 2015, the unrecognized share-based compensation costs for outstanding stock option
awards, net of expected forfeitures, was approximately $5 million which is expected to be amortized over a
weighted average period of 2.0 years. The amount of cash received from the exercise of share-based awards
granted was $58 million in 2015, $188 million in 2014 and $161 million in 2013. See Note 6, "Income Taxes"
for the tax impact on share-based award exercises.

Non-vested Awards

The following table summarizes non-vested award activity in 2015 primarily for our LTPP and restricted
stock unit awards. The amount of non-vested awards and the weighted average grant price at October 31, 2014,
have been revised to reflect the impact of the Keysight separation.

Non-vested at October 31, 2014
Granted
Vested
Forfeited
Change in LTPP shares vested in the year due to performance conditions
Non-vested at October 31, 2015

(in thousands)

2,750 $
955 $
(1,016) $
(159) $
(113) $
2,417 $

Weighted
Average
Grant Price

32
42
30
36
—
36

As of October 31, 2015, the unrecognized share-based compensation costs for non-vested restricted stock
awards, net of expected forfeitures, was approximately $32 million which is expected to be amortized over a
weighted average period of 2.3 years. The total fair value of restricted stock awards vested was $31 million for
2015, $54 million for 2014 and $44 million for 2013.

6. INCOME TAXES

The domestic and foreign components of income from continuing operations before taxes are:

U.S. operations
Non-U.S. operations
Total income from continuing operations before taxes

Years Ended October 31,

2015

2014

2013

(in millions)

77 $
403
480 $

(72) $
301
229 $

5
288
293

s
l
a
i
c
n
a
n
i
F

t
r
o
p
e
R

l
a
u
n
n
A

The provision (benefit) for income taxes is comprised of:

U.S. federal taxes:

Current
Deferred

Non-U.S. taxes:

Current
Deferred

State taxes, net of federal benefit:

Current
Deferred

Total provision (benefit)

Years Ended October 31,

2015

2014

(in millions)

2013

(91) $
97

62
(27)

1
—

42 $

17 $
(80)

176
(111)

—
(5)

(3) $

13
3

88
(43)

2
5
68

The income tax provision (benefit) does not reflect potential future tax savings resulting from excess

deductions associated with our various share-based award plans.

The significant components of deferred tax assets and deferred tax liabilities included on the consolidated

balance sheet are:

October 31,

2015

2014

Deferred
Tax Assets

Deferred Tax
Liabilities

Deferred
Tax Assets

Deferred Tax
Liabilities

Inventory
Intangibles
Property, plant and equipment
Warranty reserves
Pension benefits and retiree medical benefits
Employee benefits, other than retirement
Net operating loss, capital loss, and credit carryforwards
Unremitted earnings of foreign subsidiaries
Share-based compensation
Deferred revenue
Other

Subtotal

Tax valuation allowance
Total deferred tax assets or deferred tax liabilities

13 $
—
17
11
93
26
173
—
39
41
4
417
(131)
286 $

(in millions)
— $
95
—
—
—
—
—
33
—
—
—
128
—
128 $

18 $
—
18
9
85
27
176
—
41
41
9
424
(134)
290 $

—
142
—
—
—
—
—
44
—
—
3
189
—
189

The increase in 2015 as compared to 2014 for the deferred tax asset relating to pension benefits is due
mainly to the tax effect of changes in pension plans recognized in other comprehensive income (loss). The
decrease in the deferred tax liability relating to intangible assets is due primarily to amortization of acquired
intangible assets from Dako. The amortization expenses associated with acquired intangible assets are not
deductible for tax purposes.

Agilent records U.S. income taxes on the undistributed earnings of foreign subsidiaries unless the
subsidiaries' earnings are considered indefinitely reinvested outside the U.S. As of October 31, 2015 the
Company recognized a $33 million deferred tax liability for the overall residual tax expected to be imposed upon

the repatriation of unremitted foreign earnings that are not considered permanently reinvested. As of October 31,
2015, the cumulative amount of undistributed earnings considered indefinitely reinvested was $5 billion. No
deferred tax liability has been recognized on the basis difference created by such earnings since it is our intention
to utilize those earnings in the company’s foreign operations. Because of the availability of U.S. foreign tax
credits, the determination of the unrecognized deferred tax liability on these earnings is not practicable.

The breakdown between current and long-term deferred tax assets and deferred tax liabilities was as follows

for the years 2015 and 2014:

Current deferred tax assets (included within other current assets)
Long-term deferred tax assets (included within other assets)
Current deferred tax liabilities (included within other accrued liabilities)
Long-term deferred tax liabilities (included within other long-term liabilities)
Total

October 31,

2015

2014

(in millions)
84 $
180
(10)
(96)
158 $

88
145
(7)
(125)
101

Valuation allowances require an assessment of both positive and negative evidence when determining
whether it is more likely than not that deferred tax assets are recoverable. Such assessment is required on a
jurisdiction by jurisdiction basis. As of October 31, 2015, we continued to maintain a valuation allowance of
$131 million until sufficient positive evidence exists to support reversal. The valuation allowance is mainly
related to deferred tax assets for California R&D credits, net operating losses in the Netherlands and capital
losses in Australia.

At October 31, 2015, we had federal net operating loss carryforwards of approximately $7 million and zero
tax credit carryforwards. The federal net operating losses expire in years beginning 2022 through 2026. At
October 31, 2015, we had state net operating loss carryforwards of approximately $228 million which expire in
years beginning 2016 through 2031, if not utilized. In addition, we had net state tax credit carryforwards of $36
million that do not expire. All of the federal and some of the state net operating loss carryforwards are subject to
change of ownership limitations provided by the Internal Revenue Code and similar state provisions. At
October 31, 2015, we also had foreign net operating loss carryforwards of approximately $358 million. Of this
foreign loss, $234 million will expire in years beginning 2016 through 2024, if not utilized. The remaining $124
million has an indefinite life. Some of the foreign losses are subject to annual loss limitation rules. These annual
loss limitations in the U.S. and foreign jurisdictions may result in the expiration or reduced utilization of the net
operating losses.

The authoritative guidance prohibits recognition of a deferred tax asset for excess tax benefits related to
stock and stock option plans that have not yet been realized through reduction in income taxes payable. Such
unrecognized deferred tax benefit totals $193 million as of October 31, 2015 and will be accounted for as a credit
to shareholders' equity, if and when realized, through a reduction in income taxes payable. The Company
recognized approximately $28 million as a credit to shareholders' equity for cumulative excess tax benefits
related to stock and stock option plans that have been realized as of October 31, 2015.

s
l
a
i
c
n
a
n
i
F

t
r
o
p
e
R

l
a
u
n
n
A

The differences between the U.S. federal statutory income tax rate and our effective tax rate are:

Years Ended October 31,

2015

2014

2013

Profit before tax times statutory rate
State income taxes, net of federal benefit
Non-U.S. income taxed at different rates
Change in unrecognized U.S. tax benefits
Repatriation of foreign earnings
Valuation allowances
Transfer pricing adjustments for prior years
Adjustment to income taxes payable
Other, net
Provision (benefit) for income taxes
Effective tax rate

167
(8)
(72)
(116)
68
(2)
—
—
5
42
8.7%

(in millions)
80
(7)
(39)
(111)
75
2
—
(6)
3
(3 )
(1.3)%

103
5
(34)
—
—
(8)
8
—
(6)
68
23.4%

Agilent enjoys tax holidays in several different jurisdictions, most significantly in Singapore. The tax
holidays provide lower rates of taxation on certain classes of income and require various thresholds of
investments and employment or specific types of income in those jurisdictions. The tax holidays are due for
renewal between 2016 and 2023. As a result of the incentives, the impact of the tax holidays decreased income
taxes by $65 million, $27 million, and $44 million in 2015, 2014, and 2013, respectively. The benefit of the tax
holidays on net income per share (diluted) was approximately $0.19, $0.08, and $0.13 in 2015, 2014 and 2013,
respectively.

For 2015, the company’s effective tax rate from continuing operations was 8.7 percent. The income tax
expense from continuing operations was $42 million. The income tax provision from continuing operations for
the year ended October 31, 2015 included net discrete tax benefits of$55 million. The net discrete tax benefit for
the year ended October 31, 2015 included $32 million of net tax benefit primarily due to the settlement of an
Internal Revenue Service (“IRS) audit in the U.S. and the recognition of tax expense related to the repatriation of
dividends to the U.S. The remaining $23 million net tax benefit for the year ended October 31, 2015 included
$16 million of tax benefit related to the de-registration of certain foreign branches and statutue of limitations
lapses, $6 million of tax benefit for the extension of the U.S. research and development tax credit attributable to
the company's prior fiscal year and $1 million of other discrete benefits.

For 2014, the company's effective tax rate from continuing operations was (1.3) percent. The income tax
benefit from continuing operations was $3 million. The income tax benefit for the year ended October 31, 2014
included a net discrete benefit of $33 million Internal Revenue Service ("IRS") audit in the U.S. and the
recognition of tax expense related to the repatriation of dividends.

For 2013, the effective tax rate from continuing operations was 23.4 percent. The 23.4 percent effective tax
rate is lower than the U.S. statutory rate primarily due to the mix of earnings in non-U.S. jurisdictions taxed at
lower statutory rates; in particular Singapore where we enjoy tax holidays.

The breakdown between current and long-term income tax assets and liabilities, excluding deferred tax

assets and liabilities, was as follows for the years 2015 and 2014:

Current income tax assets (included within other current assets)
Long-term income tax assets (included within other assets)
Current income tax liabilities (included within other accrued liabilities)
Long-term income tax liabilities (included within other long-term liabilities)
Total

October 31,

2015

2014

(in millions)
104 $
20
(62)
(227)
(165) $

82
45
(100)
(285)
(258)

The calculation of our tax liabilities involves dealing with uncertainties in the application of complex tax
law and regulations in a multitude of jurisdictions. Although the guidance on the accounting for uncertainty in
income taxes prescribes the use of a recognition and measurement model, the determination of whether an
uncertain tax position has met those thresholds will continue to require significant judgment by management. In
accordance with the guidance on the accounting for uncertainty in income taxes, for all U.S. and other tax
jurisdictions, we recognize potential liabilities for anticipated tax audit issues based on our estimate of whether,
and the extent to which, additional taxes and interest will be due. The ultimate resolution of tax uncertainties may
differ from what is currently estimated, which could result in a material impact on income tax expense. If our
estimate of income tax liabilities proves to be less than the ultimate assessment, a further charge to expense
would be required. If events occur and the payment of these amounts ultimately proves to be unnecessary, the
reversal of the liabilities would result in tax benefits being recognized in the period when we determine the
liabilities are no longer necessary.

The aggregate changes in the balances of our unrecognized tax benefits including all federal, state and

foreign tax jurisdictions are as follows:

Balance, beginning of year

Additions for tax positions related to the current year
Additions for tax positions from prior years
Reductions for tax positions from prior years
Settlements with taxing authorities
Statute of limitations expirations

Balance, end of year

2015

2014

2013

(in millions)

417 $
33
3
(156)
(4)
(4)
289 $

512 $
45
11
(141)
(2)
(8)
417 $

457
52
15
(6)
(3)
(3)
512

As of October 31, 2015, we had $289 million of unrecognized tax benefits of which $269 million, if

recognized, would affect our effective tax rate.

We recognized a tax benefit of $2 million, a tax benefit of $10 million and a tax benefit $5 million of
interest and penalties related to unrecognized tax benefits in 2015, 2014 and 2013, respectively. Interest and
penalties accrued as of October 31, 2015 and 2014 were $24 million and $29 million, respectively.

On November 1, 2014, Agilent transferred deferred tax assets of $237 million, deferred tax liabilities of $37
million, current income tax payable of $40 million, and other long-term liabilities related to uncertain tax
positions totaling $8 million to Keysight as part of its separation from Agilent. A current prepaid income tax
asset of $19 million and long-term prepaid income tax asset of $3 million related to sales of intercompany assets
was also transferred to Keysight upon separation from Agilent.

In the U.S., tax years remain open back to the year 2012 for federal income tax purposes and the year 2000
for significant states. On September 22, 2015, we reached an agreement with the IRS for the tax years 2008
through 2011. We expect to make a payment of approximately $9 million as part of closing the exam. As a
result, in 2015 we reclassified a portion of other long-term liabilities to other accrued liabilities related to
uncertain tax positions of continuing operations that we expect to pay within the next twelve months. This
amount is partially offset by a prepaid tax account of approximately $3 million that the IRS is allowing as an
offset to the $12 million in incremental taxes. The settlement resulted in the recognition, within the continuing
operations, of previously unrecognized tax benefits of $119 million, offset by a tax liability on foreign
distributions of approximately $99 million principally related to the repatriation of foreign earnings.

On January 29, 2014 we reached an agreement with the IRS for the tax years 2006 through 2007. The
settlement resulted in the recognition, within the continuing operations, of previously unrecognized tax benefits
of $111 million, offset by a tax liability on foreign distributions of approximately $75 million principally related
to the repatriation of foreign earnings.

s
l
a
i
c
n
a
n
i
F

t
r
o
p
e
R

l
a
u
n
n
A

changes to our unrecognized tax benefits in the next twelve months due to either the expiration of a statute of
limitation or a tax audit settlement which will be partially offset by an anticipated tax liability related to
unremitted foreign earnings, where applicable. Given the number of years and numerous matters that remain
subject to examination in various tax jurisdictions, management is unable to estimate the range of possible
changes to the balance of our unrecognized tax benefits.

On July 27, 2015, the U.S. Tax Court issued an opinion in Altera Corp. v. Commissioner related to the
treatment of stock-based compensation expense in an intercompany cost-sharing arrangement. A final decision
was entered by the U.S. Tax Court on December 1, 2015. At this time, the U.S. Department of the Treasury has
not withdrawn the requirement from its regulations to include stock-based compensation. The I.R.S. has the right
to appeal the U.S. Tax Court decision. We concluded that no adjustment to our consolidated financial statements
is appropriate at this time due to the uncertainties with respect to the ultimate resolution of this case.

7. NET INCOME PER SHARE

The following is a reconciliation of the numerators and denominators of the basic and diluted net income per

share computations for the periods presented below.

Numerator:

Income from continuing operations
Income (loss) from discontinued operations

$
$

Net income
Denominators:

Basic weighted average shares
Potential common shares — stock options and other employee
stock plans
Diluted weighted average shares

Years Ended October 31,

2015

2014

2013

(in millions)

$
$

438
(37)
401

333

335

$
$

232
317
549

333

5
338

225
509
734

341

345

In connection with the separation of Keysight on November 1, 2014 and in accordance with the Employee
Matters Agreement we made certain adjustments to the exercise price and number of our share-based
compensation awards. These adjustments to our share-based awards did not have a material impact on our
dilutive weighted average shares.

The dilutive effect of share-based awards is reflected in diluted net income per share by application of the
treasury stock method, which includes consideration of unamortized share-based compensation expense, the tax
benefits or shortfalls charged to additional paid-in capital and the dilutive effect of in-the-money options and
non-vested restricted stock units. Under the treasury stock method, the amount the employee must pay for
exercising stock options and unamortized share-based compensation expense and tax benefits or shortfalls
collectively are assumed proceeds to be used to repurchase hypothetical shares. An increase in the fair market
value of the company's common stock can result in a greater dilutive effect from potentially dilutive awards. The
total number of share-based awards issued in 2015, 2014 and 2013 were 3 million, 6 million and 6 million,
respectively.

We exclude stock options with exercise prices greater than the average market price of our common stock
from the calculation of diluted earnings per share because their effect would be anti-dilutive. For 2015, 2014 and
2013, options to purchase 1.2 million, 1,500 and 4,200 shares respectively were excluded from the calculation of
diluted earnings per share. In addition, we also exclude from the calculation of diluted earnings per share, stock
options, ESPP, LTPP and restricted stock awards whose combined exercise price, unamortized fair value and
excess tax benefits or shortfalls collectively were greater than the average market price of our common stock
because their effect would also be anti-dilutive. For the year ended 2015, 2014 and 2013, options to purchase
368,900, 383,200 and 18,300 shares respectively were excluded from the calculation of diluted earnings per
share.

8. SUPPLEMENTAL CASH FLOW INFORMATION

Net cash paid for income taxes was $129 million in 2015, $131 million in 2014, and $110 million in 2013.

Cash paid for interest was $71 million in 2015, $142 million in 2014 and $112 million in 2013.

9. INVENTORY

Finished goods
Purchased parts and fabricated assemblies
Inventory

October 31,

2015

2014

(in millions)
362 $
179
541 $

366
208
574

Inventory-related excess and obsolescence charges, included in continuing operations, of $30 million were
recorded in total cost of products in 2015, $46 million in 2014 and $27 million in 2013, respectively. We record
excess and obsolete inventory charges for both inventory on our site as well as inventory at our contract
manufacturers and suppliers where we have non-cancellable purchase commitments.

10. PROPERTY, PLANT AND EQUIPMENT, NET

Land
Buildings and leasehold improvements
Machinery and equipment
Software

Total property, plant and equipment
Accumulated depreciation and amortization
Property, plant and equipment, net

October 31,

2015

2014

(in millions)
53 $
705
401
168
1,327
(723)
604 $

58
714
443
154
1,369
(738)
631

Asset impairments other than related to our exit of the NMR business were zero in 2015, zero in 2014 and
$3 million in 2013. Asset impairments in connection with the exit of the NMR business were $7 million in 2014.
Depreciation expenses were $98 million in 2015, $120 million in 2014 and $116 million in 2013.

11. GOODWILL AND OTHER INTANGIBLE ASSETS

The goodwill balances at October 31, 2015, 2014 and 2013 and the movements in 2015 and 2014 for each of

our reportable segments are shown in the table below:

Goodwill as of October 31, 2013
Foreign currency translation impact
Goodwill as of October 31, 2014
Foreign currency translation impact
Goodwill arising from acquisitions
Goodwill as of October 31, 2015

Life Sciences
and Applied
Markets

Diagnostics
and
Genomics

Agilent
CrossLab

Total

626 $
42
668 $
(18)
—
650 $

(in millions)

1,546 $
(201)
1,345 $
(166)
55
1,234 $

456 $
38
494 $
(12)
—
482 $

2,628
(121)
2,507
(196)
55
2,366

s
l
a
i
c
n
a
n
i
F

t
r
o
p
e
R

l
a
u
n
n
A

As of September 30, 2015, we assessed goodwill impairment for our reporting units and no impairment of

goodwill was indicated.

The component parts of other intangible assets at October 31, 2015 and 2014 are shown in the table below:

As of October 31, 2014:
Purchased technology
Trademark/Tradename
Customer relationships

Total amortizable intangible assets

In-Process R&D

Total

As of October 31, 2015:
Purchased technology
Trademark/Tradename
Customer relationships

Total amortizable intangible assets

In-Process R&D

Total

Gross
Carrying
Amount

Other Intangible Assets

Accumulated
Amortization
and Impairments

(in millions)

Net Book
Value

880 $
167
368
1,415 $
18
1,433 $

746 $
141
230
1,117 $
22
1,139 $

475 $
52
257
784 $
—
784 $

476 $
50
168
694 $
—
694 $

405
115
111
631
18
649

270
91
62
423
22
445

In 2015, we recorded additions to goodwill of $55 million and to other intangible assets of $13 million
related to the single acquisition of the company, Cartagenia. During the year other intangible assets decreased
$58 million, due to the impact of foreign exchange translation. During 2015, we also removed the gross carrying
amount of $246 million and the related accumulated amortization of fully amortized intangible assets which were
no longer being used.

In 2014, there were no additions to goodwill and intangible assets. In 2014, we recorded $12 million of

impairment of other intangibles due to the exit of the NMR business.

In addition, we recorded $3 million, $4 million and zero of impairments of other intangibles related to the

cancellation of in-process research and development projects during 2015, 2014 and 2013, respectively.

Amortization of intangible assets was $156 million in 2015, $189 million in 2014, and $190 million in 2013.

Future amortization expense related to existing finite-lived purchased intangible assets for the next five

fiscal years and thereafter is estimated below:

Estimated future amortization expense:
(in millions)
2016
2017
2018
2019
2020
Thereafter

$
$
$
$
$
$

131
92
61
47
36
56

12. INVESTMENTS

The following table summarizes the company's equity investments as of October 31, 2015 and 2014 (net

book value):

Long-Term
Cost method investments
Trading securities
Equity method investments

Total

October 31,

2015

2014

(in millions)

23 $
35
28
86 $

25
35
36
96

Cost method investments consist of non-marketable equity securities and two funds and are accounted for at
historical cost. Trading securities are reported at fair value, with gains or losses resulting from changes in fair
value recognized currently in earnings. Equity method investments are reported at the amount of the company’s
initial investment and adjusted each period for the company’s share of the investee’s income or loss and dividend
paid.

All of our investments, excluding trading securities, are subject to periodic impairment review. The
impairment analysis requires significant judgment to identify events or circumstances that would likely have
significant adverse effect on the future value of the investment. We consider various factors in determining
whether an impairment is other-than-temporary, including the severity and duration of the impairment,
forecasted recovery, the financial condition and near-term prospects of the investee, and our ability and intent to
hold the investment for a period of time sufficient to allow for any anticipated recovery in market value.

Amounts included in other income (expense), net for the appropriate share of loss on equity method

investments were as follows:

Equity method investments - share of losses

Years Ended October 31,

2015

2014

(in millions)

2013

(9) $

(7)

(2)

Net unrealized gains on our trading securities portfolio were $2 million in 2015, $2 million in 2014 and $6

million in 2013.

13. FAIR VALUE MEASUREMENTS

The authoritative guidance defines fair value as the price that would be received from selling an asset or paid
to transfer a liability in an orderly transaction between market participants at the measurement date. When
determining the fair value measurements for assets and liabilities required or permitted to be recorded at fair
value, we consider the principal or most advantageous market and assumptions that market participants would
use when pricing the asset or liability.

s
l
a
i
c
n
a
n
i
F

t
r
o
p
e
R

l
a
u
n
n
A

Fair Value Hierarchy

The guidance establishes a fair value hierarchy that prioritizes the use of inputs used in valuation techniques
into three levels. A financial instrument's categorization within the fair value hierarchy is based upon the lowest
level of input that is significant to the fair value measurement. There are three levels of inputs that may be used
to measure fair value:

Level 1 — applies to assets or liabilities for which there are quoted prices in active markets for identical

assets or liabilities.

Level 2 — applies to assets or liabilities for which there are inputs other than quoted prices included
within level 1 that are observable, either directly or indirectly, for the asset or liability such as: quoted prices for
similar assets or liabilities in active markets; quoted prices for identical or similar assets or liabilities in less
active markets; or other inputs that can be derived principally from, or corroborated by, observable market data.

Level 3 — applies to assets or liabilities for which there are unobservable inputs to the valuation

methodology that are significant to the measurement of the fair value of the assets or liabilities.

Financial Assets and Liabilities Measured at Fair Value on a Recurring Basis

Financial assets and liabilities measured at fair value on a recurring basis as of October 31, 2015 were as

follows:

Fair Value Measurement at
October 31, 2015 Using

October 31,
2015

Quoted Prices in
Active Markets
for Identical
Assets (Level 1)

Significant Other
Observable Inputs
(Level 2)

Significant
Unobservable
Inputs (Level 3)

(in millions)

1,411 $

—

35
1,450 $

35
1,446 $

5 $

35
40 $

— $

—
— $

— $

—
4 $

35
40 $

—

—
—

—

—
—

Assets:

Short-term

Cash equivalents (money market funds)
Derivative instruments (foreign exchange
contracts)

Long-term

Trading securities

Total assets measured at fair value
Liabilities:

Short-term

Derivative instruments (foreign exchange
contracts)

Long-term

Deferred compensation liability

Total liabilities measured at fair value

Financial assets and liabilities measured at fair value on a recurring basis as of October 31, 2014 were as

follows:

Fair Value Measurement at
October 31, 2014 Using

October 31,
2014

Quoted Prices in
Active Markets
for Identical
Assets (Level 1)

Significant Other
Observable Inputs
(Level 2)

Significant
Unobservable
Inputs (Level 3)

(in millions)

1,117 $

—

35
1,162 $

35
1,152 $

4 $

35
39 $

— $

—
— $

— $

—
10 $

35
39 $

—

—
—

—

—
—

Assets:

Short-term

Cash equivalents (money market funds)
Derivative instruments (foreign exchange
contracts)

Long-term

Trading securities

Total assets measured at fair value
Liabilities:

Short-term

Derivative instruments (foreign exchange
contracts)

Long-term

Deferred compensation liability

Total liabilities measured at fair value

Our money market funds and trading securities are generally valued using quoted market prices and
therefore are classified within level 1 of the fair value hierarchy. Our derivative financial instruments are
classified within level 2, as there is not an active market for each hedge contract, but the inputs used to calculate
the value of the instruments are tied to active markets. Our deferred compensation liability is classified as level 2
because although the values are not directly based on quoted market prices, the inputs used in the calculations are
observable.

Trading securities and deferred compensation liability are reported at fair value, with gains or losses
resulting from changes in fair value recognized currently in net income. Certain derivative instruments are
reported at fair value, with unrealized gains and losses, net of tax, included in stockholders' equity. Realized
gains and losses from the sale of these instruments are recorded in net income.

Assets and Liabilities Measured at Fair Value on a Non-Recurring Basis

Long-Lived Assets

For assets measured at fair value on a non-recurring basis, the following table summarizes the impairments

included in net income for the years ended October 31, 2015, 2014 and 2013:

Long-lived assets held and used
Long-lived assets held for sale

Years Ended
October 31,

2015

2014

2013

(in millions)

$
$

3 $
— $

23 $
— $

1
1

s
l
a
i
c
n
a
n
i
F

t
r
o
p
e
R

l
a
u
n
n
A

Long-lived assets held and used with a carrying amount of $3 million were written down to their fair value
of zero, resulting in an impairment charge of $3 million, which was included in net income for 2015. Long-lived
assets held and used with a carrying amount of $23 million were written down to their fair value of zero,
resulting in an impairment charge of $23 million, which was included in net income for 2014. The impairment
charge for 2014 includes $19 million relating to the exit of a business and $4 million related to various IPR&D
projects that were written down to their fair value of zero. Long-lived assets held and used with a carrying
amount of $1 million were written down to their fair value of zero, resulting in an impairment charge of $1
million, which was included in net income for 2013.

There were no impairments of long-lived assets held for sale in 2015 and 2014. Long-lived assets held for
sale with a carrying amount of $3 million were written down to their fair value of $2 million , resulting in an
impairment charge of $1 million which was included in net income for 2013.

Fair values for the impaired long-lived assets were measured using level 2 inputs.

14. DERIVATIVES

We are exposed to foreign currency exchange rate fluctuations and interest rate changes in the normal course
of our business. As part of risk management strategy, we use derivative instruments, primarily forward contracts,
purchased options, and interest rate swaps, to hedge economic and/or accounting exposures resulting from
changes in foreign currency exchange rates and interest rates.

Fair Value Hedges

We are exposed to interest rate risk due to the mismatch between the interest expense we pay on our loans at
fixed rates and the variable rates of interest we receive from cash, cash equivalents and other short-term
investments. We have issued long-term debt in U.S. dollars at fixed interest rates based on the market conditions
at the time of financing. The fair value of our fixed rate debt changes when the underlying market rates of
interest change, and, in the past, we have used interest rate swaps to change our fixed interest rate payments to
U.S. dollar LIBOR-based variable interest expense to match the floating interest income from our cash, cash
equivalents and other short term investments. As of October 31, 2015, all interest rate swap contracts had either
been terminated or had expired.

On November 25, 2008, we terminated two interest rate swap contracts associated with our 2017 senior
notes that represented the notional amount of $400 million. On October 20, 2014 we prepaid $500 million out of
$600 million principal of our 2017 senior notes and fully amortized the associated proportionate deferred gain to
other income (expense). The remaining gain to be amortized related to the $100 million of 2017 senior notes at
October 31, 2015 was $2 million. On August 9, 2011, we terminated five interest rate swap contracts related to
our 2020 senior notes that represented the notional amount of $500 million. The gain to be amortized at October
31, 2015 was $19 million. All deferred gains from terminated interest rate swaps are being amortized over the
remaining life of the respective senior notes.

Cash Flow Hedges

We enter into foreign exchange contracts to hedge our forecasted operational cash flow exposures resulting
from changes in foreign currency exchange rates. These foreign exchange contracts, carried at fair value, have
maturities between one and twelve months. These derivative instruments are designated and qualify as cash flow
hedges under the criteria prescribed in the authoritative guidance. The changes in the fair value of the effective
portion of the derivative instrument are recognized in accumulated other comprehensive income. Amounts
associated with cash flow hedges are reclassified to cost of sales in the consolidated statement of operations
when the forecasted transaction occurs. If it becomes probable that the forecasted transaction will not occur, the
hedge relationship will be de-designated and amounts accumulated in other comprehensive income will be
reclassified to other income (expense) in the current period. Changes in the fair value of the ineffective portion of
derivative instruments are recognized in other income (expense) in the consolidated statement of operations in

the current period. We record the premium paid (time value) of an option on the date of purchase as an asset. For
options designated as cash flow hedges, changes in the time value are excluded from the assessment of hedge
effectiveness and are recognized in other income (expense) over the life of the option contract. Ineffectiveness in
2015, 2014 and 2013 was not significant. For the years ended October 31, 2015, 2014 and 2013 gains and losses
recognized in earnings due to de-designation of cash flow hedge contracts were not significant.

In July 2012, Agilent executed treasury lock agreements for $400 million in connection with future interest
payments to be made on our 2022 senior notes issued on September 10, 2012. We designated the treasury lock
as a cash flow hedge. The treasury lock contracts were terminated on September 10, 2012 and we recognized a
deferred gain in accumulated other comprehensive income which is being amortized to interest expense over the
life of the 2022 senior notes. The remaining gain to be amortized related to the treasury lock agreements at
October 31, 2015 was $2 million.

Other Hedges

Additionally, we enter into foreign exchange contracts to hedge monetary assets and liabilities that are
denominated in currencies other than the functional currency of our subsidiaries. These foreign exchange
contracts are carried at fair value and do not qualify for hedge accounting treatment and are not designated as
hedging instruments. Changes in value of the derivative are recognized in other income (expense) in the
consolidated statement of operations, in the current period, along with the offsetting foreign currency gain or loss
on the underlying assets or liabilities.

Our use of derivative instruments exposes us to credit risk to the extent that the counterparties may be
unable to meet the terms of the agreement. We do, however, seek to mitigate such risks by limiting our
counterparties to major financial institutions which are selected based on their credit ratings and other factors.
We have established policies and procedures for mitigating credit risk that include establishing counterparty
credit limits, monitoring credit exposures, and continually assessing the creditworthiness of counterparties.

A number of our derivative agreements contain threshold limits to the net liability position with
counterparties and are dependent on our corporate credit rating determined by the major credit rating agencies.
The counterparties to the derivative instruments may request collateralization, in accordance with derivative
agreements, on derivative instruments in net liability positions.

The aggregate fair value of all derivative instruments with credit-risk-related contingent features that were in
a net liability position as of October 31, 2015, was $2 million. The credit-risk-related contingent features
underlying these agreements had not been triggered as of October 31, 2015.

s
l
a
i
c
n
a
n
i
F

t
r
o
p
e
R

l
a
u
n
n
A

There were 53 foreign exchange forward contracts open as of October 31, 2015 and designated as cash flow
hedges. There were 170 foreign exchange forward contracts open as of October 31, 2015 not designated as
hedging instruments. The aggregated notional amounts by currency and designation as of October 31, 2015 were
as follows:

Derivatives
Designated
as
Cash Flow
Hedges

Forward
Contracts
USD

Derivatives
Not
Designated
as Hedging
Instruments

Forward
Contracts
USD

Forward
Contracts
DKK

Currency

Buy/(Sell)

Euro
British Pound
Canadian Dollar
Australian Dollars
Malaysian Ringgit
Japanese Yen
American Dollar
Other

(in millions)

(19) $
(15)
(23)
10
—
(67)
—
(2)
(116) $

186 $
(10 )
—
13
(4 )
(5 )
—
21
201 $

(60)
(4)
(2)
(3)
—
(1)
33
(9)
(46)

Derivative instruments are subject to master netting arrangements and are disclosed gross in the balance
sheet in accordance with the authoritative guidance. The gross fair values and balance sheet location of
derivative instruments held in the consolidated balance sheet as of October 31, 2015 and 2014 were as follows:

Fair Values of Derivative Instruments

Asset Derivatives

Liability Derivatives

Balance Sheet Location

Derivatives designated as
hedging instruments:
Cash flow hedges
Foreign exchange contracts

Other current assets

Derivatives not designated as
hedging instruments:
Foreign exchange contracts

Other current assets

Total derivatives

$
$

Fair Value

October 31,
2015

October 31,
2014
(in millions)

Balance Sheet Location

Fair Value

October 31,
2015

October 31,
2014

2 $
2 $

2 $
4 $

9 Other accrued liabilities
9

$
$

1 Other accrued liabilities

$
$

1 $
1 $

4 $
5 $

1
1

3
4

The effect of derivative instruments for foreign exchange contracts designated as hedging instruments and

not designated as hedging instruments in our consolidated statement of operations were as follows:

Derivatives designated as hedging instruments:
Cash Flow Hedges

Gain recognized in accumulated other comprehensive income
Gain (loss) reclassified from accumulated other comprehensive
income into cost of sales

Derivatives not designated as hedging instruments:

Gain (loss) recognized in other income (expense), net within
continuing operations

2015

2014

2013

(in millions)

18 $

(1) $

(21) $

(20) $

The estimated net amount of existing gain at October 31, 2015 that is expected to be reclassified from other

comprehensive income to the cost of sales within the next twelve months is $1 million.

15. EXIT OF NMR BUSINESS

During the fourth quarter of fiscal year 2014, we made the decision to cease the manufacture and sale of our
nuclear magnetic resonance (“NMR”) product line within our life sciences and applied markets segment. The
exit of the NMR business was primarily due to the lack of growth and profitability of the product line. These
actions involved severance and other personnel costs related to the workforce reduction of approximately 300
employees primarily located in the United Kingdom and California and non-cash charges related to intangible
asset impairments and other asset write-downs including inventory. After including employee reductions due to
attrition and the application to open positions and acceptance of employment within the company of some
employees previously affected, we have approximately 30 employees that are pending termination under the
above actions as of October 31, 2015. We expect to complete these restructuring activities by early fiscal 2016.

A summary of total “NMR” restructuring activity and other special charges is shown in the table below:

Workforce
Reduction

Impairments of
Building and Other
Assets

Special Charges
Related to
Inventory and
Others

Total

Balance as of October 31, 2013

Income statement expense
Asset impairments/inventory charges
Cash payments

Balance as of October 31, 2014

Income statement expense/(reversal)
Asset impairments/inventory charges
Cash payments

Balance as of October 31, 2015

— $
16
—
(2)
14 $
(2)
—
(10)

2 $

(in millions)
— $
19
(19)
—
— $
—
—
—
— $

— $
33
(30)
—
3 $
8
(2)
(3)
6 $

—
68
(49)
(2)
17
6
(2)
(13)
8

The restructuring and other special accruals related to the NMR closure, which totaled $8 million at October
31, 2015, are recorded in other accrued liabilities on the consolidated balance sheet. These balances reflect
estimated future cash outlays.

s
l
a
i
c
n
a
n
i
F

t
r
o
p
e
R

l
a
u
n
n
A

A summary of the charges in the consolidated statement of operations resulting from the NMR closure is

shown below:

Cost of products and services
Research and development
Selling, general and administrative
Total restructuring, asset impairments and other special charges

Year Ended

October 31,

Year Ended

October 31,

2015

2014

(in millions)
(2 ) $
4
4
6 $

48
5
15
68

16. RETIREMENT PLANS AND POST RETIREMENT PENSION PLANS

General. Substantially all of our employees are covered under various defined benefit and/or defined
contribution retirement plans. Additionally, we sponsor post-retirement health care benefits for our eligible U.S.
employees.

Agilent provides U.S. employees, who meet eligibility criteria under the Agilent Technologies, Inc.
Retirement Plan (the "RP"), defined benefits which are based on an employee's base or target pay during the
years of employment and on length of service. For eligible service through October 31, 1993, the benefit payable
under the Agilent Retirement Plans is reduced by any amounts due to the eligible employee under the Agilent
defined contribution Deferred Profit-Sharing Plan (the "DPSP"), which was closed to new participants as of
November 1993. Effective November 1, 2014, Agilent’s U.S. defined benefit retirement plan is closed to new
entrants including new employees, new transfers to the U.S. payroll and rehires. These employees will instead be
eligible for an enhanced 6 percent employer match in the Agilent 401(k) plan. Current eligible employees will
continue to participate in the U.S. defined benefit retirement plan and will remain eligible for the 401(k) plan
with the current 4 percent employer match. Retirees maintain the retirement benefits they are eligible for as of
November 1, 2014.

As of October 31, 2015 and 2014, the fair value of plan assets of the DPSP was $169 million and $520
million, respectively. Note that the projected benefit obligation for the DPSP equals the fair value of plan assets.

In addition to the DPSP, in the U.S., Agilent maintains a Supplemental Benefits Retirement Plan ("SBRP"),
supplemental unfunded non-qualified defined benefit plan to provide benefits that would be provided under the
RP but for limitations imposed by the Internal Revenue Code. The RP and the SBRP comprise the "U.S. Plans"
in the tables below.

Eligible employees outside the U.S. generally receive retirement benefits under various retirement plans
based upon factors such as years of service and/or employee compensation levels. Eligibility is generally
determined in accordance with local statutory requirements.

401(k) defined contribution plan. Eligible Agilent U.S. employees may participate in the Agilent
Technologies, Inc. 401(k) Plan. Under the 401(k) Plan, we provide matching contributions to employees up to a
maximum of 4 percent of an employee's annual eligible compensation. Effective November 1, 2014, new
employees and new transfers to the U.S. payroll and rehires are eligible for an enhanced 6 percent employer
match in the Agilent 401(k) Plan. The maximum contribution to the 401(k) Plan is 50 percent of an employee's
annual eligible compensation, subject to regulatory limitations. The 401(k) Plan employer expense included in
income from continuing operations was $14 million in 2015, $15 million in 2014 and $13 million in 2013.

Post-retirement medical benefit plans. In addition to receiving retirement benefits, Agilent U.S. employees
who meet eligibility requirements as of their termination date may participate in the Agilent Technologies, Inc.
Health Plan for Retirees. Eligible retirees who were less than age 50 as of January 1, 2005 and who retire after
age 55 with 15 or more years of service are eligible for a fixed amount which can be utilized to pay for either

sponsored plans and/or individual medicare plans. Eligible retirees who were at least age 50 as of January 1,
2005 and who retire after age 55 with 15 or more years of service currently choose from managed-care,
indemnity options or individual medicare plans, with the company subsidization level or stipend dependent on a
number of factors including eligibility and length of service. On April 1, 2011, changes to the Agilent
Technologies, Inc. Health Plan for Retirees were approved. Effective January 1, 2012, employees who were at
least age 50 as of January 1, 2005 and who retire after age 55 with 15 or more years of service are eligible for
fixed dollar subsidies and stipends. Grandfathered retirees receive a fixed monthly subsidy toward pre-65
premium costs (subsidy capped at 2011 levels) and a fixed monthly stipend post-65. The subsidy amounts will
not increase. In addition, any new employee hired on or after November 1, 2014, will not be eligible to
participate in the retiree medical plans upon retiring. Current eligible employees will continue to participate in
the retiree medical program in place as of November 1, 2014. Retirees will maintain the retiree medical benefits
they are eligible for as of November 1, 2014.

Components of net periodic cost. The company uses alternate methods of amortization as allowed by the
authoritative guidance which amortizes the actuarial gains and losses on a consistent basis for the years
presented. For U.S. Plans, gains and losses are amortized over the average future working lifetime. For most
Non-U.S. Plans and U.S. Post-Retirement Benefit Plans, gains and losses are amortized using a separate layer for
each year's gains and losses. For the years ended October 31, 2015, 2014 and 2013, components of net periodic
benefit cost and other amounts recognized in other comprehensive income were comprised of:

Pensions

U.S. Plans

Non-U.S. Plans

U.S. Post-Retirement Benefit
Plans

2015

2014

2013

2015

2014

2013

2015

2014

2013

(in millions)

Net periodic benefit cost (benefit)

Service cost — benefits earned during
the period
Interest cost on benefit obligation
Expected return on plan assets
Amortization of net actuarial loss
Amortization of prior service benefit

Total periodic benefit cost (benefit)

Summary of total periodic benefit cost
(benefit):

Continuing operations

Discontinued operations

Total periodic benefit cost (benefit)

Other changes in plan assets and
benefit obligations recognized in other
comprehensive (income) loss

Net actuarial (gain) loss
Amortization of net actuarial loss
Prior service cost (benefit)
Amortization of prior service benefit
Foreign currency

Total recognized in other comprehensive
(income) loss

Total recognized in net periodic benefit
cost (benefit) and other comprehensive
(income) loss

25
14
(27)
3
(5)
10 $

10 $
—
10 $

44 $
(3)
—
5
—

46 $
34
(64)
1
(12)

5 $

44 $
24
(51)
13
(12)
18 $

18 $
23
(42)
25
—
24 $

36 $
74
(118)
48
(1)
39 $

2 $

9 $

24 $

27 $

—

5 $

18 $

24 $

39 $

36
68
(97)
55
(1)
61 $

38 $
23
61 $

2
4
(8)
6
(12)
(8 ) $

3 $
12
(22)
14
(35)
(28) $

(8 ) $
—
(8 ) $

(14) $

(14)

(28) $

86 $
(1)
—
12
—

(122) $
(13)
—
12
—

32 $
(25)
—
—
10

173 $
(48)
(2)
1
(28)

(85 ) $
(55)
—
1
2

16 $
(6)
—
12
—

12 $
(14)
—
35
—

4
12
(20)
18
(35)
(21)

(11)

(10)

(21)

(57)
(18)
—
35
—

97 $

(123) $

17 $

96 $

(137 ) $

33 $

(40)

102 $

(105) $

41 $

135 $

(76 ) $

5 $

(61)

s
l
a
i
c
n
a
n
i
F

t
r
o
p
e
R

l
a
u
n
n
A

Funded status. As of October 31, 2015 and 2014, the funded status of the defined benefit and post-retirement
benefit plans was:

Change in fair value of plan assets:
Fair value — beginning of year
Actual return on plan assets
Employer contributions
Participants' contributions
Benefits paid
Transfer due to Keysight separation
Currency impact

Fair value — end of year
Change in benefit obligation:

Benefit obligation — beginning of year
Service cost
Interest cost
Participants' contributions
Plan amendment
Actuarial (gain) loss
Benefits paid
Transfer due to Keysight separation
Currency impact

Benefit obligation — end of year

Overfunded (underfunded) status of PBO

Amounts recognized in the consolidated balance sheet consist
of:

Continuing operations:
Other assets
Employee compensation and benefits
Retirement and post-retirement benefits
Net asset (liability) - continuing operations

Discontinued operations:

Other assets

Employee compensation and benefits

Retirement and post-retirement benefits

Net asset (liability) - discontinued operations

Total net asset (liability)

Amounts Recognized in Accumulated Other Comprehensive
Income (loss):
Actuarial (gains) losses
Prior service costs (benefits)
Total

U.S. Defined
Benefit Plans

Non-U.S. Defined
Benefit Plans

U.S.
Post-Retirement
Benefit Plans

2015

2014

2015

2014

2015

2014

(in millions)

$
$

837 $
6
15
—
(21)
(490)
—
347 $

889 $
25
14
—
—
23
(22)
(514)
—
415 $
(68) $

782 $
64
30
—
(39)
—
—
837 $

763 $
46
34
—
—
85
(39)
—
—
889 $
(52) $

2,108 $
53
25
1
(20)
(1,327)
(62)
778 $

2,344 $
18
23
1
—
40
(20)
(1,429)
(77)
900 $
(122) $

2,045 $
180
72
3
(62 )
—
(130 )
2,108 $

2,199 $
36
74
3
(2 )
236
(62 )
—
(140 )
2,344 $
(236) $

284 $
2
—
—
(8 )
(187 )
—
91 $

309 $
2
4
—
—
11
(8 )
(206 )
—
112 $
(21) $

— $
(2)
(66)
(68) $

— $
(1)
(28)
(29) $

26 $
—
(148)
(122) $

22 $
—
(147 )
(125) $

— $
—
(21 )
(21) $

— $

—

(1)

(22)

—

(159 )

— $
(68) $

(23) $
(52) $

— $
(122) $

(111) $
(236) $

—

—
— $
(21) $

288
18
1
—
(23)
—
—
284

307
3
12
—
—
10
(23)
—
—
309
(25)

—
—
(6)
(6)

—

(19)

(19)
(25)

73 $
(18)
55 $

77 $
(55)
22 $

256 $
—
256 $

621 $
(4 )
617 $

49 $
(40 )

9 $

118
(149)
(31)

In connection with the separation of Keysight Technologies on November 1, 2014, Agilent transferred
certain liabilities and assets of the U.S. and Non-U.S. defined benefit pension plans, and U.S. Post-Retirement
Benefit Plans to similar plans created for Keysight Technologies employees. Total transfers are as follows:

Fair value of plan assets transferred to Keysight
Benefit obligation transferred to Keysight

$
$

U.S. Defined
Benefit Plans

Non-U.S. Defined
Benefit Plans

U.S. Post-Retirement
Benefit Plans

490 $
514 $

(in millions)

1,327 $
1,429 $

187
206

The amounts in accumulated other comprehensive income expected to be recognized by Agilent as

components of net expense during 2016 are as follows:

Amortization of net prior service cost (benefit)
Amortization of actuarial net loss (gain)

$
$

U.S. Defined
Benefit Plans

Non-U.S. Defined
Benefit Plans

U.S. Post-Retirement
Benefit Plans

(5) $
8 $

(in millions)

— $
26 $

(10)
10

Investment policies and strategies as of October 31, 2015 and 2014. In the U.S., target asset allocations for
our retirement and post-retirement benefit plans are approximately 80 percent to equities and approximately 20
percent to fixed income investments. Our DPSP target asset allocation is approximately 60 percent to equities
and approximately 40 percent to fixed income investments. Approximately, 5 percent of our U.S. equity portfolio
consists of limited partnerships. The general investment objective for all our plan assets is to obtain the optimum
rate of investment return on the total investment portfolio consistent with the assumption of a reasonable level of
risk. Specific investment objectives for the plans' portfolios are to: maintain and enhance the purchasing power
of the plans' assets; achieve investment returns consistent with the level of risk being taken; and earn
performance rates of return in accordance with the benchmarks adopted for each asset class. Outside the U.S.,
our target asset allocation is from 37 to 60 percent to equities, from 40 to 60 percent to fixed income investments,
and from zero to 6 percent to real estate investments and from zero to 7 percent to cash, depending on the plan.
All plans' assets are broadly diversified. Due to fluctuations in equity markets, our actual allocations of plan
assets at October 31, 2015 and 2014 differ from the target allocation. Our policy is to bring the actual allocation
in line with the target allocation.

Equity securities include exchange-traded common stock and preferred stock of companies from broadly
diversified industries. Fixed income securities include a global portfolio of corporate bonds of companies from
diversified industries, government securities, mortgage-backed securities, asset-backed securities, derivative
instruments and other. Other investments include a group trust consisting primarily of private equity partnerships
as well as other investments. Portions of the cash and cash equivalent, equity, and fixed income investments are
held in commingled funds.

Fair Value. The measurement of the fair value of pension and post-retirement plan assets uses the

valuation methodologies and the inputs as described in Note 13, "Fair Value Measurements".

Cash and Cash Equivalents - Cash and cash equivalents consist of short-term investment funds. The funds
also invest in short-term domestic fixed income securities and other securities with debt-like characteristics
emphasizing short-term maturities and quality. Cash and cash equivalents are classified as Level 1 investments
except when the cash and cash equivalents are held in commingled funds, which have a daily net value derived
from quoted prices for the underlying securities in active markets; these are classified as Level 2 investments.

Equity - Some equity securities consisting of common and preferred stock are held in commingled funds,
which have daily net asset values derived from quoted prices for the underlying securities in active markets;
these are classified as Level 2 investments. Commingled funds which have quoted prices in active markets are
classified as Level 1 investments.

s
l
a
i
c
n
a
n
i
F

t
r
o
p
e
R

l
a
u
n
n
A

Fixed Income - Some of the fixed income securities are held in commingled funds, which have daily net
asset values derived from the underlying securities; these are classified as Level 2 investments. Commingled
funds which have quoted prices in active markets are classified as Level 1 investments.

Other Investments - Other investments includes property based pooled vehicles which invest in real estate.
Market net asset values are regularly published in the financial press or on corporate websites and so these
investments are classified as Level 2. Other investments also includes partnership investments where, due to their
private nature, pricing inputs are not readily observable. Asset valuations are developed by the general partners
that manage the partnerships. These valuations are based on proprietary appraisals, application of public market
multiples to private company cash flows, utilization of market transactions that provide valuation information for
comparable companies and other methods. Holdings of limited partnerships are classified as Level 3.

The following tables present the fair value of U.S. Defined Benefit Plans assets classified under the

appropriate level of the fair value hierarchy as of October 31, 2015 and 2014.

Cash and Cash Equivalents
Equity
Fixed Income
Other Investments

Total assets measured at fair value

Cash and Cash Equivalents
Equity
Fixed Income
Other Investments

Total assets measured at fair value

Assets measured at fair value - continuing $
Assets measured at fair value - discontinued
operations

Total assets measured at fair value

Fair Value Measurement
at October 31, 2015 Using

Quoted Prices
in Active
Markets for
Identical Assets
(Level 1)

Significant
Other
Observable
Inputs
(Level 2)

Significant
Unobservable
Inputs
(Level 3)

October 31,
2015

3 $

258
76
10
347 $

(in millions)
1 $

61
22
—
84 $

2 $

197
54
1
254 $

Fair Value Measurement
at October 31, 2014 Using

—
—
—
9
9

Quoted Prices
in Active
Markets for
Identical Assets
(Level 1)

Significant
Other
Observable
Inputs
(Level 2)

Significant
Unobservable
Inputs
(Level 3)

October 31,
2014

(in millions)
2 $

156
40
1
199 $

73 $

126
199 $

7 $

512
105
—
624 $

260 $

364
624 $

—
—
—
14
14

—
14

9 $

668
145
15
837 $

347 $

490
837 $

For U.S. Defined Benefit Plans assets measured at fair value using significant unobservable inputs (level 3),

the following table summarizes the change in balances during 2015 and 2014 for continuing operations:

Balance, beginning of year
Realized gains/(losses)
Unrealized gains/(losses)
Purchases, sales, issuances, and settlements
Transfers in (out)
Balance, end of year

Years Ended
October 31.

2015

2014

14 $
(1)
(2)
(2)
—
9 $

17
(1)
2
(4)
—
14

The following tables present the fair value of U.S. Post-Retirement Benefit Plans assets classified under the

appropriate level of the fair value hierarchy as of October 31, 2015 and 2014.

Cash and Cash Equivalents
Equity
Fixed Income
Other Investments

Total assets measured at fair value

Cash and Cash Equivalents
Equity
Fixed Income
Other Investments

Total assets measured at fair value

Assets measured at fair value - continuing
operations
Assets measured at fair value - discontinued
operations

Total assets measured at fair value

Fair Value Measurement at
October 31, 2015 Using

Quoted Prices
in Active
Markets for
Identical Assets
(Level 1)

Significant
Other
Observable
Inputs
(Level 2)

Significant
Unobservable
Inputs
(Level 3)

October 31,
2015

3 $

62
20
6
91 $

(in millions)
2 $

15
6
—
23 $

1 $
47
14
—
62 $

—
—
—
6
6

Fair Value Measurement
at October 31, 2014 Using

Quoted Prices
in Active
Markets for
Identical Assets
(Level 1)

Significant
Other
Observable
Inputs
(Level 2)

Significant
Unobservable
Inputs
(Level 3)

October 31,
2014

(in millions)
3 $

51
14
—
68 $

19 $

49
68 $

3 $

166
39
—
208 $

138
208 $

—
—
—
8
8

—
8

s
l
a
i
c
n
a
n
i
F

t
r
o
p
e
R

l
a
u
n
n
A

6 $

217
53
8
284 $

97 $

187
284 $

For U.S. Post-Retirement Benefit Plans assets measured at fair value using significant unobservable inputs
(level 3), the following table summarizes the change in balances during 2015 and 2014 for continuing operations:

Balance, beginning of year
Realized gains/(losses)
Unrealized gains/(losses)
Purchases, sales, issuances, and settlements
Transfers in (out)
Balance, end of year

Years Ended
October 31,

2015

2014

8 $
(1 )
—
(1 )
—
6 $

10
(1)
1
(2)
—
8

The following tables present the fair value of non-U.S. Defined Benefit Plans assets classified under the

appropriate level of the fair value hierarchy as of October 31, 2015 and 2014:

Fair Value Measurement at
October 31, 2015 Using

Quoted Prices
in Active
Markets for
Identical Assets
(Level 1)

Significant
Other
Observable
Inputs
(Level 2)

Significant
Unobservable
Inputs
(Level 3)

October 31,
2015

Cash and Cash Equivalents
Equity
Fixed Income
Other Investments

Total assets measured at fair value

3 $

396
379
—
778 $

(in millions)
1 $

172
13
—
186 $

2 $

224
366
—
592 $

—
—
—
—
—

Fair Value Measurement
at October 31, 2014 Using

Quoted Prices
in Active
Markets for
Identical Assets
(Level 1)

Significant
Other
Observable
Inputs
(Level 2)

Significant
Unobservable
Inputs
(Level 3)

October 31,
2014

Cash and Cash Equivalents
Equity
Fixed Income
Other Investments

Total assets measured at fair value

Assets measured at fair value -
Assets measured at fair value -
discontinued operations

Total assets measured at fair value

10 $

1,078
974
46
2,108 $

790 $

1,318
2,108 $

(in millions)
3 $

335
37
—
375 $

200 $

175
375 $

7 $

743
937
25
1,712 $

586 $

1,126
1,712 $

—
—
—
21
21

17
21

For non-U.S. Defined Benefit Plans, assets measured at fair value using significant unobservable inputs
(level 3), the following table summarizes the changes in balances during 2015 and 2014 for continuing
operations:

Balance, beginning of year
Realized gains/(losses)
Unrealized gains/(losses)
Purchases, sales, issuances, and settlements
Transfers in (out)
Balance, end of year

Years Ended
October 31,

2015

2014

4 $
1
—
(5)
—
— $

—
—
—
—
4
4

s
l
a
i
c
n
a
n
i
F

t
r
o
p
e
R

l
a
u
n
n
A

The table below presents the combined projected benefit obligation ("PBO"), accumulated benefit obligation
("ABO") and fair value of plan assets, grouping plans using comparisons of the PBO and ABO relative to the
plan assets as of October 31, 2015 or 2014.

2015

2014

Benefit
Obligation

PBO

Fair Value of
Plan Assets

Benefit
Obligation

PBO

Fair Value of
Plan Assets

(in millions)

U.S. defined benefit plans where PBO exceeds the fair value of plan
assets - continuing operations

U.S. defined benefit plans where PBO exceeds the fair value of plan
assets - discontinued operations

Total

Non-U.S. defined benefit plans where PBO exceeds or is equal to the
fair value of plan assets - continuing operations
Non-U.S. defined benefit plans where PBO exceeds or is equal to the
fair value of plan assets - discontinued operations

Non-U.S. defined benefit plans where fair value of plan assets
exceeds PBO - continuing operations

Non-U.S. defined benefit plans where fair value of plan assets
exceeds PBO - discontinued operations

Total

U.S. defined benefit plans where ABO exceeds the fair value of plan
assets - continuing operations

U.S. defined benefit plans where ABO exceeds the fair value of plan
assets - discontinued operations

U.S. defined benefit plans where the fair value of plan assets exceeds
ABO - continuing operations

U.S. defined benefit plans where the fair value of plan assets exceeds
ABO - discontinued operations

Total

Non-U.S. defined benefit plans where ABO exceeds or is equal to the
fair value of plan assets - continuing operations
Non-U.S. defined benefit plans where ABO exceeds or is equal to the
fair value of plan assets - discontinued operations

Non-U.S. defined benefit plans where fair value of plan assets
exceeds ABO - continuing operations

Non-U.S. defined benefit plans where fair value of plan assets
exceeds ABO - discontinued operations

415 $

347 $

375

—

415 $

347 $

514
889 $

771 $

623 $

754

1,111

161

—

129

—

155

—

900 $

778 $

318
2,344 $

366

2,108

ABO

389 $

347 $

—

389 $

347 $

340

472
826 $

732 $

623 $

714

—

127

—

155

—

1,081

158

310
2,263 $

366

2,108

347

490

837

607

952

183

—

347

490

837

607

952

183

Total

859 $

778 $

Contributions and estimated future benefit payments. During fiscal year 2016, we expect to contribute $0
million to the U.S. defined benefit plans, $25 million to plans outside the U.S., and $1 million to the Post-
retirement Medical Plans. The following table presents expected future benefit payments for the next 10 years:

2016
2017
2018
2019
2020
2021 - 2025

U.S. Defined
Benefit Plans

Non-U.S. Defined
Benefit Plans
(in millions)

U.S. Post-Retirement
Benefit Plans

$
$
$
$
$
$

25 $
26 $
28 $
30 $
33 $
177 $

21 $
22 $
24 $
26 $
27 $
166 $

8
9
8
8
8
40

Assumptions. The assumptions used to determine the benefit obligations and expense for our defined
benefit and post-retirement benefit plans are presented in the tables below. The expected long-term return on
assets below represents an estimate of long-term returns on investment portfolios consisting of a mixture of
equities, fixed income and alternative investments in proportion to the asset allocations of each of our plans. We
consider long-term rates of return, which are weighted based on the asset classes (both historical and forecasted)
in which we expect our pension and post-retirement funds to be invested. Discount rates reflect the current rate at
which pension and post-retirement obligations could be settled based on the measurement dates of the plans -
October 31. The U.S. discount rates at October 31, 2014 and 2015, were determined based on the results of
matching expected plan benefit payments with cash flows from a hypothetically constructed bond portfolio. The
non-U.S. rates were generally based on published rates for high-quality corporate bonds. The range of
assumptions that were used for the non-U.S. defined benefit plans reflects the different economic environments
within various countries.

Assumptions used to calculate the net periodic cost in each year were as follows:

U.S. defined benefit plans:

Discount rate
Average increase in compensation levels
Expected long-term return on assets

Non-U.S. defined benefit plans:

Discount rate
Average increase in compensation levels
Expected long-term return on assets

U.S. post-retirement benefits plans:

For years ended October 31,

2015

2014

2013

4.00%
3.50%
8.00%

4.00-4.50%
3.50%
8.00%

3.25%
3.50%
8.00%

1.50-4.00%
2.5-3.25%
4.00-6.50%

1.50-4.50%
2.50-3.25%
4.00-6.50%

1.50-4.50%
2.50-3.00%
4.00-6.50%

Discount rate
Expected long-term return on assets
Current medical cost trend rate
Ultimate medical cost trend rate
Medical cost trend rate decreases to ultimate rate in year

4.00%
8.00%
8.00%
3.50%
2028

4.00-4.25%
8.00%
8.00%
3.50%
2028

3.50%
8.00%
9.00%
3.50%
2027

s
l
a
i
c
n
a
n
i
F

t
r
o
p
e
R

l
a
u
n
n
A

Assumptions used to calculate the benefit obligation were as follows:

U.S. defined benefit plans:

Discount rate
Average increase in compensation levels

Non-U.S. defined benefit plans:

Discount rate
Average increase in compensation levels

U.S. post-retirement benefits plans:

Discount rate
Current medical cost trend rate
Ultimate medical cost trend rate
Medical cost trend rate decreases to ultimate rate in year

As of the Years Ending October 31,

2015

2014

4.20%
3.50%

4.00%
3.50%

0.77-3.76%
2.25-4.00%

1.50-4.00%
2.50-3.25%

4.00%
7.00%
3.50%
2029

3.75-4.00%
8.00%
3.50%
2028

Health care trend rates do not have a significant effect on the total service and interest cost components or on
the post-retirement benefit obligation amounts reported for the U.S. Post-Retirement Benefit Plan for the year
ended October 31, 2015.

17. GUARANTEES

Standard Warranty

We accrue for standard warranty costs based on historical trends in warranty charges as a percentage of net
product shipments. The accrual is reviewed regularly and periodically adjusted to reflect changes in warranty
cost estimates. Estimated warranty charges are recorded within cost of products at the time products are sold.
The standard warranty accrual balances are held in other accrued and other long-term liabilities on our
consolidated balance sheet. Our standard warranty terms typically extend between one and three years from the
date of delivery, depending on the product.

A summary of the standard warranty accrual activity is shown in the table below. The standard warranty

accrual balances are held in other accrued and other long-term liabilities.

Balance as of October 31, 2014 and 2013
Accruals for warranties including change in estimates
Settlements made during the period
Balance as of October 31, 2015 and 2014

Accruals for warranties due within one year
Accruals for warranties due after one year
Balance as of October 31, 2015 and 2014

October 31,

2015

2014

(in millions)
30 $
53
(52)
31 $

29
2
31 $

31
44
(45)
30

26
4
30

Indemnifications to Keysight

In connection with the separation of Keysight from Agilent on November 1, 2014 we agreed to indemnify
Keysight and its affiliates against certain damages and expenses that might occur in the future. These
indemnifications cover a variety of liabilities, including, but not limited to, employee, tax and environmental
matters. The agreements containing these indemnifications have been previously disclosed as exhibits to our
current report on Form 8-K filed on August 1, 2014. In our opinion, the fair value of these indemnification
obligations was not material as of October 31, 2015.

Indemnifications to Avago

In connection with the sale of our semiconductor products business in December 2005, we agreed to
indemnify Avago, its affiliates and other related parties against certain damages and expenses that it might incur
in the future. The continuing indemnifications primarily cover damages and expenses relating to liabilities of the
businesses that Agilent retained and did not transfer to Avago, as well as pre-closing taxes and other specified
items. In connection with the separation of Keysight from Agilent, Keysight assumed the indemnification
obligations to Avago. In our opinion, the fair value of these indemnification obligations was not material as of
October 31, 2015.

Indemnifications to Verigy

In connection with the spin-off of Verigy, we agreed to indemnify Verigy and its affiliates against certain
damages which it might incur in the future. These indemnifications primarily cover damages relating to liabilities
of the businesses that Agilent did not transfer to Verigy, liabilities that might arise under limited portions of
Verigy's IPO materials that relate to Agilent, and costs and expenses incurred by Agilent or Verigy to effect the
IPO, arising out of the distribution of Agilent's remaining holding in Verigy ordinary shares to Agilent's
stockholders, or incurred to effect the separation of the semiconductor test solutions business from Agilent to the
extent incurred prior to the separation on June 1, 2006. On July 4, 2011, Verigy announced the completion by
Advantest Corporation of its acquisition of Verigy. Verigy will operate as a wholly-owned subsidiary of
Advantest and our indemnification obligations to Verigy should be unaffected. In connection with the separation
of Keysight from Agilent, Keysight assumed the indemnification obligations to Verigy. In our opinion, the fair
value of these indemnification obligations was not material as of October 31, 2015.

Indemnifications to HP Inc. and Hewlett-Packard Enterprise (formerly Hewlett-Packard Company)

We have given multiple indemnities to HP Inc. and Hewlett-Packard Enterprise (formerly Hewlett-Packard
Company) (together "HP") in connection with our activities prior to our spin-off from HP for the businesses that
constituted Agilent prior to the spin-off. These indemnifications cover a variety of aspects of our business,
including, but not limited to, employee, tax, intellectual property and environmental matters. The agreements
containing these indemnifications have been previously disclosed as exhibits to our registration statement on
Form S-1 filed on August 16, 1999. In our opinion, the fair value of these indemnification obligations was not
material as of October 31, 2015.

Indemnifications to Varian Medical Systems and Varian Semiconductor Equipment Associates

In connection with our acquisition of Varian, we are subject to certain indemnification obligations to Varian
Medical Systems (formerly Varian Associates, Inc. ("VAI")) and Varian Semiconductor Equipment Associates
("VSEA") in connection with the Instruments business as conducted by VAI prior to the Distribution (as
described in Note 1 of Varian's Annual Report on Form 10-K filed on November 25, 2009). These
indemnification obligations cover a variety of aspects of our business, including, but not limited to, employee,
tax, intellectual property, litigation and environmental matters. Certain of the agreements containing these
indemnification obligations are disclosed as exhibits to Varian's Annual Report on Form 10-K filed on
November 25, 2009. On November 10, 2011, Applied Materials announced that it had completed the acquisition
of VSEA, which is now a wholly-owned subsidiary of Applied Materials; our indemnification obligations to

s
l
a
i
c
n
a
n
i
F

t
r
o
p
e
R

l
a
u
n
n
A

VSEA should be unaffected. In our opinion, the fair value of these indemnification obligations was not material
as of October 31, 2015.

Indemnifications to Officers and Directors

Our corporate by-laws require that we indemnify our officers and directors, as well as those who act as
directors and officers of other entities at our request, against expenses, judgments, fines, settlements and other
amounts actually and reasonably incurred in connection with any proceedings arising out of their services to
Agilent and such other entities, including service with respect to employee benefit plans. In addition, we have
entered into separate indemnification agreements with each director and each board-appointed officer of Agilent
which provide for indemnification of these directors and officers under similar circumstances and under
additional circumstances. The indemnification obligations are more fully described in the by-laws and the
indemnification agreements. We purchase standard insurance to cover claims or a portion of the claims made
against our directors and officers. Since a maximum obligation is not explicitly stated in our by-laws or in our
indemnification agreements and will depend on the facts and circumstances that arise out of any future claims,
the overall maximum amount of the obligations cannot be reasonably estimated. Historically, we have not made
payments related to these obligations, and the fair value for these indemnification obligations was not material as
of October 31, 2015.

Other Indemnifications

As is customary in our industry and as provided for in local law in the U.S. and other jurisdictions, many of
our standard contracts provide remedies to our customers and others with whom we enter into contracts, such as
defense, settlement, or payment of judgment for intellectual property claims related to the use of our products.
From time to time, we indemnify customers, as well as our suppliers, contractors, lessors, lessees, companies that
purchase our businesses or assets and others with whom we enter into contracts, against combinations of loss,
expense, or liability arising from various triggering events related to the sale and the use of our products and
services, the use of their goods and services, the use of facilities and state of our owned facilities, the state of the
assets and businesses that we sell and other matters covered by such contracts, usually up to a specified
maximum amount. In addition, from time to time we also provide protection to these parties against claims
related to undiscovered liabilities, additional product liability or environmental obligations. In our experience,
claims made under such indemnifications are rare and the associated estimated fair value of the liability was not
material as of October 31, 2015.

In connection with the sale of several of our businesses, we have agreed to indemnify the buyers of such
business, their respective affiliates and other related parties against certain damages that they might incur in the
future. The continuing indemnifications primarily cover damages relating to liabilities of the businesses that
Agilent retained and did not transfer to the buyers, as well as other specified items. In our opinion, the fair value
of these indemnification obligations was not material as of October 31, 2015.

18. COMMITMENTS AND CONTINGENCIES

Operating Lease Commitments: We lease certain real and personal property from unrelated third parties
under non-cancelable operating leases. Future minimum lease payments under operating leases at October 31,
2015 were $35 million for 2016, $31 million for 2017, $23 million for 2018, $15 million for 2019, $11 million
for 2020 and $34 million thereafter. Future minimum lease income under leases at October 31, 2015 was $9
million for 2016, $9 million for 2017, $7 million for 2018, and $23 million thereafter. Certain leases require us to
pay property taxes, insurance and routine maintenance, and include escalation clauses. Total rent expense was
$65 million in 2015, $55 million in 2014 and $53 million in 2013.

Contingencies: We are involved in lawsuits, claims, investigations and proceedings, including, but not
limited to, patent, commercial and environmental matters, which arise in the ordinary course of business. There
are no matters pending that we currently believe are reasonably possible of having a material impact to our
business, consolidated financial condition, results of operations or cash flows.

19. SHORT-TERM DEBT

Credit Facilities

On September 15, 2014, Agilent entered into a credit agreement with a financial institution which provides
for a $400 million five-year unsecured credit facility that will expire on September 15, 2019. On June 9, 2015,
the commitments under the existing credit facility were increased by $300 million so that the aggregate
commitments under the facility now total $700 million. As of October 31, 2015, the company had no borrowings
outstanding under the facility. We were in compliance with the covenants for the credit facility during the years
ended October 31, 2015 and 2014.

20. LONG-TERM DEBT

Senior Notes

The following table summarizes the company's long-term senior notes and the related interest rate swaps:

October 31, 2015

October 31, 2014

Amortized
Principal

Swap

Total

Amortized
Principal

Swap

Total

100
499
399
598
1,596 $

(in millions)
102
518
399
598

2
19
—
—
21 $ 1,617 $

100
499
399
598
1,596 $

3
103
22
521
—
399
—
598
25 $ 1,621

2017 Senior Notes
2020 Senior Notes
2022 Senior Notes
2023 Senior Notes
Total

2017 Senior Notes

On October 20, 2014, we settled the redemption of $500 million of the $600 million outstanding aggregate
principal amount of our 2017 senior notes due November 1, 2017 that had been called for redemption on
September 19, 2014. The redemption price of approximately $580 million included a $80 million prepayment
penalty computed in accordance with the terms of the 2017 senior notes as the present value of the remaining
scheduled payments of principal and unpaid interest related to $500 million partial redemption. The prepayment
penalty less partial amortization of previously deferred interest rate swap gain of approximately $14 million
together with $2 million of amortization of debt issuance costs and discount was disclosed in other income
(expense), net in the condensed consolidated statement of operations. We also paid accrued and unpaid interest
of $15 million on the 2017 senior notes up to but not including the redemption date.

s
l
a
i
c
n
a
n
i
F

t
r
o
p
e
R

l
a
u
n
n
A

2020 Senior Notes

In July 2010, the company issued an aggregate principal amount of $500 million in senior notes ("2020
senior notes"). The 2020 senior notes were issued at 99.54% of their principal amount. The notes will mature on
July 15, 2020, and bear interest at a fixed rate of 5.00% per annum. The interest is payable semi-annually on
January 15th and July 15th of each year, payments commenced on January 15, 2011.

On August 9, 2011, we terminated our interest rate swap contracts related to our 2020 senior notes that
represented the notional amount of $500 million. The asset value, including interest receivable, upon termination
for these contracts was approximately $34 million and the amount to be amortized at October 31, 2015 was $19
million. The gain is being deferred and amortized to interest expense over the remaining life of the 2020 senior
notes.

2022 Senior Notes

In September 2012, the company issued an aggregate principal amount of $400 million in senior notes
("2022 senior notes"). The 2022 senior notes were issued at 99.80% of their principal amount. The notes will
mature on October 1, 2022, and bear interest at a fixed rate of 3.20% per annum. The interest is payable semi-
annually on April 1st and October 1st of each year, payments commenced on April 1, 2013.

2023 Senior Notes

In June 2013, the company issued aggregate principal amount of $600 million in senior notes ("2023 senior
notes"). The 2023 senior notes were issued at 99.544% of their principal amount. The notes will mature on
July 15, 2023 and bear interest at a fixed rate of 3.875% per annum. The interest is payable semi annually on
January 15th and July 15th of each year and payments will commence January 15, 2014.

All notes issued are unsecured and rank equally in right of payment with all of Agilent's other senior

unsecured indebtedness.

Other debt

As of October 31, 2015, and as a result of the Dako acquisition, we have mortgage debts, secured on
buildings in Denmark, in Danish Krone equivalent of $38 million aggregate principal outstanding with a Danish
financial institution. The loans have a variable interest rate based on 3 months Copenhagen Interbank Rate
("Cibor") and will mature on September 30, 2027. Interest payments are made in March, June, September and
December of each year.

21. STOCKHOLDERS' EQUITY

Stock Repurchase Program

On November 22, 2013 we announced that our board of directors had authorized a share repurchase
program. The existing program is designed to reduce or eliminate dilution resulting from issuance of stock under
the company's employee equity incentive programs to target maintaining a weighted average share count of
approximately 335 million diluted shares. For the year ended October 31, 2015, we repurchased 6 million shares
for $267 million. For the year ended October 31, 2014 we repurchased approximately 4 million shares for $200
million. For the year ended October 31, 2013 we repurchased 20 million shares for $900 million. All such shares
and related costs are held as treasury stock and accounted for using the cost method.

purchase of the remaining $98 million for a total of $365 million of common stock in fiscal 2015 under the
existing stock repurchase program. Upon commencement, the 2015 share repurchase program replaces our
existing stock repurchase program, which authorized the repurchase of shares to reduce or eliminate share
dilution from equity programs. The 2015 repurchase program does not require the company to acquire a specific
number of shares and may be suspended or discontinued at any time.

Cash Dividends on Shares of Common Stock

During the year ended October 31, 2015, cash dividends of $0.40 per share, or $133 million were declared
and paid on the company's outstanding common stock. During the year ended October 31, 2014, cash dividends
of $0.53 per share, or $176 million were declared and paid on the company's outstanding common stock. During
the year ended October 31, 2013, cash dividends of $0.46 per share, or $156 million were declared and paid on
the company's outstanding common stock. On November 19, 2015, we declared a quarterly dividend of $0.115
per share of common stock, or approximately $38 million which will be paid on January 27, 2016 to shareholders
of record as of the close of business on January 5, 2016. The timing and amounts of any future dividends are
subject to determination and approval by our board of directors.

Accumulated other comprehensive income (loss)

The following table summarizes the components of our accumulated other comprehensive income (loss) as

of October 31, 2015 and 2014, net of tax effect:

Unrealized gain on equity securities, net of $(0) and $(3) of tax expense for 2015
and 2014, respectively
Foreign currency translation, net of $(2) and $(86) of tax expense for 2015 and
2014, respectively
Unrealized losses on defined benefit plans, net of tax benefit of $126 and $145 for
2015 and 2014, respectively
Unrealized gains (losses) on derivative instruments, net of tax expense of $(2) and
$(7) for 2015 and 2014, respectively
Total accumulated other comprehensive loss

October 31,

2015

2014

(in millions)

—

(189)

(204)

2
(391 ) $

156

(516)

9
(334)

s
l
a
i
c
n
a
n
i
F

t
r
o
p
e
R

l
a
u
n
n
A

Changes in accumulated other comprehensive income (loss) by component and related tax effects for the

years ended October 31, 2015 and 2014 were as follows (in millions):

Unrealized
gain on
investments

Foreign
currency
translation

Net defined benefit pension cost
and post retirement plan costs

Prior service
credits

Actuarial
Losses

(in millions)

Unrealized
gains (losses)
on derivatives

Total

As of October 31, 2013

425 $

287 $

(628) $

—

(277)

—

(273)

(525)

(5)

9
$
(3 ) $

(18)

(425)

(334)
332

(2)

(439)

—

(4)

(389)

(391)

Other comprehensive income
(loss) before reclassifications

Amounts reclassified out of
accumulated other
comprehensive income

Tax (expense) benefit

Other comprehensive income
(loss)

(1)

—

(48)

(269)

(32)

(143)

As of October 31, 2014
Transfer to Keysight

$
$

17
$
(17) $

156 $
(9) $

255 $
(83) $

(771) $
444 $

Balance after transfer to
Keysight
Other comprehensive income
(loss) before reclassifications

Amounts reclassified out of
accumulated other
comprehensive income

Tax benefit

Other comprehensive loss

—

147

(360)

—

(336)

172

—

(17)

(11)

(327)

(90)

(38)

As of October 31, 2015

—

(189) $

161 $

(365) $

Reclassifications out of accumulated other comprehensive income (loss) for the years ended October 31,

2015 and 2014 were as follows (in millions):

Details about accumulated other
comprehensive income components

Unrealized gain on equity securities

Unrealized gains and (losses) on derivatives

Net defined benefit pension cost and post retirement plan
costs:

Actuarial net loss
Prior service benefit

Amounts Reclassified
from other comprehensive
income

2015

2014

Affected line item in
statement of operations

— $
—
—
—

Other income (expense),
net

1
1 Total before income tax
— Provision for income tax
1 Total net of income tax

18
18

(6)
12

(35)
17
(18)

5
(13)

(1) Cost of products
(1) Total before income tax
(Provision)/benefit for
income tax

—
(1) Total net of income tax

(65)
48
(17) Total before income tax
(Provision)/benefit for
income tax

(2)
(19) Total net of income tax

Total reclassifications for the period

(1) $

(19)

Amounts in parentheses indicate reductions to income and increases to other comprehensive income.

Reclassifications of prior service benefit and actuarial net loss in respect of retirement plans and post
retirement pension plans are included in the computation of net periodic cost (see Note 16 "Retirement Plans and
Post Retirement Pension Plans").

22. SEGMENT INFORMATION

Description of segments. We are a global leader in life sciences, diagnostics and applied chemical markets,
providing application focused solutions that include instruments, software, services and consumables for the
entire laboratory workflow. In the first fiscal quarter of 2015, we completed the separation of our electronic
measurement business. See Note 4, "Discontinued Operations" for further information.

In November 2014, we announced a change in organizational structure designed to better serve our
customers. Our new structure reflects our strategy to focus our expertise on the market segments we serve and
utilize our resources to offer product solutions to address our customer needs. The new operating structure
ensures that we are able to respond to market demand while reducing costs through increased efficiencies. As a
result, our life sciences business, excluding the nucleic acid solutions division, together with the chemical

s
l
a
i
c
n
a
n
i
F

t
r
o
p
e
R

l
a
u
n
n
A

analysis business merged to form a new segment called life sciences and applied markets business. Our
diagnostics and genomics businesses combined and includes the nucleic acid solutions division of our life
sciences business and became the diagnostics and genomics segment. Finally, the Agilent CrossLab segment was
formed from the services and consumables businesses. The historical financial segment information has been
recast to conform to this new presentation.

Following this reorganization, Agilent has three business segments comprised of the life sciences and
applied markets business, diagnostics and genomics business and the Agilent CrossLab business each of which
comprises a reportable segment. The three operating segments were determined based primarily on how the chief
operating decision maker views and evaluates our operations. Operating results are regularly reviewed by the
chief operating decision maker to make decisions about resources to be allocated to the segment and to assess its
performance. Other factors, including market separation and customer specific applications, go-to-market
channels, products and services and manufacturing are considered in determining the formation of these
operating segments.

A description of our three reportable segments is as follows:

Our life sciences and applied markets business provides application-focused solutions that include
instruments and software that enable customers to identify, quantify and analyze the physical and biological
properties of substances and products, as well as enable customers in the clinical and life sciences research areas
to interrogate samples at the molecular level. Key product categories include: liquid chromatography ("LC")
systems and components; liquid chromatography mass spectrometry ("LCMS") systems; gas chromatography
("GC") systems and components; gas chromatography mass spectrometry ("GCMS") systems; inductively
coupled plasma mass spectrometry ("ICP-MS") instruments; atomic absorption ("AA") instruments; microwave
plasma-atomic emission spectrometry (“MP-AES”) instruments; inductively coupled plasma optical emission
spectrometry ("ICP-OES") instruments; laboratory software and informatics systems; laboratory automation and
robotic systems; dissolution testing; vacuum pumps and measurement technologies.

Our diagnostics and genomics business is comprised of three areas of activity providing solutions that
include pathology, reagents, instruments, software and consumables, which enable customers in the clinical and
life sciences research areas to interrogate samples at the cellular and molecular level. First, our Pathology
solutions business is focused on product offerings to cancer diagnostics and anatomic pathology workflows. The
broad portfolio of offerings includes immunohistochemistry (“IHC”), In Situ Hybridization (“ISH”),
Hematoxylin and Eosin (“H&E”) staining and special staining. We also collaborate with a number of major
pharmaceutical companies to develop new potential pharmacodiagnostics, also known as companion diagnostics,
which may be used to identify patients most likely to benefit from a specific targeted therapy. Second, our
genomics business includes arrays for DNA mutation detection, genotyping, gene copy number determination,
identification of gene rearrangements, DNA methylation profiling, gene expression profiling, as well as Next
Generation Sequencing ("NGS") target enrichment. Finally, our nucleic acid solutions business provides
equipment and expertise focused on production of synthesized oligonucleotides under pharmaceutical Good
Manufacturing Practices ("GMP") conditions for use as Active Pharmaceutical Ingredients ("API") in an
emerging class of drugs that utilize nucleic acid molecules for disease therapy.

The Agilent CrossLab business spans the entire lab with its extensive consumables and services portfolio,
which is designed to improve customer outcomes. The majority of the portfolio is vendor neutral, meaning
Agilent can serve and supply customers regardless of their instrument purchase choices. Solutions range from
chemistries and supplies to services and software helping to connect the entire lab. Key product categories in
consumables include GC and LC columns, sample preparation products, custom chemistries, and a large
selection of laboratory instrument supplies. Services include startup, operational, training and compliance
support, as well as asset management and consultative services that help increase customer productivity. Custom
service and consumable bundles are tailored to meet the specific application needs of various industries and to
keep instruments fully operational and compliant with the respective industry requirements.

A significant portion of the segments' expenses arise from shared services and infrastructure that we have
historically provided to the segments in order to realize economies of scale and to efficiently use resources.
These expenses, collectively called corporate charges, include legal, accounting, real estate, insurance services,

information technology services, treasury, other corporate infrastructure expenses and costs of centralized
research and development. Charges are allocated to the segments, and the allocations have been determined on a
basis that we consider to be a reasonable reflection of the utilization of services provided to or benefits received
by the segments. Corporate charges previously allocated to our electronic measurement business, but not
classified within discontinued operations, were not reallocated to our other segments. These charges are
presented below as a component of the reconciliation between segments' income from operations and Agilent's
income from continuing operations and are classified as unallocated corporate charges. In addition, we do not
allocate amortization and impairment of acquisition-related intangible assets, restructuring and transformational
expenses, acquisition and integration costs and certain other charges to the operating margin for each segment
because management does not include this information in its measurement of the performance of the operating
segments.

The following tables reflect the results of our reportable segments under our management reporting system.
The performance of each segment is measured based on several metrics, including segment income from
operations. These results are used, in part, by the chief operating decision maker in evaluating the performance
of, and in allocating resources to, each of the segments.

The profitability of each of the segments is measured after excluding restructuring and asset impairment
charges, investment gains and losses, interest income, interest expense, acquisition and integration costs, non-
cash amortization and other items as noted in the reconciliations below.

Year ended October 31, 2015:

Total net revenue
Income from operations
Depreciation expense
Share-based compensation expense

Year ended October 31, 2014:

Total net revenue
Income from operations
Depreciation expense
Share-based compensation expense

Year ended October 31, 2013:

Total net revenue
Income from operations
Depreciation expense
Share-based compensation expense

Life Sciences
and Applied
Markets

Diagnostics
and
Genomics

Agilent
CrossLab

Total
Segments

(in millions)

$
$
$
$

2,046 $
380 $
27 $
27 $

2,078 $
369 $
29 $
29 $

2,035 $
338 $
28 $
27 $

662 $
88 $
37 $
9 $

663 $
93 $
43 $
9 $

635 $
95 $
43 $
4 $

1,330 $
299 $
34 $
18 $

1,307 $
301 $
33 $
18 $

1,224 $
299 $
27 $
16 $

4,038
767
98
54

4,048
763
105
56

3,894
732
98
47

For the years ended October 31, 2014 and 2013, depreciation expense and share-based compensation

expense exclude unallocated corporate charges.

s
l
a
i
c
n
a
n
i
F

t
r
o
p
e
R

l
a
u
n
n
A

The following table reconciles reportable segments' income from operations to Agilent's total enterprise

income before taxes:

Years Ended October 31,

2015

2014

2013

(in millions)

Total reportable segments' income from operations
Restructuring and business exit related costs
Asset Impairments
Transformational programs
Amortization of intangibles
Acquisition and integration costs
Acceleration of share-based compensation expense related to
workforce reduction
One-time and pre-separation costs
Other
Interest Income
Interest Expense
Other income (expense), net
Unallocated corporate charges
Income before taxes, as reported

767 $
(12)
(3)
(56)
(156)
(13)

(2)
—
(3)
7
(66)
17
—
480 $

763 $
(66 )
(4 )
(29 )
(189 )
(11 )

(1 )
(14 )
10
9
(110 )
(89 )
(40 )
229 $

732
(34)
(2)
(19)
(190)
(22)

(2)
—
(13)
7
(107)
7
(64)
293

Major customers. No customer represented 10 percent or more of our total net revenue in 2015, 2014 or

2013.

The following table presents assets and capital expenditures directly managed by each segment. Unallocated
assets primarily consist of cash, cash equivalents, accumulated amortization of other intangibles and other assets.

As of October 31, 2015:

Assets
Capital expenditures
As of October 31, 2014:

Assets
Capital expenditures

Life Sciences
and Applied
Markets

Diagnostics
and
Genomics

Agilent
CrossLab

Total
Segments

(in millions)

$
$

1,539 $
28 $

2,027 $
33 $

1,663 $
33 $

2,302 $
40 $

1,008 $
37 $

1,001 $
37 $

4,574
98

4,966
110

The following table reconciles segment assets to Agilent's total assets:

Total reportable segments' assets
Cash, cash equivalents and short-term investments
Short-term restricted cash and cash equivalents
Prepaid expenses
Investments
Long-term and other receivables
Other
Current and non-current assets of discontinued operations
Total assets

October 31,

2015

2014

(in millions)

4,574 $
2,003
242
105
86
104
365
— $
7,479 $

4,966
2,218
—
85
96
90
377
2,983
10,815

$
$

The other category primarily represents the difference between how segments report deferred taxes.

The following table represents total revenue by product category:

Instrumentation
Analytical lab services
Analytical lab consumables
Diagnostics and genomics solutions
Informatics and other
Total

Years Ended October 31,

2015

2014

2013

(in millions)

1,827 $
843
489
662
217
4,038 $

1,839 $
831
476
663
239
4,048 $

1,802
768
456
635
233
3,894

The following table presents summarized information for net revenue and long-lived assets by geographic
region. Revenues from external customers are generally attributed to countries based upon the location of the
Agilent sales representative. Long lived assets consist of property, plant, and equipment, long-term receivables
and other long-term assets excluding intangible assets. The rest of the world primarily consists of rest of Asia
and Europe.

Net revenue:

Year ended October 31, 2015
Year ended October 31, 2014
Year ended October 31, 2013

Long-lived assets:
October 31, 2015
October 31, 2014

United
States

China

Rest of the
World

Total

(in millions)

$
$
$

1,206 $
1,019 $
1,077 $

633 $
543 $
619 $

2,199 $
2,486 $
2,198 $

4,038
4,048
3,894

United
States

Rest of the
World

Total

(in millions)

$
$

391 $
379 $

379 $
451 $

770
830

s
l
a
i
c
n
a
n
i
F

t
r
o
p
e
R

l
a
u
n
n
A

23. SUBSEQUENT EVENT

On November 2, 2015 we completed the acquisition of Seahorse Bioscience ("Seahorse"), a leader in
providing instruments and assay kits for measuring cell metabolism and bioenergetics for $242 million in cash.
Seahorse's technology enables researchers to better understand cell health, function and signaling, and how the
cell may be impacted by the introduction of a specific drug, by providing real-time kinetics to unlock essential
cellular bioenergetics data. As of October 31, 2015 $242 million of cash and cash equivalents was held in
escrow relating to the Seahorse acquisition and was classified as short-term restricted cash and cash equivalents
in the consolidated balance sheet. We have not yet finished allocating the purchase price to the net assets
acquired. The financial results of Seahorse will be included within Agilent's from the beginning of the first
quarter of 2016.

QUARTERLY SUMMARY
(Unaudited)

Three Months Ended

January 31, (As
Revised)

April 30, (As
Revised)

July 31, (As
Revised)

October 31, (As
Revised)

(in millions, except per share data)

2015
Net revenue
Gross profit
Income from operations
Income from continuing operations
Loss from discontinued operations, net of tax
Net income

Net income per share — basic:
Income from continuing operations
Loss from discontinued operations
Net income per share - basic

Net income per share — diluted:
Income from continuing operations
Loss from discontinued operations
Net income per share — diluted

Weighted average shares used in computing net
income per share:

Basic
Diluted

Cash dividends per common share
Range of stock prices on NYSE
2014
Net revenue
Gross profit
Income from operations
Income from continuing operations
Income from discontinued operations, net of tax
Net income

Net income per share — basic:
Income from continuing operations
Income from discontinued operations
Net income per share - basic

Net income per share — diluted:
Income from continuing operations

Income from discontinued operations

Net income per share — diluted

Weighted average shares used in computing net
income per share:

Basic
Diluted

Cash dividends per common share
Range of stock prices on NYSE

1,026 $
513
115
93
(30)
63 $

0.28 $
(0.09) $
0.19 $

0.28 $
(0.09)
0.19 $

336
338
0.100 $

963 $
480
107
92
(5)
87 $

0.28 $
(0.02) $
0.26 $

0.27 $
(0.01)
0.26 $

334
337
0.100 $

$ 37.68-42.99

$ 37.71-43.59

1,008 $
510
124
123
75
198 $

0.37 $
0.22
0.59 $

0.36 $

0.23

0.59 $

333
338
0.132 $

988 $
485
94
53
100
153 $

0.16 $
0.30
0.46 $

0.16 $

0.29

0.45 $

333
337
0.132 $

$ 49.84-61.22

$ 51.96-60.46

1,014 $
513
144
113
(2)
111 $

0.34 $
(0.01) $
0.33 $

0.34 $
(0.01)
0.33 $

1,035
535
156
140
—
140

0.42
—
0.42

332
334
0.100
$ 38.48-42.93

331
333
0.100
$ 33.12-41.35

1,009 $
502
131
54
85
139 $

0.16 $
0.26
0.42 $

0.16

0.25
0.41 $

1,043
479
70
2
57
59

0.01
0.17
0.18

0.01

0.16

0.17

334
338
0.132
$ 53.66-59.58

334
338
0.132
$ 49.80-59.40

The above quarterly financial data includes Keysight which is presented as discontinued operations. See
Note 4, "Discontinued Operations" for additional information. In addition, we made adjustments to correct
immaterial misstatements within our quarterly financial statements. For a detailed explanation of these
adjustments, please refer to Note 2, "Revision of Prior Period Financial Statements."

s
l
a
i
c
n
a
n
i
F

t
r
o
p
e
R

l
a
u
n
n
A

RISKS, UNCERTAINTIES AND OTHER FACTORS THAT MAY AFFECT FUTURE RESULTS

Our operating results and financial condition could be harmed if the markets into which we sell our

products decline or do not grow as anticipated.

Visibility into our markets is limited. Our quarterly sales and operating results are highly dependent on the
volume and timing of orders received during the fiscal quarter, which are difficult to forecast and may be
cancelled by our customers. A large amount of our orders are back-end loaded toward the end of our second and
fourth fiscal quarters and their timing may be influenced by the sales incentive programs we have in place. In
addition, our revenues and earnings forecasts for future fiscal quarters are often based on the expected
seasonality of our markets. However, the markets we serve do not always experience the seasonality that we
expect. Any decline in our customers' markets or in general economic conditions would likely result in a
reduction in demand for our products and services. Also, if our customers' markets decline, we may not be able
to collect on outstanding amounts due to us. Such declines could harm our consolidated financial position, results
of operations, cash flows and stock price, and could limit our profitability. Also, in such an environment, pricing
pressures could intensify. Since a significant portion of our operating expenses is relatively fixed in nature due to
sales, research and development and manufacturing costs, if we were unable to respond quickly enough these
pricing pressures could further reduce our operating margins.

If we do not introduce successful new products and services in a timely manner to address increased
competition through frequent new product and service introductions, rapid technological changes and
changing industry standards, our products and services will become obsolete, and our operating results will
suffer.

We generally sell our products in industries that are characterized by increased competition through frequent
new product and service introductions, rapid technological changes and changing industry standards. In addition,
many of the markets in which we operate are seasonal. Without the timely introduction of new products, services
and enhancements, our products and services will become technologically obsolete over time, in which case our
revenue and operating results would suffer. The success of our new products and services will depend on several
factors, including our ability to:

•
properly identify customer needs and predict future needs;
•
innovate and develop new technologies, services and applications;
successfully commercialize new technologies in a timely manner;
•
• manufacture and deliver our products in sufficient volumes and on time;
•
•
•

differentiate our offerings from our competitors' offerings;
price our products competitively;
anticipate our competitors' development of new products, services or technological innovations;
and
control product quality in our manufacturing process.

•

General economic conditions may adversely affect our operating results and financial condition.

Our business is sensitive to negative changes in general economic conditions, both inside and outside the
U.S. Slower global economic growth and uncertainty in the markets in which we operate may adversely impact
our business resulting in:

•

reduced demand for our products, delays in the shipment of orders, or increases in order
cancellations;
increased risk of excess and obsolete inventories;

•
•

increased price pressure for our products and services; and
greater risk of impairment to the value, and a detriment to the liquidity, of our investment
portfolio.

Failure to adjust our purchases due to changing market conditions or failure to estimate our customers'

demand could adversely affect our income.

Our income could be harmed if we are unable to adjust our purchases to reflect market fluctuations,
including those caused by the seasonal nature of the markets in which we operate. The sale of our products and
services are dependent, to a large degree, on customers whose industries are subject to seasonal trends in the
demand for their products. During a market upturn, we may not be able to purchase sufficient supplies or
components to meet increasing product demand, which could materially affect our results. In the past we have
seen a shortage of parts for some of our products. In addition, some of the parts that require custom design are
not readily available from alternate suppliers due to their unique design or the length of time necessary for design
work. Should a supplier cease manufacturing such a component, we would be forced to reengineer our product.
In addition to discontinuing parts, suppliers may also extend lead times, limit supplies or increase prices due to
capacity constraints or other factors. In order to secure components for the production of products, we may
continue to enter into non-cancelable purchase commitments with vendors, or at times make advance payments
to suppliers, which could impact our ability to adjust our inventory to declining market demands. If demand for
our products is less than we expect, we may experience additional excess and obsolete inventories and be forced
to incur additional charges.

Demand for some of our products and services depends on capital spending policies of our customers,

research and development budgets and on government funding policies.

Our customers

include pharmaceutical companies,

laboratories, universities, healthcare providers,
government agencies and public and private research institutions. Fluctuations in the research and development
budgets at these organizations could have a significant effect on the demand for our products and services. Many
factors, including public policy spending priorities, available resources, mergers and consolidation, spending
priorities, institutional and governmental budgetary policies and product and economic cycles, have a significant
effect on the capital spending policies of these entities. Research and development budgets fluctuate due to
changes in available resources, consolidation, spending priorities, general economic conditions and institutional
and governmental budgetary policies. The timing and amount of revenues from customers that rely on
government funding or research may vary significantly due to factors that can be difficult to forecast. These
policies in turn can have a significant effect on the demand for our products and services. If demand for our
products and services is adversely affected, our revenue and operating results would suffer.

Economic, political, foreign currency and other risks associated with international sales and operations

could adversely affect our results of operations.

Because we sell our products worldwide, our business is subject to risks associated with doing business
internationally. We anticipate that revenue from international operations will continue to represent a majority of
our total revenue. International revenues and costs are subject to the risk that fluctuations in foreign currency
exchange rates could adversely affect our financial results when translated into U.S. dollars for financial
reporting purposes. The unfavorable effects of changes in foreign currency exchange rates has decreased
revenues by approximately 6 percentage points in the year ended October 31, 2015. In addition, many of our
employees, contract manufacturers, suppliers, job functions and manufacturing facilities are located outside the
U.S. Accordingly, our future results could be harmed by a variety of factors, including:

•

interruption to transportation flows for delivery of parts to us and finished goods to our
customers;
changes in foreign currency exchange rates;

s
l
a
i
c
n
a
n
i
F

t
r
o
p
e
R

l
a
u
n
n
A

•
•
•

•
•
•
•
•

changes in a specific country's or region's political, economic or other conditions;
trade protection measures and import or export licensing requirements;
negative consequences from changes in tax laws including changes to U.S. tax legislation that
could materially increase our effective tax rate;
difficulty in staffing and managing widespread operations;
differing labor regulations;
differing protection of intellectual property;
unexpected changes in regulatory requirements; and
geopolitical turmoil, including terrorism and war.

We centralized most of our accounting and tax processes to two locations: India and Malaysia. These
processes include general accounting, cost accounting, accounts payable, accounts receivables and tax functions.
If conditions change in those countries, it may adversely affect operations, including impairing our ability to pay
our suppliers and collect our receivables. Our results of operations, as well as our liquidity, may be adversely
affected and possible delays may occur in reporting financial results.

Additionally, we must comply with complex foreign and U.S. laws and regulations, such as the U.S. Foreign
Corrupt Practices Act, the U.K. Bribery Act, and other local laws prohibiting corrupt payments to governmental
officials, and anti-competition regulations. Violations of these laws and regulations could result in fines and
penalties, criminal sanctions, restrictions on our business conduct and on our ability to offer our products in one
or more countries, and could also materially affect our brand, our ability to attract and retain employees, our
international operations, our business and our operating results. Although we have implemented policies and
procedures designed to ensure compliance with these laws and regulations, there can be no assurance that our
employees, contractors, or agents will not violate our policies.

In addition, although the majority of our products are priced and paid for in U.S. dollars, a significant
amount of certain types of expenses, such as payroll, utilities, tax, and marketing expenses, are paid in local
currencies. Our hedging programs reduce, but do not always entirely eliminate, within any given twelve month
period, the impact of currency exchange rate movements, and therefore fluctuations in exchange rates, including
those caused by currency controls, could impact our business operating results and financial condition by
resulting in lower revenue or increased expenses. However, for expenses beyond that twelve month period, our
hedging strategy does not mitigate our exposure. In addition, our currency hedging programs involve third party
financial institutions as counterparties. The weakening or failure of financial institution counterparties may
adversely affect our hedging programs and our financial condition through, among other things, a reduction in
available counterparties, increasingly unfavorable terms, and the failure of the counterparties to perform under
hedging contracts.

Our strategic initiatives could have long-term adverse effects on our business and we may not realize the

operational or financial benefits from such actions.

We have implemented multiple strategic initiatives across our businesses to adjust our cost structure, and we
may engage in similar activities in the future. These strategic initiatives and our regular ongoing cost reduction
activities may distract management, could slow improvements in our products and services and limit our ability
to increase production quickly if demand for our products increases. In addition, delays in implementing our
strategic initiatives, unexpected costs or failure to meet targeted improvements may diminish the operational and
financial benefits we realize from such actions. Any of the above circumstances could have an adverse effect on
our business and financial statements.

Our business will suffer if we are not able to retain and hire key personnel.

Our future success depends partly on the continued service of our key research, engineering, sales,
marketing, manufacturing, executive and administrative personnel. If we fail to retain and hire a sufficient

number of these personnel, we will not be able to maintain or expand our business. The markets in which we
operate are very dynamic, and our businesses continue to respond with reorganizations, workforce reductions and
site closures. We believe our pay levels are very competitive within the regions that we operate. However, there
is an intense competition for certain highly technical specialties in geographic areas where we continue to recruit,
and it may become more difficult to retain our key employees.

Our acquisitions, strategic alliances, joint ventures and divestitures may result in financial results that

are different than expected.

In the normal course of business, we frequently engage in discussions with third parties relating to
possible acquisitions, strategic alliances, joint ventures and divestitures, and generally expect to complete several
transactions per year. As a result of such transactions, our financial results may differ from our own or the
investment community's expectations in a given fiscal quarter, or over the long term. We may have difficulty
developing, manufacturing and marketing the products of a newly acquired company in a way that enhances the
performance of our combined businesses or product lines. Transactions such as acquisitions have resulted, and
may in the future result, in unexpected significant costs and expenses. In the future, we may be required to record
charges to earnings during the period if we determine there is an impairment of goodwill or intangible assets, up
to the full amount of the value of the assets. In addition, acquisitions and strategic alliances may require us to
integrate a different company culture, management team and business infrastructure. Depending on the size and
complexity of an acquisition, our successful integration of the entity depends on a variety of factors, including
introducing new products and meeting revenue targets as expected, the retention of key employees and the
retention of key customers.

The integration of acquired businesses is likely to result in our systems and internal controls becoming
increasingly complex and more difficult to manage. Any difficulties in the assimilation of acquired businesses
into our control system could harm our operating results or cause us to fail to meet our financial reporting
obligations.

A successful divestiture depends on various factors, including our ability to effectively transfer liabilities,
contracts, facilities and employees to the purchaser, identify and separate the intellectual property to be divested
from the intellectual property that we wish to keep and reduce fixed costs previously associated with the divested
assets or business. In addition, if customers of the divested business do not receive the same level of service
from the new owners, this may adversely affect our other businesses to the extent that these customers also
purchase other Agilent products. All of these efforts require varying levels of management resources, which may
divert our attention from other business operations. If we do not realize the expected benefits or synergies of
such transactions, our consolidated financial position, results of operations, cash flows and stock price could be
negatively impacted.

If we fail to maintain an effective system of internal controls, we may not be able to accurately report our
financial results, which could lead to a loss of investor confidence in our financial statements and have an
adverse effect on our stock price.

Effective internal controls are necessary for us to provide reliable and accurate financial statements and to
effectively prevent fraud. We devote significant resources and time to comply with the internal control over
financial reporting requirements of the Sarbanes Oxley Act of 2002. As further described in Part II Item 9A
“Controls and Procedures.” management has concluded that, because of a material weakness in accounting for
income taxes, our disclosure controls and procedures were not effective as of October 31, 2015. The Company
has and will continue to enhance its controls and expects to remediate the material weakness. However, we
cannot be certain that these measures will be successful or that we will be able to prevent future significant
deficiencies or material weaknesses. Inadequate internal controls could cause investors to lose confidence in our
reported financial information, which could have a negative effect on investor confidence in our financial
statements, the trading price of our stock and our access to capital.

s
l
a
i
c
n
a
n
i
F

t
r
o
p
e
R

l
a
u
n
n
A

Integrating Dako A/S may be more difficult, costly or time consuming than expected and our business

and financial condition may be materially impaired.

We may not achieve the desired benefits from our acquisition and integration of Dako. In addition, the
operation of Dako within Agilent may be a difficult, costly and time-consuming process that involves a number
of risks, including, but not limited to:

•
•
•
•
•

•
•

our response to significant competitive pressure;
difficulties in meeting new product timelines;
the ability to grow in emerging markets;
increased exposure to certain governmental regulations and compliance requirements;
increased costs to address certain governmental regulations and compliance issues, such as the
United States Food and Drug Administration (“FDA”) warning letter received in August 2013
which has now been lifted by the FDA;
increased costs and use of resources; and
difficulties in the assimilation of different corporate cultures, practices and sales and distribution
methodologies, as well as in the assimilation and retention of geographically dispersed,
decentralized operations and personnel.

Even if we are able to successfully operate Dako within Agilent, we may not be able to realize the revenue
and other synergies and growth that we anticipated from the acquisition in the time frame that we expected, and
the costs of achieving these benefits may be higher than what we expected. As a result, the Dako acquisition and
integration may not contribute to our earnings as expected, we may not achieve our operating margin targets
when expected, or at all, and we may not achieve the other anticipated strategic and financial benefits of this
transaction.

Our customers and we are subject to various governmental regulations, compliance with or changes in
such regulations may cause us to incur significant expenses, and if we fail to maintain satisfactory
compliance with certain regulations, we may be forced to recall products and cease their manufacture and
distribution, and we could be subject to civil or criminal penalties.

Our customers and we are subject to various significant international, federal, state and local regulations,
including but not limited to health and safety, packaging, product content, labor and import/export regulations.
These regulations are complex, change frequently and have tended to become more stringent over time. We may
be required to incur significant expenses to comply with these regulations or to remedy violations of these
regulations. Any failure by us to comply with applicable government regulations could also result in cessation of
our operations or portions of our operations, product recalls or impositions of fines and restrictions on our ability
to carry on or expand our operations. In addition, because many of our products are regulated or sold into
regulated industries, we must comply with additional regulations in marketing our products. We develop,
configure and market our products to meet customer needs created by these regulations. Any significant change
in these regulations could reduce demand for our products, force us to modify our products to comply with new
regulations or increase our costs of producing these products. If demand for our products is adversely affected or
our costs increase, our business would suffer.

Our products and operations are also often subject to the rules of industrial standards bodies, like the
International Standards Organization, as well as regulation by other agencies such as the United States Food and
Drug Administration (“FDA”). We also must comply with work safety rules. If we fail to adequately address any
of these regulations, our businesses could be harmed.

We are subject to extensive regulation by the FDA and certain similar foreign regulatory agencies, and
failure to comply with such regulations could harm our reputation, business, financial condition and results
of operations.

A number of our products are subject to regulation by the FDA and certain similar foreign regulatory
agencies. In addition, a number of our products may be in the future subject to regulation by the FDA and certain
similar foreign regulatory agencies. These regulations govern a wide variety of product related activities, from
quality management, design and development to labeling, manufacturing, promotion, sales and distribution. If we
or any of our suppliers or distributors fail to comply with FDA and other applicable regulatory requirements or
are perceived to potentially have failed to comply, we may face, among other things, warning letters, adverse
publicity affecting both us and our customers; investigations or notices of non-compliance, fines, injunctions,
and civil penalties; import or export restrictions; partial suspensions or total shutdown of production facilities or
the imposition of operating restrictions; increased difficulty in obtaining required FDA clearances or approvals or
foreign equivalents; seizures or recalls of our products or those of our customers; or the inability to sell our
products. Any such FDA actions could disrupt our business and operations, lead to significant remedial costs and
have a material adverse impact on our financial position and results of operations.

Some of our products are exposed to particular complex regulations such as regulations of toxic

substances and failure to comply with such regulations could harm our business.

Some of our products and related consumables are used in conjunction with chemicals whose manufacture,
processing, distribution and notification requirements are regulated by the U.S. Environmental Protection
Agency (“EPA”) under the Toxic Substances Control Act, and by regulatory bodies in other countries with
similar laws. The Toxic Substances Control Act regulations govern, among other things, the testing,
manufacture, processing and distribution of chemicals, the testing of regulated chemicals for their effects on
human health and safety and import and export of chemicals. The Toxic Substances Control Act prohibits
persons from manufacturing any chemical in the U.S. that has not been reviewed by EPA for its effect on health
and safety, and placed on an EPA inventory of chemical substances. We must ensure conformance of the
manufacturing, processing, distribution of and notification about these chemicals to these laws and adapt to
regulatory requirements in all applicable countries as these requirements change. If we fail to comply with the
notification, record-keeping and other requirements in the manufacture or distribution of our products, then we
could be made to pay civil penalties, face criminal prosecution and, in some cases, be prohibited from
distributing or marketing our products until the products or component substances are brought into compliance.

Our business may suffer if we fail to comply with government contracting laws and regulations.

We derive a portion of our revenues from direct and indirect sales to U.S., state, local, and foreign
governments and their respective agencies. Such contracts are subject to various procurement laws and
regulations, and contract provisions relating to their formation, administration and performance. Failure to
comply with these laws, regulations or provisions in our government contracts could result in the imposition of
various civil and criminal penalties, termination of contracts, forfeiture of profits, suspension of payments, or
suspension from future government contracting. If our government contracts are terminated, if we are suspended
from government work, or if our ability to compete for new contracts is adversely affected, our business could
suffer.

Our retirement and post retirement pension plans are subject to financial market risks that could

adversely affect our future results of operations and cash flows.

We have significant retirement and post retirement pension plans assets and obligations. The performance of
the financial markets and interest rates impact our plan expenses and funding obligations. Significant decreases
in market interest rates, decreases in the fair value of plan assets and investment losses on plan assets will
increase our funding obligations, and adversely impact our results of operations and cash flows.

s
l
a
i
c
n
a
n
i
F

t
r
o
p
e
R

l
a
u
n
n
A

The impact of consolidation and acquisitions of competitors is difficult to predict and may harm our

business.

The life sciences industry is intensely competitive and has been subject to increasing consolidation.
Consolidation in our industries could result in existing competitors increasing their market share through
business combinations and result in stronger competitors, which could have a material adverse effect on our
business, financial condition and results of operations. We may not be able to compete successfully in
increasingly consolidated industries and cannot predict with certainty how industry consolidation will affect our
competitors or us.

If we are unable to successfully manage the consolidation and streamlining of our manufacturing
operations, we may not achieve desired efficiencies and our ability to deliver products to our customers could
be disrupted.

Although we utilize manufacturing facilities throughout the world, we have been consolidating, and may
continue to consolidate, our manufacturing operations to certain of our plants to achieve efficiencies and gross
margin improvements. Additionally, we typically consolidate the production of products from our acquisitions
into our supply chain and manufacturing processes, which are technically complex and require expertise to
operate. If we are unable to establish processes to efficiently and effectively produce high quality products in the
consolidated locations, we may not achieve the anticipated synergies and production may be disrupted, which
could adversely affect our business and operating results.

Our operating results may suffer if our manufacturing capacity does not match the demand for our

products.

Because we cannot immediately adapt our production capacity and related cost structures to rapidly
changing market conditions, when demand does not meet our expectations, our manufacturing capacity will
likely exceed our production requirements. If, during a general market upturn or an upturn in one of our
segments, we cannot increase our manufacturing capacity to meet product demand, we will not be able to fulfill
orders in a timely manner which could lead to order cancellations, contract breaches or indemnification
obligations. This inability could materially and adversely limit our ability to improve our results. By contrast, if
during an economic downturn we had excess manufacturing capacity, then our fixed costs associated with excess
manufacturing capacity would adversely affect our income, margins, and operating results.

Dependence on contract manufacturing and outsourcing other portions of our supply chain including
logistics services, may adversely affect our ability to bring products to market and damage our reputation.
Dependence on outsourced information technology and other administrative functions may impair our ability
to operate effectively.

As part of our efforts to streamline operations and to cut costs, we outsource aspects of our manufacturing
processes and other functions and continue to evaluate additional outsourcing. If our contract manufacturers or
other outsourcers fail to perform their obligations in a timely manner or at satisfactory quality levels, our ability
to bring products to market and our reputation could suffer. For example, during a market upturn, our contract
manufacturers may be unable to meet our demand requirements, which may preclude us from fulfilling our
customers' orders on a timely basis. The ability of these manufacturers to perform is largely outside of our
control. Additionally, changing or replacing our contract manufacturers, logistics providers or other outsourcers
could cause disruptions or delays. In addition, we outsource significant portions of our information technology
("IT") and other administrative functions. Since IT is critical to our operations, any failure to perform on the part
of our IT providers could impair our ability to operate effectively. In addition to the risks outlined above,
problems with manufacturing or IT outsourcing could result in lower revenues, unexecuted efficiencies, and
impact our results of operations and our stock price. Much of our outsourcing takes place in developing countries
and, as a result, may be subject to geopolitical uncertainty.

Environmental contamination from past operations could subject us to unreimbursed costs and could
harm on-site operations and the future use and value of the properties involved and environmental
contamination caused by ongoing operations could subject us to substantial liabilities in the future.

Certain properties transferred to Keysight as part of the separation are undergoing remediation by HP Inc.
and Hewlett-Packard Enterprise (formerly Hewlett-Packard Company) (together "HP") for subsurface
contaminations that were known at the time of our separation from HP. HP has agreed to retain the liability for
this subsurface contamination, perform the required remediation and indemnify Keysight with respect to claims
arising out of that contamination. HP will have access to those Keysight properties to perform remediation.
While HP has agreed to minimize interference with on-site operations at those properties, remediation activities
and subsurface contamination may require Keysight to incur unreimbursed costs and could harm on-site
operations and the future use and value of the properties. We cannot be sure that Keysight will not seek
additional reimbursement from us for that interference or unreimbursed costs. We cannot be sure that HP will
continue to fulfill its indemnification or remediation obligations, in which case Keysight may seek
indemnification from us. In addition, the determination of the existence and cost of any additional contamination
caused by us prior to the separation could involve costly and time-consuming negotiations and litigation.

Other than those properties currently undergoing remediation by HP, we have agreed to indemnify HP, with
respect to any liability associated with contamination from past operations, and Keysight, with respect to any
liability associated with contamination prior to the separation, at, respectively, properties transferred from HP to
us and properties transferred by us to Keysight. While we are not aware of any material liabilities associated
with any potential subsurface contamination at any of those properties, subsurface contamination may exist, and
we may be exposed to material liability as a result of the existence of that contamination.

Our current and historical manufacturing processes involve, or have involved, the use of substances
regulated under various international, federal, state and local laws governing the environment. As a result, we
may become subject to liabilities for environmental contamination, and these liabilities may be substantial. While
we have divested substantially all of our semiconductor related businesses to Avago and Advantest Corporation
and regardless of indemnification arrangements with those parties, we may still become subject to liabilities for
historical environmental contamination related to those businesses. Although our policy is to apply strict
standards for environmental protection at our sites inside and outside the U.S., even if the sites outside the U.S.
are not subject to regulations imposed by foreign governments, we may not be aware of all conditions that could
subject us to liability.

As part of our acquisition of Varian, we assumed the liabilities of Varian, including Varian's costs and
potential liabilities for environmental matters. One such cost is our obligation, along with the obligation of
Varian Semiconductor Equipment Associates, Inc. ("VSEA") (under the terms of a Distribution Agreement
between Varian, VSEA and Varian Medical Systems, Inc. ("VMS")) to each indemnify VMS for one-third of
certain costs (after adjusting for any insurance proceeds and tax benefits recognized or realized by VMS for such
costs) relating to (a) environmental investigation, monitoring and/or remediation activities at certain facilities
previously operated by Varian Associates, Inc. ("VAI") and third-party claims made in connection with
environmental conditions at those facilities, and (b) U.S. Environmental Protection Agency or third-party claims
alleging that VAI or VMS is a potentially responsible party under the Comprehensive Environmental Response
Compensation and Liability Act of 1980, as amended ("CERCLA") in connection with certain sites to which
VAI allegedly shipped manufacturing waste for recycling, treatment or disposal (the "CERCLA sites"). With
respect to the facilities formerly operated by VAI, VMS is overseeing the environmental investigation,
monitoring and/or remediation activities, in most cases under the direction of, or in consultation with, federal,
state and/or local agencies, and handling third-party claims. VMS is also handling claims relating to the
CERCLA sites. Although any ultimate liability arising from environmental- related matters could result in
significant expenditures that, if aggregated and assumed to occur within a single fiscal year, could be material to
our financial statements, the likelihood of such occurrence is considered remote. Based on information currently
available and our best assessment of the ultimate amount and timing of environmental-related events,
management believes that the costs of environmental-related matters are unlikely to have a material adverse
effect on our financial condition or results of operations.

s
l
a
i
c
n
a
n
i
F

t
r
o
p
e
R

l
a
u
n
n
A

Regulations related to “conflict minerals” may cause us to incur additional expenses and could limit the

supply and increase the cost of certain metals used in manufacturing our products.

In August 2012, the SEC adopted a new rule requiring disclosures by public companies of specified
minerals, known as conflict minerals, that are necessary to the functionality or production of products
manufactured or contracted to be manufactured. The rule, which went into effect for calendar year 2013 and
requires an annual disclosure report to be filed with the SEC by May 31st of each year, requires companies to
perform due diligence, disclose and report whether or not such minerals originate from the Democratic Republic
of Congo or an adjoining country. There are costs associated with complying with these disclosure requirements,
including for diligence in regards to the sources of any conflict minerals used in our products, in addition to the
cost of remediation and other changes to products, processes, or sources of supply as a consequence of such
verification activities. In addition, our ongoing implementation of these rules could adversely affect the
sourcing, supply, and pricing of materials used in our products. The rule could affect sourcing at competitive
prices and availability in sufficient quantities of certain minerals used in the manufacture of our products,
including tin, tantalum, gold and tungsten. The number of suppliers who provide conflict-free minerals may be
limited. In addition, there may be material costs associated with complying with the disclosure requirements,
such as costs related to the due diligence process of determining the source of certain minerals used in our
products, as well as costs of possible changes to products, processes, or sources of supply as a consequence of
such verification activities. As our supply chain is complex and we use contract manufacturers for some of our
products, we may not be able to sufficiently verify the origins of the relevant minerals used in our products
through the due diligence procedures that we implement, which may harm our reputation. We may also
encounter challenges to satisfy those customers who require that all of the components of our products be
certified as conflict-free, which could place us at a competitive disadvantage if we are unable to do so.

Third parties may claim that we are infringing their intellectual property and we could suffer significant

litigation or licensing expenses or be prevented from selling products or services.

From time to time, third parties may claim that one or more of our products or services infringe their
intellectual property rights. We analyze and take action in response to such claims on a case by case basis. Any
dispute or litigation regarding patents or other intellectual property could be costly and time-consuming due to
the complexity of our technology and the uncertainty of intellectual property litigation and could divert our
management and key personnel from our business operations. A claim of intellectual property infringement
could force us to enter into a costly or restrictive license agreement, which might not be available under
acceptable terms or at all, could require us to redesign our products, which would be costly and time-consuming,
and/or could subject us to significant damages or to an injunction against development and sale of certain of our
products or services. Our intellectual property portfolio may not be useful in asserting a counterclaim, or
negotiating a license, in response to a claim of intellectual property infringement. In certain of our businesses we
rely on third party intellectual property licenses and we cannot ensure that these licenses will be available to us in
the future on favorable terms or at all.

Third parties may infringe our intellectual property and we may suffer competitive injury or expend

significant resources enforcing our rights.

Our success depends in large part on our proprietary technology, including technology we obtained through
acquisitions. We rely on various intellectual property rights, including patents, copyrights, trademarks and trade
secrets, as well as confidentiality provisions and licensing arrangements, to establish our proprietary rights. If we
do not enforce our intellectual property rights successfully our competitive position may suffer which could harm
our operating results.

Our pending patent applications, and our pending copyright and trademark registration applications, may not
be allowed or competitors may challenge the validity or scope of our patents, copyrights or trademarks. In

addition, our patents, copyrights, trademarks and other intellectual property rights may not provide us a
significant competitive advantage.

We may need to spend significant resources monitoring our intellectual property rights and we may or may
not be able to detect infringement by third parties. Our competitive position may be harmed if we cannot detect
infringement and enforce our intellectual property rights quickly or at all. In some circumstances, we may choose
to not pursue enforcement because an infringer has a dominant intellectual property position or for other business
reasons. In addition, competitors might avoid infringement by designing around our intellectual property rights
or by developing non-infringing competing technologies. Intellectual property rights and our ability to enforce
them may be unavailable or limited in some countries which could make it easier for competitors to capture
market share and could result in lost revenues. Furthermore, some of our intellectual property is licensed to
others which allow them to compete with us using that intellectual property.

We are subject to ongoing tax examinations of our tax returns by the Internal Revenue Service and other
tax authorities. An adverse outcome of any such audit or examination by the IRS or other tax authority could
have a material adverse effect on our results of operations, financial condition and liquidity.

We are subject to ongoing tax examinations of our tax returns by the U.S. Internal Revenue Service and
other tax authorities in various jurisdictions. We regularly assess the likelihood of adverse outcomes resulting
from ongoing tax examinations to determine the adequacy of our provision for income taxes. These assessments
can require considerable estimates and judgments. Intercompany transactions associated with the sale of
inventory, services, intellectual property and cost share arrangements are complex and affect our tax liabilities.
The calculation of our tax liabilities involves dealing with uncertainties in the application of complex tax laws
and regulations in multiple jurisdictions. There can be no assurance that the outcomes from ongoing tax
examinations will not have an adverse effect on our operating results and financial condition. A difference in the
ultimate resolution of tax uncertainties from what is currently estimated could have an adverse effect on our
operating results and financial condition.

If tax incentives change or cease to be in effect, our income taxes could increase significantly.

Agilent benefits from tax incentives extended to its foreign subsidiaries to encourage investment or
employment. Several jurisdictions have granted Agilent tax incentives which require renewal at various times in
the future. The incentives are conditioned on achieving various thresholds of investments and employment, or
specific types of income. Agilent's taxes could increase if the incentives are not renewed upon expiration. If
Agilent cannot or does not wish to satisfy all or parts of the tax incentive conditions, we may lose the related tax
incentive and could be required to refund tax incentives previously realized. As a result, our effective tax rate
could be higher than it would have been had we maintained the benefits of the tax incentives.

We have substantial cash requirements in the United States while most of our cash is generated outside of
the United States. The failure to maintain a level of cash sufficient to address our cash requirements in the
United States could adversely affect our financial condition and results of operations.

Although the cash generated in the United States from our operations should cover our normal operating
requirements and debt service requirements, a substantial amount of additional cash is required for special
purposes such as the maturity of our debt obligations, our stock repurchase program, our declared dividends and
acquisitions of third parties. Our business operating results, financial condition, and strategic initiatives could be
adversely impacted if we were unable to address our U.S. cash requirements through the efficient and timely
repatriations of overseas cash or other sources of cash obtained at an acceptable cost.

s
l
a
i
c
n
a
n
i
F

t
r
o
p
e
R

l
a
u
n
n
A

We have outstanding debt and may incur other debt in the future, which could adversely affect our

financial condition, liquidity and results of operations.

We currently have outstanding an aggregate principal amount of $1.6 billion in senior unsecured notes, and
a $38 million secured mortgage. We also are party to a five-year unsecured revolving credit facility which
expires in September 2019. On June 9, 2015, we increased the commitments under the existing credit facility by
$300 million so that the aggregate commitments under the facility now total $700 million and retained a
provision that allows us to further increase commitments to the credit facility by $300 million in the aggregate,
subject to certain conditions. We may borrow additional amounts in the future and use the proceeds from any
future borrowing for general corporate purposes, other future acquisitions, expansion of our business or
repurchases of our outstanding shares of common stock.

Our incurrence of this debt, and increases in our aggregate levels of debt, may adversely affect our operating

results and financial condition by, among other things:

•

increasing our vulnerability to downturns in our business, to competitive pressures and to
adverse economic and industry conditions;
requiring the dedication of an increased portion of our expected cash from operations to service
our indebtedness, thereby reducing the amount of expected cash flow available for other
purposes, including capital expenditures, acquisitions stock repurchases and dividends; and
limiting our flexibility in planning for, or reacting to, changes in our business and our industry.

Our current revolving credit facility imposes restrictions on us, including restrictions on our ability to create
liens on our assets and the ability of our subsidiaries to incur indebtedness, and requires us to maintain
compliance with specified financial ratios. Our ability to comply with these ratios may be affected by events
beyond our control. In addition, the indenture governing our senior notes contains covenants that may adversely
affect our ability to incur certain liens or engage in certain types of sale and leaseback transactions. If we breach
any of the covenants and do not obtain a waiver from the lenders, then, subject to applicable cure periods, our
outstanding indebtedness could be declared immediately due and payable.

If we suffer a loss to our factories, facilities or distribution system due to catastrophe, our operations

could be seriously harmed.

Our factories, facilities and distribution system are subject to catastrophic loss due to fire, flood, terrorism or
other natural or man-made disasters. In particular, several of our facilities could be subject to a catastrophic loss
caused by earthquake due to their locations. Our production facilities, headquarters and Agilent Technologies
Laboratories in California, and our production facilities in Japan, are all located in areas with above-average
seismic activity. If any of these facilities were to experience a catastrophic loss, it could disrupt our operations,
delay production, shipments and revenue and result in large expenses to repair or replace the facility. If such a
disruption were to occur, we could breach agreements, our reputation could be harmed, and our business and
operating results could be adversely affected. In addition, since we have consolidated our manufacturing
facilities, we are more likely to experience an interruption to our operations in the event of a catastrophe in any
one location. Although we carry insurance for property damage and business interruption, we do not carry
insurance or financial reserves for interruptions or potential losses arising from earthquakes or terrorism. Also,
our third party insurance coverage will vary from time to time in both type and amount depending on
availability, cost and our decisions with respect to risk retention. Economic conditions and uncertainties in global
markets may adversely affect the cost and other terms upon which we are able to obtain third party insurance. If
our third party insurance coverage is adversely affected, or to the extent we have elected to self-insure, we may
be at a greater risk that our operations will be harmed by a catastrophic loss.

If we experience a significant disruption in, or breach in security of, our information technology systems,

or if we fail to implement new systems and software successfully, our business could be adversely affected.

We rely on several centralized information technology systems throughout our company to provide products
and services, keep financial records, process orders, manage inventory, process shipments to customers and
operate other critical functions. Our information technology systems may be susceptible to damage, disruptions
or shutdowns due to power outages, hardware failures, computer viruses, attacks by computer hackers,
telecommunication failures, user errors, catastrophes or other unforeseen events. Our information technology
systems also may experience interruptions, delays or cessations of service or produce errors in connection with
system integration, software upgrades or system migration work that takes place from time to time. If we were
to experience a prolonged system disruption in the information technology systems that involve our interactions
with customers or suppliers, it could result in the loss of sales and customers and significant incremental costs,
which could adversely affect our business. In addition, security breaches of our information technology systems
could result in the misappropriation or unauthorized disclosure of confidential information belonging to us or to
our employees, partners, customers or suppliers, which could result in our suffering significant financial or
reputational damage.

Adverse conditions in the global banking industry and credit markets may adversely impact the value of

our cash investments or impair our liquidity.

As of October 31 2015, we had cash and cash equivalents of approximately $2.0 billion invested or held in a
mix of money market funds, time deposit accounts and bank demand deposit accounts. Disruptions in the
financial markets may, in some cases, result in an inability to access assets such as money market funds that
traditionally have been viewed as highly liquid. Any failure of our counterparty financial institutions or funds in
which we have invested may adversely impact our cash and cash equivalent positions and, in turn, our results and
financial condition.

We could incur significant liability if the distribution of Keysight common stock to our shareholders is

determined to be a taxable transaction.

We have received an opinion from outside tax counsel to the effect that the separation and distribution of
Keysight qualifies as a transaction that is described in Sections 355(a) and 368(a)(1)(D) of the Internal Revenue
Code. The opinion relies on certain facts, assumptions, representations and undertakings from Keysight and us
regarding the past and future conduct of the companies’ respective businesses and other matters. If any of these
facts, assumptions, representations or undertakings are incorrect or not satisfied, our shareholders and we may
not be able to rely on the opinion of tax counsel and could be subject to significant tax liabilities.
Notwithstanding the opinion of tax counsel we have received, the IRS could determine on audit that the
separation is taxable if it determines that any of these facts, assumptions, representations or undertakings are not
correct or have been violated or if it disagrees with the conclusions in the opinion. If the separation is determined
to be taxable for U.S. federal income tax purposes, our shareholders that are subject to U.S. federal income tax
and we could incur significant U.S. federal income tax liabilities.

We may be exposed to claims and liabilities as a result of the separation with Keysight.

We entered into a separation and distribution agreement and various other agreements with Keysight to
govern the separation and the relationship of the two companies going forward. These agreements provide for
specific indemnity and liability obligations and could lead to disputes between us. The indemnity rights we
have against Keysight under the agreements may not be sufficient to protect us. In addition, our indemnity
obligations to Keysight may be significant and these risks could negatively affect our financial condition.

s
l
a
i
c
n
a
n
i
F

t
r
o
p
e
R

l
a
u
n
n
A

CONTROLS AND PROCEDURES

Evaluation of Disclosure Controls and Procedures

Our management has evaluated, under the supervision and with the participation of our Chief Executive
Officer and Chief Financial Officer, the effectiveness of our disclosure controls and procedures as of October 31,
2015, pursuant to and as required by Rule 13a-15(b) under the Securities Exchange Act of 1934 (“Exchange
Act”). Based on that evaluation, our Chief Executive Officer and Chief Financial Officer have concluded that, as
of October 31, 2015, the company's disclosure controls and procedures, as defined by Rule 13a-15(e) under the
Exchange Act, were not effective due to a material weakness in internal control over financial reporting
described below in Management's Report on Internal Control over Financial Reporting.

Notwithstanding the identified material weakness, management, including our principal executive officer
and principal financial officer, believes the consolidated financial statements included in this annual report fairly
represent in all material respects our financial condition, results of operations and cash flows at and for the
periods presented in accordance with U.S. GAAP.

Management's Report on Internal Control over Financial Reporting

Our management is responsible for establishing and maintaining adequate internal control over financial
reporting, as such term is defined in Exchange Act Rule 13a-15(f). Under the supervision and with the
participation of our management, including our Chief Executive Officer and Chief Financial Officer, we
conducted an evaluation of the effectiveness of our internal control over financial reporting based on the
framework in
issued by the Committee of Sponsoring
Organizations of the Treadway Commission ("COSO"). As a result of that evaluation, management concluded
that a material weakness exists as described below. A material weakness is “a deficiency or a combination of
deficiencies, in internal control over financial reporting, such that there is a reasonable possibility that a material
misstatement of the registrant’s annual or interim financial statement will not be prevented or detected in a
timely basis.”

Internal Control - Integrated Framework (2013)

During the year ended October 31, 2015, management identified certain errors in the tax accounts, primarily
related to prior years, and as a result, concluded that the Company did not design and maintain effective controls
over the accounting for income taxes. Specifically, certain controls activities over the completeness and
accuracy of our accounting for (i) U.S. taxes on foreign earnings, (ii) international provision for income taxes
and (iii) reconciliation of income taxes payable were not performed on a timely basis or at the appropriate level
of precision. The errors identified by management during the year ended October 31, 2015, when combined with
errors identified in prior years, resulted in the Company revising its consolidated financial statements as of
October 31, 2014, 2013 and 2012, for the years ended October 31, 2014 and 2013, and for each of the quarters of
the years ended October 31, 2015 and 2014. These control deficiencies in the accounting for income taxes could
result in a material misstatement that would not be prevented or detected.

Because of the material weakness, management concluded that the Company did not maintain effective
internal control over financial reporting as of October 31, 2015 based on criteria in Internal Control - Integrated
Framework (2013) issued by COSO.

The effectiveness of our internal control over financial reporting as of October 31, 2015 has been audited by
PricewaterhouseCoopers LLP, an independent registered public accounting firm, as stated in their report which
appears in this annual report.

Changes in Internal Control Over Financial Reporting

There were no changes in our internal control over financial reporting that occurred during Agilent's last
fiscal quarter that have materially affected, or are reasonably likely to materially affect, our internal control over
financial reporting.

100

Material Weakness Remediation Efforts

Management has and will continue to enhance its controls which include refinements and enhancements to
the design (including the review and supervision and the level of precision) of certain controls over the
accounting for income taxes. Enhancements previously made to certain controls contributed to the identification
of the errors which impacted prior periods. The Company’s enhanced controls however had an insufficient
period of time to operate for management to conclude that they were operating effectively. As such, at October
31, 2015 there continues to be a reasonable possibility that a material misstatement related to the accounting for
income taxes may still not be prevented or detected. With the effective operation of these enhanced controls, the
Company expects remediation of the material weakness in fiscal 2016.

s
l
a
i
c
n
a
n
i
F

t
r
o
p
e
R

l
a
u
n
n
A

101

This page is intentionally left blank.This page is intentionally left blank.This page is intentionally left blank.© Agilent Technologies, Inc. 2016www.agilent.com